#FORMAT=WebAnno TSV 3.3
#T_SP=webanno.custom.ConceptLayer|identifier


#Text=Brain responses to different types of salience in antipsychotic naïve first episode psychosis: An fMRI study
#Text=Abnormal salience processing has been suggested to contribute to the formation of positive psychotic symptoms in schizophrenia and related conditions.
1-1	0-5	Brain	_	
1-2	6-15	responses	_	
1-3	16-18	to	_	
1-4	19-28	different	_	
1-5	29-34	types	_	
1-6	35-37	of	_	
1-7	38-46	salience	_	
1-8	47-49	in	_	
1-9	50-63	antipsychotic	_	
1-10	64-69	naïve	_	
1-11	70-75	first	_	
1-12	76-83	episode	_	
1-13	84-93	psychosis	http://maven.renci.org/NeuroBridge/neurobridge#PsychoticDisorder	
1-14	93-94	:	_	
1-15	95-97	An	_	
1-16	98-102	fMRI	_	
1-17	103-108	study	_	
1-18	109-117	Abnormal	_	
1-19	118-126	salience	_	
1-20	127-137	processing	_	
1-21	138-141	has	_	
1-22	142-146	been	_	
1-23	147-156	suggested	_	
1-24	157-159	to	_	
1-25	160-170	contribute	_	
1-26	171-173	to	_	
1-27	174-177	the	_	
1-28	178-187	formation	_	
1-29	188-190	of	_	
1-30	191-199	positive	_	
1-31	200-209	psychotic	_	
1-32	210-218	symptoms	_	
1-33	219-221	in	_	
1-34	222-235	schizophrenia	http://maven.renci.org/NeuroBridge/neurobridge#Schizophrenia	
1-35	236-239	and	_	
1-36	240-247	related	_	
1-37	248-258	conditions	_	
1-38	258-259	.	_	

#Text=Previous research utilising reward learning or anticipation paradigms has demonstrated cortical and subcortical abnormalities in people with psychosis, specifically in the prefrontal cortex, the dopaminergic midbrain and the striatum.
2-1	260-268	Previous	_	
2-2	269-277	research	_	
2-3	278-287	utilising	_	
2-4	288-294	reward	_	
2-5	295-303	learning	_	
2-6	304-306	or	_	
2-7	307-319	anticipation	_	
2-8	320-329	paradigms	_	
2-9	330-333	has	_	
2-10	334-346	demonstrated	_	
2-11	347-355	cortical	_	
2-12	356-359	and	_	
2-13	360-371	subcortical	_	
2-14	372-385	abnormalities	_	
2-15	386-388	in	_	
2-16	389-395	people	_	
2-17	396-400	with	_	
2-18	401-410	psychosis	http://maven.renci.org/NeuroBridge/neurobridge#PsychoticDisorder	
2-19	410-411	,	_	
2-20	412-424	specifically	_	
2-21	425-427	in	_	
2-22	428-431	the	_	
2-23	432-442	prefrontal	_	
2-24	443-449	cortex	_	
2-25	449-450	,	_	
2-26	451-454	the	_	
2-27	455-467	dopaminergic	_	
2-28	468-476	midbrain	_	
2-29	477-480	and	_	
2-30	481-484	the	_	
2-31	485-493	striatum	_	
2-32	493-494	.	_	

#Text=In these paradigms, reward prediction errors attribute motivational salience to stimuli.
3-1	495-497	In	_	
3-2	498-503	these	_	
3-3	504-513	paradigms	_	
3-4	513-514	,	_	
3-5	515-521	reward	_	
3-6	522-532	prediction	_	
3-7	533-539	errors	_	
3-8	540-549	attribute	_	
3-9	550-562	motivational	_	
3-10	563-571	salience	_	
3-11	572-574	to	_	
3-12	575-582	stimuli	_	
3-13	582-583	.	_	

#Text=However, little is known about possible abnormalities across different forms of salience processing in psychosis patients, and whether any such abnormalities involve the dopaminergic midbrain.
4-1	584-591	However	_	
4-2	591-592	,	_	
4-3	593-599	little	_	
4-4	600-602	is	_	
4-5	603-608	known	_	
4-6	609-614	about	_	
4-7	615-623	possible	_	
4-8	624-637	abnormalities	_	
4-9	638-644	across	_	
4-10	645-654	different	_	
4-11	655-660	forms	_	
4-12	661-663	of	_	
4-13	664-672	salience	_	
4-14	673-683	processing	_	
4-15	684-686	in	_	
4-16	687-696	psychosis	http://maven.renci.org/NeuroBridge/neurobridge#PsychoticDisorder	
4-17	697-705	patients	_	
4-18	705-706	,	_	
4-19	707-710	and	_	
4-20	711-718	whether	_	
4-21	719-722	any	_	
4-22	723-727	such	_	
4-23	728-741	abnormalities	_	
4-24	742-749	involve	_	
4-25	750-753	the	_	
4-26	754-766	dopaminergic	_	
4-27	767-775	midbrain	_	
4-28	775-776	.	_	

#Text=The aim of our study was, therefore, to investigate possible alterations in psychosis in neural activity in response to various forms of salience: novelty, negative emotion, targetness (task-driven salience) and rareness/deviance.
5-1	777-780	The	_	
5-2	781-784	aim	_	
5-3	785-787	of	_	
5-4	788-791	our	_	
5-5	792-797	study	_	
5-6	798-801	was	_	
5-7	801-802	,	_	
5-8	803-812	therefore	_	
5-9	812-813	,	_	
5-10	814-816	to	_	
5-11	817-828	investigate	_	
5-12	829-837	possible	_	
5-13	838-849	alterations	_	
5-14	850-852	in	_	
5-15	853-862	psychosis	http://maven.renci.org/NeuroBridge/neurobridge#PsychoticDisorder	
5-16	863-865	in	_	
5-17	866-872	neural	_	
5-18	873-881	activity	_	
5-19	882-884	in	_	
5-20	885-893	response	_	
5-21	894-896	to	_	
5-22	897-904	various	_	
5-23	905-910	forms	_	
5-24	911-913	of	_	
5-25	914-922	salience	_	
5-26	922-923	:	_	
5-27	924-931	novelty	_	
5-28	931-932	,	_	
5-29	933-941	negative	_	
5-30	942-949	emotion	_	
5-31	949-950	,	_	
5-32	951-961	targetness	_	
5-33	962-963	(	_	
5-34	963-974	task-driven	_	
5-35	975-983	salience	_	
5-36	983-984	)	_	
5-37	985-988	and	_	
5-38	989-997	rareness	_	
5-39	997-998	/	_	
5-40	998-1006	deviance	_	
5-41	1006-1007	.	_	

#Text=We studied 14 antipsychotic naïve participants with first episode psychosis, and 37 healthy volunteers.
6-1	1008-1010	We	_	
6-2	1011-1018	studied	_	
6-3	1019-1021	14	_	
6-4	1022-1035	antipsychotic	_	
6-5	1036-1041	naïve	_	
6-6	1042-1054	participants	_	
6-7	1055-1059	with	_	
6-8	1060-1065	first	_	
6-9	1066-1073	episode	_	
6-10	1074-1083	psychosis	http://maven.renci.org/NeuroBridge/neurobridge#PsychoticDisorder	
6-11	1083-1084	,	_	
6-12	1085-1088	and	_	
6-13	1089-1091	37	_	
6-14	1092-1099	healthy	http://maven.renci.org/NeuroBridge/neurobridge#NoKnownDisorder[1]	
6-15	1100-1110	volunteers	http://maven.renci.org/NeuroBridge/neurobridge#NoKnownDisorder[1]	
6-16	1110-1111	.	_	

#Text=During fMRI scanning, participants performed a visual oddball task containing these four forms of salience.
7-1	1112-1118	During	_	
7-2	1119-1123	fMRI	http://maven.renci.org/NeuroBridge/neurobridge#FunctionalMagneticResonanceImaging	
7-3	1124-1132	scanning	_	
7-4	1132-1133	,	_	
7-5	1134-1146	participants	_	
7-6	1147-1156	performed	_	
7-7	1157-1158	a	_	
7-8	1159-1165	visual	_	
7-9	1166-1173	oddball	_	
7-10	1174-1178	task	_	
7-11	1179-1189	containing	_	
7-12	1190-1195	these	_	
7-13	1196-1200	four	_	
7-14	1201-1206	forms	_	
7-15	1207-1209	of	_	
7-16	1210-1218	salience	_	
7-17	1218-1219	.	_	

#Text=Psychosis patients showed abnormally reduced signalling in the substantia nigra/ventral tegmental area (SN/VTA) for novelty, negative emotional salience and targetness; reduced striatal and occipital (lingual gyrus) signalling to novelty and negative emotional salience, reduced signalling in the amygdala, anterior cingulate cortex and parahippocamal gyrus to negative emotional salience, and reduced cerebellar signalling to novelty and negative emotional salience.
8-1	1220-1229	Psychosis	http://maven.renci.org/NeuroBridge/neurobridge#PsychoticDisorder	
8-2	1230-1238	patients	_	
8-3	1239-1245	showed	_	
8-4	1246-1256	abnormally	_	
8-5	1257-1264	reduced	_	
8-6	1265-1275	signalling	_	
8-7	1276-1278	in	_	
8-8	1279-1282	the	_	
8-9	1283-1293	substantia	_	
8-10	1294-1299	nigra	_	
8-11	1299-1300	/	_	
8-12	1300-1307	ventral	_	
8-13	1308-1317	tegmental	_	
8-14	1318-1322	area	_	
8-15	1323-1324	(	_	
8-16	1324-1326	SN	_	
8-17	1326-1327	/	_	
8-18	1327-1330	VTA	_	
8-19	1330-1331	)	_	
8-20	1332-1335	for	_	
8-21	1336-1343	novelty	_	
8-22	1343-1344	,	_	
8-23	1345-1353	negative	_	
8-24	1354-1363	emotional	_	
8-25	1364-1372	salience	_	
8-26	1373-1376	and	_	
8-27	1377-1387	targetness	_	
8-28	1387-1388	;	_	
8-29	1389-1396	reduced	_	
8-30	1397-1405	striatal	_	
8-31	1406-1409	and	_	
8-32	1410-1419	occipital	_	
8-33	1420-1421	(	_	
8-34	1421-1428	lingual	_	
8-35	1429-1434	gyrus	_	
8-36	1434-1435	)	_	
8-37	1436-1446	signalling	_	
8-38	1447-1449	to	_	
8-39	1450-1457	novelty	_	
8-40	1458-1461	and	_	
8-41	1462-1470	negative	_	
8-42	1471-1480	emotional	_	
8-43	1481-1489	salience	_	
8-44	1489-1490	,	_	
8-45	1491-1498	reduced	_	
8-46	1499-1509	signalling	_	
8-47	1510-1512	in	_	
8-48	1513-1516	the	_	
8-49	1517-1525	amygdala	_	
8-50	1525-1526	,	_	
8-51	1527-1535	anterior	_	
8-52	1536-1545	cingulate	_	
8-53	1546-1552	cortex	_	
8-54	1553-1556	and	_	
8-55	1557-1571	parahippocamal	_	
8-56	1572-1577	gyrus	_	
8-57	1578-1580	to	_	
8-58	1581-1589	negative	_	
8-59	1590-1599	emotional	_	
8-60	1600-1608	salience	_	
8-61	1608-1609	,	_	
8-62	1610-1613	and	_	
8-63	1614-1621	reduced	_	
8-64	1622-1632	cerebellar	_	
8-65	1633-1643	signalling	_	
8-66	1644-1646	to	_	
8-67	1647-1654	novelty	_	
8-68	1655-1658	and	_	
8-69	1659-1667	negative	_	
8-70	1668-1677	emotional	_	
8-71	1678-1686	salience	_	
8-72	1686-1687	.	_	

#Text=Our results indicate alterations of several forms of salience processing in patients with psychosis in the midbrain SN/VTA, with additional subcortical and cortical regions also showing alterations in salience signalling, the exact pattern of alterations depending on the form of salience in question.
9-1	1688-1691	Our	_	
9-2	1692-1699	results	_	
9-3	1700-1708	indicate	_	
9-4	1709-1720	alterations	_	
9-5	1721-1723	of	_	
9-6	1724-1731	several	_	
9-7	1732-1737	forms	_	
9-8	1738-1740	of	_	
9-9	1741-1749	salience	_	
9-10	1750-1760	processing	_	
9-11	1761-1763	in	_	
9-12	1764-1772	patients	_	
9-13	1773-1777	with	_	
9-14	1778-1787	psychosis	http://maven.renci.org/NeuroBridge/neurobridge#PsychoticDisorder	
9-15	1788-1790	in	_	
9-16	1791-1794	the	_	
9-17	1795-1803	midbrain	_	
9-18	1804-1806	SN	_	
9-19	1806-1807	/	_	
9-20	1807-1810	VTA	_	
9-21	1810-1811	,	_	
9-22	1812-1816	with	_	
9-23	1817-1827	additional	_	
9-24	1828-1839	subcortical	_	
9-25	1840-1843	and	_	
9-26	1844-1852	cortical	_	
9-27	1853-1860	regions	_	
9-28	1861-1865	also	_	
9-29	1866-1873	showing	_	
9-30	1874-1885	alterations	_	
9-31	1886-1888	in	_	
9-32	1889-1897	salience	_	
9-33	1898-1908	signalling	_	
9-34	1908-1909	,	_	
9-35	1910-1913	the	_	
9-36	1914-1919	exact	_	
9-37	1920-1927	pattern	_	
9-38	1928-1930	of	_	
9-39	1931-1942	alterations	_	
9-40	1943-1952	depending	_	
9-41	1953-1955	on	_	
9-42	1956-1959	the	_	
9-43	1960-1964	form	_	
9-44	1965-1967	of	_	
9-45	1968-1976	salience	_	
9-46	1977-1979	in	_	
9-47	1980-1988	question	_	
9-48	1988-1989	.	_	

#Text=Introduction
#Text=Salience is a property that enables a stimulus to attract attention, and to drive cognition and behaviour.
10-1	1990-2002	Introduction	_	
10-2	2003-2011	Salience	_	
10-3	2012-2014	is	_	
10-4	2015-2016	a	_	
10-5	2017-2025	property	_	
10-6	2026-2030	that	_	
10-7	2031-2038	enables	_	
10-8	2039-2040	a	_	
10-9	2041-2049	stimulus	_	
10-10	2050-2052	to	_	
10-11	2053-2060	attract	_	
10-12	2061-2070	attention	_	
10-13	2070-2071	,	_	
10-14	2072-2075	and	_	
10-15	2076-2078	to	_	
10-16	2079-2084	drive	_	
10-17	2085-2094	cognition	_	
10-18	2095-2098	and	_	
10-19	2099-2108	behaviour	_	
10-20	2108-2109	.	_	

#Text=It can be described as a product of matched/mismatched stimulus features and internal, driving factors of an individual, such as goals, beliefs and experiences at a particular point in time.
11-1	2110-2112	It	_	
11-2	2113-2116	can	_	
11-3	2117-2119	be	_	
11-4	2120-2129	described	_	
11-5	2130-2132	as	_	
11-6	2133-2134	a	_	
11-7	2135-2142	product	_	
11-8	2143-2145	of	_	
11-9	2146-2153	matched	_	
11-10	2153-2154	/	_	
11-11	2154-2164	mismatched	_	
11-12	2165-2173	stimulus	_	
11-13	2174-2182	features	_	
11-14	2183-2186	and	_	
11-15	2187-2195	internal	_	
11-16	2195-2196	,	_	
11-17	2197-2204	driving	_	
11-18	2205-2212	factors	_	
11-19	2213-2215	of	_	
11-20	2216-2218	an	_	
11-21	2219-2229	individual	_	
11-22	2229-2230	,	_	
11-23	2231-2235	such	_	
11-24	2236-2238	as	_	
11-25	2239-2244	goals	_	
11-26	2244-2245	,	_	
11-27	2246-2253	beliefs	_	
11-28	2254-2257	and	_	
11-29	2258-2269	experiences	_	
11-30	2270-2272	at	_	
11-31	2273-2274	a	_	
11-32	2275-2285	particular	_	
11-33	2286-2291	point	_	
11-34	2292-2294	in	_	
11-35	2295-2299	time	_	
11-36	2299-2300	.	_	

#Text=Salience is a multifaceted concept, including different dimensions, such as reward and threat prediction, prediction error, novelty, emotional salience or rareness/deviance.
12-1	2301-2309	Salience	_	
12-2	2310-2312	is	_	
12-3	2313-2314	a	_	
12-4	2315-2327	multifaceted	_	
12-5	2328-2335	concept	_	
12-6	2335-2336	,	_	
12-7	2337-2346	including	_	
12-8	2347-2356	different	_	
12-9	2357-2367	dimensions	_	
12-10	2367-2368	,	_	
12-11	2369-2373	such	_	
12-12	2374-2376	as	_	
12-13	2377-2383	reward	_	
12-14	2384-2387	and	_	
12-15	2388-2394	threat	_	
12-16	2395-2405	prediction	_	
12-17	2405-2406	,	_	
12-18	2407-2417	prediction	_	
12-19	2418-2423	error	_	
12-20	2423-2424	,	_	
12-21	2425-2432	novelty	_	
12-22	2432-2433	,	_	
12-23	2434-2443	emotional	_	
12-24	2444-2452	salience	_	
12-25	2453-2455	or	_	
12-26	2456-2464	rareness	_	
12-27	2464-2465	/	_	
12-28	2465-2473	deviance	_	
12-29	2473-2474	.	_	

#Text=The literature well describes the role of dopamine (DA) for reward prediction error, with neural signals originating in the substantia nigra/ventral tegmental area (SN/VTA).
13-1	2475-2478	The	_	
13-2	2479-2489	literature	_	
13-3	2490-2494	well	_	
13-4	2495-2504	describes	_	
13-5	2505-2508	the	_	
13-6	2509-2513	role	_	
13-7	2514-2516	of	_	
13-8	2517-2525	dopamine	_	
13-9	2526-2527	(	_	
13-10	2527-2529	DA	_	
13-11	2529-2530	)	_	
13-12	2531-2534	for	_	
13-13	2535-2541	reward	_	
13-14	2542-2552	prediction	_	
13-15	2553-2558	error	_	
13-16	2558-2559	,	_	
13-17	2560-2564	with	_	
13-18	2565-2571	neural	_	
13-19	2572-2579	signals	_	
13-20	2580-2591	originating	_	
13-21	2592-2594	in	_	
13-22	2595-2598	the	_	
13-23	2599-2609	substantia	_	
13-24	2610-2615	nigra	_	
13-25	2615-2616	/	_	
13-26	2616-2623	ventral	_	
13-27	2624-2633	tegmental	_	
13-28	2634-2638	area	_	
13-29	2639-2640	(	_	
13-30	2640-2642	SN	_	
13-31	2642-2643	/	_	
13-32	2643-2646	VTA	_	
13-33	2646-2647	)	_	
13-34	2647-2648	.	_	

#Text=However, DA neuron firing is not exclusive to reward prediction error, but has also been reported in response to non-rewarding unexpected events, such as aversive or alerting, as well as novel events, suggesting that DA release, at least in some contexts, reflects general salience.
14-1	2649-2656	However	_	
14-2	2656-2657	,	_	
14-3	2658-2660	DA	_	
14-4	2661-2667	neuron	_	
14-5	2668-2674	firing	_	
14-6	2675-2677	is	_	
14-7	2678-2681	not	_	
14-8	2682-2691	exclusive	_	
14-9	2692-2694	to	_	
14-10	2695-2701	reward	_	
14-11	2702-2712	prediction	_	
14-12	2713-2718	error	_	
14-13	2718-2719	,	_	
14-14	2720-2723	but	_	
14-15	2724-2727	has	_	
14-16	2728-2732	also	_	
14-17	2733-2737	been	_	
14-18	2738-2746	reported	_	
14-19	2747-2749	in	_	
14-20	2750-2758	response	_	
14-21	2759-2761	to	_	
14-22	2762-2775	non-rewarding	_	
14-23	2776-2786	unexpected	_	
14-24	2787-2793	events	_	
14-25	2793-2794	,	_	
14-26	2795-2799	such	_	
14-27	2800-2802	as	_	
14-28	2803-2811	aversive	_	
14-29	2812-2814	or	_	
14-30	2815-2823	alerting	_	
14-31	2823-2824	,	_	
14-32	2825-2827	as	_	
14-33	2828-2832	well	_	
14-34	2833-2835	as	_	
14-35	2836-2841	novel	_	
14-36	2842-2848	events	_	
14-37	2848-2849	,	_	
14-38	2850-2860	suggesting	_	
14-39	2861-2865	that	_	
14-40	2866-2868	DA	_	
14-41	2869-2876	release	_	
14-42	2876-2877	,	_	
14-43	2878-2880	at	_	
14-44	2881-2886	least	_	
14-45	2887-2889	in	_	
14-46	2890-2894	some	_	
14-47	2895-2903	contexts	_	
14-48	2903-2904	,	_	
14-49	2905-2913	reflects	_	
14-50	2914-2921	general	_	
14-51	2922-2930	salience	_	
14-52	2930-2931	.	_	

#Text=In psychosis, abnormal salience processing secondary to dysregulation of the dopaminergic system—described as the ‘aberrant salience’ hypothesis of psychosis—has been linked to the formation and maintenance of psychotic symptoms.
15-1	2932-2934	In	_	
15-2	2935-2944	psychosis	_	
15-3	2944-2945	,	_	
15-4	2946-2954	abnormal	_	
15-5	2955-2963	salience	_	
15-6	2964-2974	processing	_	
15-7	2975-2984	secondary	_	
15-8	2985-2987	to	_	
15-9	2988-3001	dysregulation	_	
15-10	3002-3004	of	_	
15-11	3005-3008	the	_	
15-12	3009-3021	dopaminergic	_	
15-13	3022-3038	system—described	_	
15-14	3039-3041	as	_	
15-15	3042-3045	the	_	
15-16	3046-3047	‘	_	
15-17	3047-3055	aberrant	_	
15-18	3056-3064	salience	_	
15-19	3064-3065	’	_	
15-20	3066-3076	hypothesis	_	
15-21	3077-3079	of	_	
15-22	3080-3093	psychosis—has	_	
15-23	3094-3098	been	_	
15-24	3099-3105	linked	_	
15-25	3106-3108	to	_	
15-26	3109-3112	the	_	
15-27	3113-3122	formation	_	
15-28	3123-3126	and	_	
15-29	3127-3138	maintenance	_	
15-30	3139-3141	of	_	
15-31	3142-3151	psychotic	_	
15-32	3152-3160	symptoms	_	
15-33	3160-3161	.	_	

#Text=It has been suggested that aberrant salience attribution in psychosis is caused by faulty DA signalling in the striatum, possibly driven by dysregulation from the prefrontal cortex (PFC) and hippocampus.
16-1	3162-3164	It	_	
16-2	3165-3168	has	_	
16-3	3169-3173	been	_	
16-4	3174-3183	suggested	_	
16-5	3184-3188	that	_	
16-6	3189-3197	aberrant	_	
16-7	3198-3206	salience	_	
16-8	3207-3218	attribution	_	
16-9	3219-3221	in	_	
16-10	3222-3231	psychosis	_	
16-11	3232-3234	is	_	
16-12	3235-3241	caused	_	
16-13	3242-3244	by	_	
16-14	3245-3251	faulty	_	
16-15	3252-3254	DA	_	
16-16	3255-3265	signalling	_	
16-17	3266-3268	in	_	
16-18	3269-3272	the	_	
16-19	3273-3281	striatum	_	
16-20	3281-3282	,	_	
16-21	3283-3291	possibly	_	
16-22	3292-3298	driven	_	
16-23	3299-3301	by	_	
16-24	3302-3315	dysregulation	_	
16-25	3316-3320	from	_	
16-26	3321-3324	the	_	
16-27	3325-3335	prefrontal	_	
16-28	3336-3342	cortex	_	
16-29	3343-3344	(	_	
16-30	3344-3347	PFC	_	
16-31	3347-3348	)	_	
16-32	3349-3352	and	_	
16-33	3353-3364	hippocampus	_	
16-34	3364-3365	.	_	

#Text=In psychosis, there is increased synthesis and release of DA in the striatum, which is present even at the prodromal stages of the disease.
17-1	3366-3368	In	_	
17-2	3369-3378	psychosis	_	
17-3	3378-3379	,	_	
17-4	3380-3385	there	_	
17-5	3386-3388	is	_	
17-6	3389-3398	increased	_	
17-7	3399-3408	synthesis	_	
17-8	3409-3412	and	_	
17-9	3413-3420	release	_	
17-10	3421-3423	of	_	
17-11	3424-3426	DA	_	
17-12	3427-3429	in	_	
17-13	3430-3433	the	_	
17-14	3434-3442	striatum	_	
17-15	3442-3443	,	_	
17-16	3444-3449	which	_	
17-17	3450-3452	is	_	
17-18	3453-3460	present	_	
17-19	3461-3465	even	_	
17-20	3466-3468	at	_	
17-21	3469-3472	the	_	
17-22	3473-3482	prodromal	_	
17-23	3483-3489	stages	_	
17-24	3490-3492	of	_	
17-25	3493-3496	the	_	
17-26	3497-3504	disease	_	
17-27	3504-3505	.	_	

#Text=Several studies reported reduced midbrain, striatal, and/or cortical processing of reward prediction errors and non-reward related prediction errors in psychosis.
18-1	3506-3513	Several	_	
18-2	3514-3521	studies	_	
18-3	3522-3530	reported	_	
18-4	3531-3538	reduced	_	
18-5	3539-3547	midbrain	_	
18-6	3547-3548	,	_	
18-7	3549-3557	striatal	_	
18-8	3557-3558	,	_	
18-9	3559-3562	and	_	
18-10	3562-3563	/	_	
18-11	3563-3565	or	_	
18-12	3566-3574	cortical	_	
18-13	3575-3585	processing	_	
18-14	3586-3588	of	_	
18-15	3589-3595	reward	_	
18-16	3596-3606	prediction	_	
18-17	3607-3613	errors	_	
18-18	3614-3617	and	_	
18-19	3618-3628	non-reward	_	
18-20	3629-3636	related	_	
18-21	3637-3647	prediction	_	
18-22	3648-3654	errors	_	
18-23	3655-3657	in	_	
18-24	3658-3667	psychosis	_	
18-25	3667-3668	.	_	

#Text=In our recent work, we documented meso-cortico-striatal prediction error deficits, involving midbrain, striatum and right lateral frontal cortex in medicated psychosis patients at different stages and in unmedicated first episode psychosis patients and patients at clinical risk for developing psychosis.
19-1	3669-3671	In	_	
19-2	3672-3675	our	_	
19-3	3676-3682	recent	_	
19-4	3683-3687	work	_	
19-5	3687-3688	,	_	
19-6	3689-3691	we	_	
19-7	3692-3702	documented	_	
19-8	3703-3724	meso-cortico-striatal	_	
19-9	3725-3735	prediction	_	
19-10	3736-3741	error	_	
19-11	3742-3750	deficits	_	
19-12	3750-3751	,	_	
19-13	3752-3761	involving	_	
19-14	3762-3770	midbrain	_	
19-15	3770-3771	,	_	
19-16	3772-3780	striatum	_	
19-17	3781-3784	and	_	
19-18	3785-3790	right	_	
19-19	3791-3798	lateral	_	
19-20	3799-3806	frontal	_	
19-21	3807-3813	cortex	_	
19-22	3814-3816	in	_	
19-23	3817-3826	medicated	_	
19-24	3827-3836	psychosis	_	
19-25	3837-3845	patients	_	
19-26	3846-3848	at	_	
19-27	3849-3858	different	_	
19-28	3859-3865	stages	_	
19-29	3866-3869	and	_	
19-30	3870-3872	in	_	
19-31	3873-3884	unmedicated	_	
19-32	3885-3890	first	_	
19-33	3891-3898	episode	_	
19-34	3899-3908	psychosis	_	
19-35	3909-3917	patients	_	
19-36	3918-3921	and	_	
19-37	3922-3930	patients	_	
19-38	3931-3933	at	_	
19-39	3934-3942	clinical	_	
19-40	3943-3947	risk	_	
19-41	3948-3951	for	_	
19-42	3952-3962	developing	_	
19-43	3963-3972	psychosis	_	
19-44	3972-3973	.	_	

#Text=Another study in people at clinical risk of psychosis showed a relation between the striatal reward prediction signal and psychotic symptoms.
20-1	3974-3981	Another	_	
20-2	3982-3987	study	_	
20-3	3988-3990	in	_	
20-4	3991-3997	people	_	
20-5	3998-4000	at	_	
20-6	4001-4009	clinical	_	
20-7	4010-4014	risk	_	
20-8	4015-4017	of	_	
20-9	4018-4027	psychosis	_	
20-10	4028-4034	showed	_	
20-11	4035-4036	a	_	
20-12	4037-4045	relation	_	
20-13	4046-4053	between	_	
20-14	4054-4057	the	_	
20-15	4058-4066	striatal	_	
20-16	4067-4073	reward	_	
20-17	4074-4084	prediction	_	
20-18	4085-4091	signal	_	
20-19	4092-4095	and	_	
20-20	4096-4105	psychotic	_	
20-21	4106-4114	symptoms	_	
20-22	4114-4115	.	_	

#Text=Novel events activate DA neurons even in the absence of reward, which is associated with increased attention, memory and goal-directed behaviour.
21-1	4116-4121	Novel	_	
21-2	4122-4128	events	_	
21-3	4129-4137	activate	_	
21-4	4138-4140	DA	_	
21-5	4141-4148	neurons	_	
21-6	4149-4153	even	_	
21-7	4154-4156	in	_	
21-8	4157-4160	the	_	
21-9	4161-4168	absence	_	
21-10	4169-4171	of	_	
21-11	4172-4178	reward	_	
21-12	4178-4179	,	_	
21-13	4180-4185	which	_	
21-14	4186-4188	is	_	
21-15	4189-4199	associated	_	
21-16	4200-4204	with	_	
21-17	4205-4214	increased	_	
21-18	4215-4224	attention	_	
21-19	4224-4225	,	_	
21-20	4226-4232	memory	_	
21-21	4233-4236	and	_	
21-22	4237-4250	goal-directed	_	
21-23	4251-4260	behaviour	_	
21-24	4260-4261	.	_	

#Text=Together with the fact that novelty exploration engages the areas of the brain involved in appetitive reinforcement learning (i.e. dopaminergic midbrain areas, striatum, medial prefrontal cortex), novelty may be intrinsically rewarding, irrespective of the choice outcome, and can provide a ‘bonus’ for exploration.
22-1	4262-4270	Together	_	
22-2	4271-4275	with	_	
22-3	4276-4279	the	_	
22-4	4280-4284	fact	_	
22-5	4285-4289	that	_	
22-6	4290-4297	novelty	_	
22-7	4298-4309	exploration	_	
22-8	4310-4317	engages	_	
22-9	4318-4321	the	_	
22-10	4322-4327	areas	_	
22-11	4328-4330	of	_	
22-12	4331-4334	the	_	
22-13	4335-4340	brain	_	
22-14	4341-4349	involved	_	
22-15	4350-4352	in	_	
22-16	4353-4363	appetitive	_	
22-17	4364-4377	reinforcement	_	
22-18	4378-4386	learning	_	
22-19	4387-4388	(	_	
22-20	4388-4391	i.e	_	
22-21	4391-4392	.	_	
22-22	4393-4405	dopaminergic	_	
22-23	4406-4414	midbrain	_	
22-24	4415-4420	areas	_	
22-25	4420-4421	,	_	
22-26	4422-4430	striatum	_	
22-27	4430-4431	,	_	
22-28	4432-4438	medial	_	
22-29	4439-4449	prefrontal	_	
22-30	4450-4456	cortex	_	
22-31	4456-4457	)	_	
22-32	4457-4458	,	_	
22-33	4459-4466	novelty	_	
22-34	4467-4470	may	_	
22-35	4471-4473	be	_	
22-36	4474-4487	intrinsically	_	
22-37	4488-4497	rewarding	_	
22-38	4497-4498	,	_	
22-39	4499-4511	irrespective	_	
22-40	4512-4514	of	_	
22-41	4515-4518	the	_	
22-42	4519-4525	choice	_	
22-43	4526-4533	outcome	_	
22-44	4533-4534	,	_	
22-45	4535-4538	and	_	
22-46	4539-4542	can	_	
22-47	4543-4550	provide	_	
22-48	4551-4552	a	_	
22-49	4553-4554	‘	_	
22-50	4554-4559	bonus	_	
22-51	4559-4560	’	_	
22-52	4561-4564	for	_	
22-53	4565-4576	exploration	_	
22-54	4576-4577	.	_	

#Text=A recent study by Schott and colleagues reported alterations in a fronto-limbic novelty processing network in unmedicated (not necessarily first episode) patients with acute psychosis.
23-1	4578-4579	A	_	
23-2	4580-4586	recent	_	
23-3	4587-4592	study	_	
23-4	4593-4595	by	_	
23-5	4596-4602	Schott	_	
23-6	4603-4606	and	_	
23-7	4607-4617	colleagues	_	
23-8	4618-4626	reported	_	
23-9	4627-4638	alterations	_	
23-10	4639-4641	in	_	
23-11	4642-4643	a	_	
23-12	4644-4657	fronto-limbic	_	
23-13	4658-4665	novelty	_	
23-14	4666-4676	processing	_	
23-15	4677-4684	network	_	
23-16	4685-4687	in	_	
23-17	4688-4699	unmedicated	_	
23-18	4700-4701	(	_	
23-19	4701-4704	not	_	
23-20	4705-4716	necessarily	_	
23-21	4717-4722	first	_	
23-22	4723-4730	episode	_	
23-23	4730-4731	)	_	
23-24	4732-4740	patients	_	
23-25	4741-4745	with	_	
23-26	4746-4751	acute	_	
23-27	4752-4761	psychosis	_	
23-28	4761-4762	.	_	

#Text=However, it is unclear whether novelty processing is disrupted in key dopaminergic regions for salience processing, such as the SN/VTA.
24-1	4763-4770	However	_	
24-2	4770-4771	,	_	
24-3	4772-4774	it	_	
24-4	4775-4777	is	_	
24-5	4778-4785	unclear	_	
24-6	4786-4793	whether	_	
24-7	4794-4801	novelty	_	
24-8	4802-4812	processing	_	
24-9	4813-4815	is	_	
24-10	4816-4825	disrupted	_	
24-11	4826-4828	in	_	
24-12	4829-4832	key	_	
24-13	4833-4845	dopaminergic	_	
24-14	4846-4853	regions	_	
24-15	4854-4857	for	_	
24-16	4858-4866	salience	_	
24-17	4867-4877	processing	_	
24-18	4877-4878	,	_	
24-19	4879-4883	such	_	
24-20	4884-4886	as	_	
24-21	4887-4890	the	_	
24-22	4891-4893	SN	_	
24-23	4893-4894	/	_	
24-24	4894-4897	VTA	_	
24-25	4897-4898	.	_	

#Text=Emotional events are also salient, capture attention, enhance memory and modify behavioural responses.
25-1	4899-4908	Emotional	_	
25-2	4909-4915	events	_	
25-3	4916-4919	are	_	
25-4	4920-4924	also	_	
25-5	4925-4932	salient	_	
25-6	4932-4933	,	_	
25-7	4934-4941	capture	_	
25-8	4942-4951	attention	_	
25-9	4951-4952	,	_	
25-10	4953-4960	enhance	_	
25-11	4961-4967	memory	_	
25-12	4968-4971	and	_	
25-13	4972-4978	modify	_	
25-14	4979-4990	behavioural	_	
25-15	4991-5000	responses	_	
25-16	5000-5001	.	_	

#Text=Presynaptic DA levels in the amygdala and SN/VTA predict brain activity in response to emotional salience.
26-1	5002-5013	Presynaptic	_	
26-2	5014-5016	DA	_	
26-3	5017-5023	levels	_	
26-4	5024-5026	in	_	
26-5	5027-5030	the	_	
26-6	5031-5039	amygdala	_	
26-7	5040-5043	and	_	
26-8	5044-5046	SN	_	
26-9	5046-5047	/	_	
26-10	5047-5050	VTA	_	
26-11	5051-5058	predict	_	
26-12	5059-5064	brain	_	
26-13	5065-5073	activity	_	
26-14	5074-5076	in	_	
26-15	5077-5085	response	_	
26-16	5086-5088	to	_	
26-17	5089-5098	emotional	_	
26-18	5099-5107	salience	_	
26-19	5107-5108	.	_	

#Text=Schizophrenia and first episode psychosis patients have problems processing emotions, especially in the context of facial recognition.
27-1	5109-5122	Schizophrenia	_	
27-2	5123-5126	and	_	
27-3	5127-5132	first	_	
27-4	5133-5140	episode	_	
27-5	5141-5150	psychosis	_	
27-6	5151-5159	patients	_	
27-7	5160-5164	have	_	
27-8	5165-5173	problems	_	
27-9	5174-5184	processing	_	
27-10	5185-5193	emotions	_	
27-11	5193-5194	,	_	
27-12	5195-5205	especially	_	
27-13	5206-5208	in	_	
27-14	5209-5212	the	_	
27-15	5213-5220	context	_	
27-16	5221-5223	of	_	
27-17	5224-5230	facial	_	
27-18	5231-5242	recognition	_	
27-19	5242-5243	.	_	

#Text=In a PET study, Taylor and colleagues showed impaired neural processing in the ventral striatum in response to emotional salient events in chronic and acute psychosis patients.
28-1	5244-5246	In	_	
28-2	5247-5248	a	_	
28-3	5249-5252	PET	_	
28-4	5253-5258	study	_	
28-5	5258-5259	,	_	
28-6	5260-5266	Taylor	_	
28-7	5267-5270	and	_	
28-8	5271-5281	colleagues	_	
28-9	5282-5288	showed	_	
28-10	5289-5297	impaired	_	
28-11	5298-5304	neural	_	
28-12	5305-5315	processing	_	
28-13	5316-5318	in	_	
28-14	5319-5322	the	_	
28-15	5323-5330	ventral	_	
28-16	5331-5339	striatum	_	
28-17	5340-5342	in	_	
28-18	5343-5351	response	_	
28-19	5352-5354	to	_	
28-20	5355-5364	emotional	_	
28-21	5365-5372	salient	_	
28-22	5373-5379	events	_	
28-23	5380-5382	in	_	
28-24	5383-5390	chronic	_	
28-25	5391-5394	and	_	
28-26	5395-5400	acute	_	
28-27	5401-5410	psychosis	_	
28-28	5411-5419	patients	_	
28-29	5419-5420	.	_	

#Text=However, results regarding processing alterations in the amygdala were unclear.
29-1	5421-5428	However	_	
29-2	5428-5429	,	_	
29-3	5430-5437	results	_	
29-4	5438-5447	regarding	_	
29-5	5448-5458	processing	_	
29-6	5459-5470	alterations	_	
29-7	5471-5473	in	_	
29-8	5474-5477	the	_	
29-9	5478-5486	amygdala	_	
29-10	5487-5491	were	_	
29-11	5492-5499	unclear	_	
29-12	5499-5500	.	_	

#Text=Furthermore, it is unknown whether processing of the dopaminergic SN/VTA is altered in psychosis in response to emotional salience.
30-1	5501-5512	Furthermore	_	
30-2	5512-5513	,	_	
30-3	5514-5516	it	_	
30-4	5517-5519	is	_	
30-5	5520-5527	unknown	_	
30-6	5528-5535	whether	_	
30-7	5536-5546	processing	_	
30-8	5547-5549	of	_	
30-9	5550-5553	the	_	
30-10	5554-5566	dopaminergic	_	
30-11	5567-5569	SN	_	
30-12	5569-5570	/	_	
30-13	5570-5573	VTA	_	
30-14	5574-5576	is	_	
30-15	5577-5584	altered	_	
30-16	5585-5587	in	_	
30-17	5588-5597	psychosis	_	
30-18	5598-5600	in	_	
30-19	5601-5609	response	_	
30-20	5610-5612	to	_	
30-21	5613-5622	emotional	_	
30-22	5623-5631	salience	_	
30-23	5631-5632	.	_	

#Text=Various studies suggest that SN/VTA neurons respond to a general form of salience (see reviews in Refs. ), sometimes referred to as ‘physical salience’ or ‘alerting’ salience, which is triggered by unexpected sensory events including surprise, attention, arousal, or novelty.
31-1	5633-5640	Various	_	
31-2	5641-5648	studies	_	
31-3	5649-5656	suggest	_	
31-4	5657-5661	that	_	
31-5	5662-5664	SN	_	
31-6	5664-5665	/	_	
31-7	5665-5668	VTA	_	
31-8	5669-5676	neurons	_	
31-9	5677-5684	respond	_	
31-10	5685-5687	to	_	
31-11	5688-5689	a	_	
31-12	5690-5697	general	_	
31-13	5698-5702	form	_	
31-14	5703-5705	of	_	
31-15	5706-5714	salience	_	
31-16	5715-5716	(	_	
31-17	5716-5719	see	_	
31-18	5720-5727	reviews	_	
31-19	5728-5730	in	_	
31-20	5731-5735	Refs	_	
31-21	5735-5736	.	_	
31-22	5737-5738	)	_	
31-23	5738-5739	,	_	
31-24	5740-5749	sometimes	_	
31-25	5750-5758	referred	_	
31-26	5759-5761	to	_	
31-27	5762-5764	as	_	
31-28	5765-5766	‘	_	
31-29	5766-5774	physical	_	
31-30	5775-5783	salience	_	
31-31	5783-5784	’	_	
31-32	5785-5787	or	_	
31-33	5788-5789	‘	_	
31-34	5789-5797	alerting	_	
31-35	5797-5798	’	_	
31-36	5799-5807	salience	_	
31-37	5807-5808	,	_	
31-38	5809-5814	which	_	
31-39	5815-5817	is	_	
31-40	5818-5827	triggered	_	
31-41	5828-5830	by	_	
31-42	5831-5841	unexpected	_	
31-43	5842-5849	sensory	_	
31-44	5850-5856	events	_	
31-45	5857-5866	including	_	
31-46	5867-5875	surprise	_	
31-47	5875-5876	,	_	
31-48	5877-5886	attention	_	
31-49	5886-5887	,	_	
31-50	5888-5895	arousal	_	
31-51	5895-5896	,	_	
31-52	5897-5899	or	_	
31-53	5900-5907	novelty	_	
31-54	5907-5908	.	_	

#Text=If dopaminergic signalling is generally compromised in psychosis, it then follows that there should be overlapping patterns of abnormal activation to various forms of salient stimuli in the dopaminergic midbrain and associated target regions in psychosis patients.
32-1	5909-5911	If	_	
32-2	5912-5924	dopaminergic	_	
32-3	5925-5935	signalling	_	
32-4	5936-5938	is	_	
32-5	5939-5948	generally	_	
32-6	5949-5960	compromised	_	
32-7	5961-5963	in	_	
32-8	5964-5973	psychosis	_	
32-9	5973-5974	,	_	
32-10	5975-5977	it	_	
32-11	5978-5982	then	_	
32-12	5983-5990	follows	_	
32-13	5991-5995	that	_	
32-14	5996-6001	there	_	
32-15	6002-6008	should	_	
32-16	6009-6011	be	_	
32-17	6012-6023	overlapping	_	
32-18	6024-6032	patterns	_	
32-19	6033-6035	of	_	
32-20	6036-6044	abnormal	_	
32-21	6045-6055	activation	_	
32-22	6056-6058	to	_	
32-23	6059-6066	various	_	
32-24	6067-6072	forms	_	
32-25	6073-6075	of	_	
32-26	6076-6083	salient	_	
32-27	6084-6091	stimuli	_	
32-28	6092-6094	in	_	
32-29	6095-6098	the	_	
32-30	6099-6111	dopaminergic	_	
32-31	6112-6120	midbrain	_	
32-32	6121-6124	and	_	
32-33	6125-6135	associated	_	
32-34	6136-6142	target	_	
32-35	6143-6150	regions	_	
32-36	6151-6153	in	_	
32-37	6154-6163	psychosis	_	
32-38	6164-6172	patients	_	
32-39	6172-6173	.	_	

#Text=Under an alternative account, salience processing may still be generally impaired in psychosis, but this may be secondary to dysfunction of diverse neural systems.
33-1	6174-6179	Under	_	
33-2	6180-6182	an	_	
33-3	6183-6194	alternative	_	
33-4	6195-6202	account	_	
33-5	6202-6203	,	_	
33-6	6204-6212	salience	_	
33-7	6213-6223	processing	_	
33-8	6224-6227	may	_	
33-9	6228-6233	still	_	
33-10	6234-6236	be	_	
33-11	6237-6246	generally	_	
33-12	6247-6255	impaired	_	
33-13	6256-6258	in	_	
33-14	6259-6268	psychosis	_	
33-15	6268-6269	,	_	
33-16	6270-6273	but	_	
33-17	6274-6278	this	_	
33-18	6279-6282	may	_	
33-19	6283-6285	be	_	
33-20	6286-6295	secondary	_	
33-21	6296-6298	to	_	
33-22	6299-6310	dysfunction	_	
33-23	6311-6313	of	_	
33-24	6314-6321	diverse	_	
33-25	6322-6328	neural	_	
33-26	6329-6336	systems	_	
33-27	6336-6337	.	_	

#Text=In the current study, we, therefore, investigated brain responses in the SN/VTA and other target areas to four types of salience—stimulus novelty, negative emotional salience, rareness/deviance (or ‘contextual deviance’), and targetness (task-driven attentional salience)—in patients with early psychosis and healthy volunteers.
34-1	6338-6340	In	_	
34-2	6341-6344	the	_	
34-3	6345-6352	current	_	
34-4	6353-6358	study	_	
34-5	6358-6359	,	_	
34-6	6360-6362	we	_	
34-7	6362-6363	,	_	
34-8	6364-6373	therefore	_	
34-9	6373-6374	,	_	
34-10	6375-6387	investigated	_	
34-11	6388-6393	brain	_	
34-12	6394-6403	responses	_	
34-13	6404-6406	in	_	
34-14	6407-6410	the	_	
34-15	6411-6413	SN	_	
34-16	6413-6414	/	_	
34-17	6414-6417	VTA	_	
34-18	6418-6421	and	_	
34-19	6422-6427	other	_	
34-20	6428-6434	target	_	
34-21	6435-6440	areas	_	
34-22	6441-6443	to	_	
34-23	6444-6448	four	_	
34-24	6449-6454	types	_	
34-25	6455-6457	of	_	
34-26	6458-6475	salience—stimulus	_	
34-27	6476-6483	novelty	_	
34-28	6483-6484	,	_	
34-29	6485-6493	negative	_	
34-30	6494-6503	emotional	_	
34-31	6504-6512	salience	_	
34-32	6512-6513	,	_	
34-33	6514-6522	rareness	_	
34-34	6522-6523	/	_	
34-35	6523-6531	deviance	_	
34-36	6532-6533	(	_	
34-37	6533-6535	or	_	
34-38	6536-6537	‘	_	
34-39	6537-6547	contextual	_	
34-40	6548-6556	deviance	_	
34-41	6556-6557	’	_	
34-42	6557-6558	)	_	
34-43	6558-6559	,	_	
34-44	6560-6563	and	_	
34-45	6564-6574	targetness	_	
34-46	6575-6576	(	_	
34-47	6576-6587	task-driven	_	
34-48	6588-6599	attentional	_	
34-49	6600-6608	salience	_	
34-50	6608-6609	)	_	
34-51	6609-6610	—	_	
34-52	6610-6612	in	_	
34-53	6613-6621	patients	_	
34-54	6622-6626	with	_	
34-55	6627-6632	early	_	
34-56	6633-6642	psychosis	_	
34-57	6643-6646	and	_	
34-58	6647-6654	healthy	_	
34-59	6655-6665	volunteers	_	
34-60	6665-6666	.	_	

#Text=By focussing on early psychosis, we can avoid confounds of exposure to dopaminergic medications and other effects of chronic illness.
35-1	6667-6669	By	_	
35-2	6670-6679	focussing	_	
35-3	6680-6682	on	_	
35-4	6683-6688	early	_	
35-5	6689-6698	psychosis	_	
35-6	6698-6699	,	_	
35-7	6700-6702	we	_	
35-8	6703-6706	can	_	
35-9	6707-6712	avoid	_	
35-10	6713-6722	confounds	_	
35-11	6723-6725	of	_	
35-12	6726-6734	exposure	_	
35-13	6735-6737	to	_	
35-14	6738-6750	dopaminergic	_	
35-15	6751-6762	medications	_	
35-16	6763-6766	and	_	
35-17	6767-6772	other	_	
35-18	6773-6780	effects	_	
35-19	6781-6783	of	_	
35-20	6784-6791	chronic	_	
35-21	6792-6799	illness	_	
35-22	6799-6800	.	_	

#Text=We used a fMRI paradigm that previously was shown to significantly activate parts of the midbrain, amygdala and striatum to various forms of salience, and which importantly provides a baseline condition (a neutral oddball event) that is matched in frequency with other conditions of interest.
36-1	6801-6803	We	_	
36-2	6804-6808	used	_	
36-3	6809-6810	a	_	
36-4	6811-6815	fMRI	_	
36-5	6816-6824	paradigm	_	
36-6	6825-6829	that	_	
36-7	6830-6840	previously	_	
36-8	6841-6844	was	_	
36-9	6845-6850	shown	_	
36-10	6851-6853	to	_	
36-11	6854-6867	significantly	_	
36-12	6868-6876	activate	_	
36-13	6877-6882	parts	_	
36-14	6883-6885	of	_	
36-15	6886-6889	the	_	
36-16	6890-6898	midbrain	_	
36-17	6898-6899	,	_	
36-18	6900-6908	amygdala	_	
36-19	6909-6912	and	_	
36-20	6913-6921	striatum	_	
36-21	6922-6924	to	_	
36-22	6925-6932	various	_	
36-23	6933-6938	forms	_	
36-24	6939-6941	of	_	
36-25	6942-6950	salience	_	
36-26	6950-6951	,	_	
36-27	6952-6955	and	_	
36-28	6956-6961	which	_	
36-29	6962-6973	importantly	_	
36-30	6974-6982	provides	_	
36-31	6983-6984	a	_	
36-32	6985-6993	baseline	_	
36-33	6994-7003	condition	_	
36-34	7004-7005	(	_	
36-35	7005-7006	a	_	
36-36	7007-7014	neutral	_	
36-37	7015-7022	oddball	_	
36-38	7023-7028	event	_	
36-39	7028-7029	)	_	
36-40	7030-7034	that	_	
36-41	7035-7037	is	_	
36-42	7038-7045	matched	_	
36-43	7046-7048	in	_	
36-44	7049-7058	frequency	_	
36-45	7059-7063	with	_	
36-46	7064-7069	other	_	
36-47	7070-7080	conditions	_	
36-48	7081-7083	of	_	
36-49	7084-7092	interest	_	
36-50	7092-7093	.	_	

#Text=Based on the potentially general role in salience signalling of DA neurons in the SN/VTA and the ‘aberrant salience’ hypothesis of psychosis, we hypothesised that psychosis patients demonstrate altered SN/VTA and striatal responses to novelty, negative emotional salience and targetness.
37-1	7094-7099	Based	_	
37-2	7100-7102	on	_	
37-3	7103-7106	the	_	
37-4	7107-7118	potentially	_	
37-5	7119-7126	general	_	
37-6	7127-7131	role	_	
37-7	7132-7134	in	_	
37-8	7135-7143	salience	_	
37-9	7144-7154	signalling	_	
37-10	7155-7157	of	_	
37-11	7158-7160	DA	_	
37-12	7161-7168	neurons	_	
37-13	7169-7171	in	_	
37-14	7172-7175	the	_	
37-15	7176-7178	SN	_	
37-16	7178-7179	/	_	
37-17	7179-7182	VTA	_	
37-18	7183-7186	and	_	
37-19	7187-7190	the	_	
37-20	7191-7192	‘	_	
37-21	7192-7200	aberrant	_	
37-22	7201-7209	salience	_	
37-23	7209-7210	’	_	
37-24	7211-7221	hypothesis	_	
37-25	7222-7224	of	_	
37-26	7225-7234	psychosis	_	
37-27	7234-7235	,	_	
37-28	7236-7238	we	_	
37-29	7239-7251	hypothesised	_	
37-30	7252-7256	that	_	
37-31	7257-7266	psychosis	_	
37-32	7267-7275	patients	_	
37-33	7276-7287	demonstrate	_	
37-34	7288-7295	altered	_	
37-35	7296-7298	SN	_	
37-36	7298-7299	/	_	
37-37	7299-7302	VTA	_	
37-38	7303-7306	and	_	
37-39	7307-7315	striatal	_	
37-40	7316-7325	responses	_	
37-41	7326-7328	to	_	
37-42	7329-7336	novelty	_	
37-43	7336-7337	,	_	
37-44	7338-7346	negative	_	
37-45	7347-7356	emotional	_	
37-46	7357-7365	salience	_	
37-47	7366-7369	and	_	
37-48	7370-7380	targetness	_	
37-49	7380-7381	.	_	

#Text=Furthermore, we predicted to find group differences in the prefrontal cortex in response to novelty, in the amygdala in response to emotional salience, and in the hippocampus in responses to all forms of salience.
38-1	7382-7393	Furthermore	_	
38-2	7393-7394	,	_	
38-3	7395-7397	we	_	
38-4	7398-7407	predicted	_	
38-5	7408-7410	to	_	
38-6	7411-7415	find	_	
38-7	7416-7421	group	_	
38-8	7422-7433	differences	_	
38-9	7434-7436	in	_	
38-10	7437-7440	the	_	
38-11	7441-7451	prefrontal	_	
38-12	7452-7458	cortex	_	
38-13	7459-7461	in	_	
38-14	7462-7470	response	_	
38-15	7471-7473	to	_	
38-16	7474-7481	novelty	_	
38-17	7481-7482	,	_	
38-18	7483-7485	in	_	
38-19	7486-7489	the	_	
38-20	7490-7498	amygdala	_	
38-21	7499-7501	in	_	
38-22	7502-7510	response	_	
38-23	7511-7513	to	_	
38-24	7514-7523	emotional	_	
38-25	7524-7532	salience	_	
38-26	7532-7533	,	_	
38-27	7534-7537	and	_	
38-28	7538-7540	in	_	
38-29	7541-7544	the	_	
38-30	7545-7556	hippocampus	_	
38-31	7557-7559	in	_	
38-32	7560-7569	responses	_	
38-33	7570-7572	to	_	
38-34	7573-7576	all	_	
38-35	7577-7582	forms	_	
38-36	7583-7585	of	_	
38-37	7586-7594	salience	_	
38-38	7594-7595	.	_	

#Text=Methods
#Text=Subjects
#Text=Sample characteristics for healthy controls, and patients with first-episode psychosis (FEP)
#Text=Variable\tControls (n = 34)\t\tFEP (n = 13)\t\t\tGroup statistics\t \t\tMean\tSD\tMean\tSD\t\tt\tdf\tp\t \tAge (years)\t22.85\t3.3\t23.85\t6.3\t\t0.21\t47\t0.48\t \tGender (male/female)\t18/16\t8/6\t\t0.45\t47\t0.61\t\t\t \tHandedness (right/left)\t27/7\t9/3 (1 missing)\t\t0.06\t46\t0.76\t\t\t \tIQ\t119.4\t18.2\t105.1\t16.2\t\t3.03\t47\t0.02\t \tLevel of education\t2.47\t0.8\t2.38\t1.1\t\t0.51\t47\t0.77\t \tMother’s level of education\t2.36\t1.1\t2.73\t1.3\t\t0.8\t43\t0.36\t \tSmoking (yes/no)\t0.32\t0.5\t0.54\t0.5\t\t1.61\t46\t0.18\t \tAlcohol\t2.6\t0.7\t1.54\t1.5\t\t3.34\t46\t0.002\t \tCannabis\t0.85\t0.8\t1.38\t1.6\t\t2.08\t45\t0.12\t \tHallucinogens\t0.21\t0.5\t0.46\t0.7\t\t1.32\t46\t0.15\t \tStimulants\t0.41\t0.7\t0.77\t0.8\t\t1.87\t46\t0.15\t \tDepressants\t0.06\t0.2\t0.23\t0.6\t\t1.33\t46\t0.16\t \t
#Text=Education was measured on a 5-point scale (from no education to higher university degree).
39-1	7596-7603	Methods	http://www.case.edu/ProvCaRe/provcare#StudyMethod	
39-2	7604-7612	Subjects	_	
39-3	7613-7619	Sample	_	
39-4	7620-7635	characteristics	_	
39-5	7636-7639	for	_	
39-6	7640-7647	healthy	_	
39-7	7648-7656	controls	_	
39-8	7656-7657	,	_	
39-9	7658-7661	and	_	
39-10	7662-7670	patients	_	
39-11	7671-7675	with	_	
39-12	7676-7689	first-episode	_	
39-13	7690-7699	psychosis	_	
39-14	7700-7701	(	_	
39-15	7701-7704	FEP	_	
39-16	7704-7705	)	_	
39-17	7706-7714	Variable	_	
39-18	7715-7723	Controls	_	
39-19	7724-7725	(	_	
39-20	7725-7726	n	_	
39-21	7727-7728	=	_	
39-22	7729-7731	34	_	
39-23	7731-7732	)	_	
39-24	7734-7737	FEP	_	
39-25	7738-7739	(	_	
39-26	7739-7740	n	_	
39-27	7741-7742	=	_	
39-28	7743-7745	13	_	
39-29	7745-7746	)	_	
39-30	7749-7754	Group	_	
39-31	7755-7765	statistics	_	
39-32	7769-7773	Mean	_	
39-33	7774-7776	SD	_	
39-34	7777-7781	Mean	_	
39-35	7782-7784	SD	_	
39-36	7786-7787	t	_	
39-37	7788-7790	df	_	
39-38	7791-7792	p	_	
39-39	7795-7798	Age	_	
39-40	7799-7800	(	_	
39-41	7800-7805	years	_	
39-42	7805-7806	)	_	
39-43	7807-7812	22.85	_	
39-44	7813-7816	3.3	_	
39-45	7817-7822	23.85	_	
39-46	7823-7826	6.3	_	
39-47	7828-7832	0.21	_	
39-48	7833-7835	47	_	
39-49	7836-7840	0.48	_	
39-50	7843-7849	Gender	_	
39-51	7850-7851	(	_	
39-52	7851-7855	male	_	
39-53	7855-7856	/	_	
39-54	7856-7862	female	_	
39-55	7862-7863	)	_	
39-56	7864-7866	18	_	
39-57	7866-7867	/	_	
39-58	7867-7869	16	_	
39-59	7870-7871	8	_	
39-60	7871-7872	/	_	
39-61	7872-7873	6	_	
39-62	7875-7879	0.45	_	
39-63	7880-7882	47	_	
39-64	7883-7887	0.61	_	
39-65	7892-7902	Handedness	_	
39-66	7903-7904	(	_	
39-67	7904-7909	right	_	
39-68	7909-7910	/	_	
39-69	7910-7914	left	_	
39-70	7914-7915	)	_	
39-71	7916-7918	27	_	
39-72	7918-7919	/	_	
39-73	7919-7920	7	_	
39-74	7921-7922	9	_	
39-75	7922-7923	/	_	
39-76	7923-7924	3	_	
39-77	7925-7926	(	_	
39-78	7926-7927	1	_	
39-79	7928-7935	missing	_	
39-80	7935-7936	)	_	
39-81	7938-7942	0.06	_	
39-82	7943-7945	46	_	
39-83	7946-7950	0.76	_	
39-84	7955-7957	IQ	_	
39-85	7958-7963	119.4	_	
39-86	7964-7968	18.2	_	
39-87	7969-7974	105.1	_	
39-88	7975-7979	16.2	_	
39-89	7981-7985	3.03	_	
39-90	7986-7988	47	_	
39-91	7989-7993	0.02	_	
39-92	7996-8001	Level	_	
39-93	8002-8004	of	_	
39-94	8005-8014	education	_	
39-95	8015-8019	2.47	_	
39-96	8020-8023	0.8	_	
39-97	8024-8028	2.38	_	
39-98	8029-8032	1.1	_	
39-99	8034-8038	0.51	_	
39-100	8039-8041	47	_	
39-101	8042-8046	0.77	_	
39-102	8049-8055	Mother	_	
39-103	8055-8056	’	_	
39-104	8056-8057	s	_	
39-105	8058-8063	level	_	
39-106	8064-8066	of	_	
39-107	8067-8076	education	_	
39-108	8077-8081	2.36	_	
39-109	8082-8085	1.1	_	
39-110	8086-8090	2.73	_	
39-111	8091-8094	1.3	_	
39-112	8096-8099	0.8	_	
39-113	8100-8102	43	_	
39-114	8103-8107	0.36	_	
39-115	8110-8117	Smoking	_	
39-116	8118-8119	(	_	
39-117	8119-8122	yes	_	
39-118	8122-8123	/	_	
39-119	8123-8125	no	_	
39-120	8125-8126	)	_	
39-121	8127-8131	0.32	_	
39-122	8132-8135	0.5	_	
39-123	8136-8140	0.54	_	
39-124	8141-8144	0.5	_	
39-125	8146-8150	1.61	_	
39-126	8151-8153	46	_	
39-127	8154-8158	0.18	_	
39-128	8161-8168	Alcohol	_	
39-129	8169-8172	2.6	_	
39-130	8173-8176	0.7	_	
39-131	8177-8181	1.54	_	
39-132	8182-8185	1.5	_	
39-133	8187-8191	3.34	_	
39-134	8192-8194	46	_	
39-135	8195-8200	0.002	_	
39-136	8203-8211	Cannabis	_	
39-137	8212-8216	0.85	_	
39-138	8217-8220	0.8	_	
39-139	8221-8225	1.38	_	
39-140	8226-8229	1.6	_	
39-141	8231-8235	2.08	_	
39-142	8236-8238	45	_	
39-143	8239-8243	0.12	_	
39-144	8246-8259	Hallucinogens	_	
39-145	8260-8264	0.21	_	
39-146	8265-8268	0.5	_	
39-147	8269-8273	0.46	_	
39-148	8274-8277	0.7	_	
39-149	8279-8283	1.32	_	
39-150	8284-8286	46	_	
39-151	8287-8291	0.15	_	
39-152	8294-8304	Stimulants	_	
39-153	8305-8309	0.41	_	
39-154	8310-8313	0.7	_	
39-155	8314-8318	0.77	_	
39-156	8319-8322	0.8	_	
39-157	8324-8328	1.87	_	
39-158	8329-8331	46	_	
39-159	8332-8336	0.15	_	
39-160	8339-8350	Depressants	_	
39-161	8351-8355	0.06	_	
39-162	8356-8359	0.2	_	
39-163	8360-8364	0.23	_	
39-164	8365-8368	0.6	_	
39-165	8370-8374	1.33	_	
39-166	8375-8377	46	_	
39-167	8378-8382	0.16	_	
39-168	8386-8395	Education	_	
39-169	8396-8399	was	_	
39-170	8400-8408	measured	_	
39-171	8409-8411	on	_	
39-172	8412-8413	a	_	
39-173	8414-8415	5	_	
39-174	8415-8416	-	_	
39-175	8416-8421	point	_	
39-176	8422-8427	scale	_	
39-177	8428-8429	(	_	
39-178	8429-8433	from	_	
39-179	8434-8436	no	_	
39-180	8437-8446	education	_	
39-181	8447-8449	to	_	
39-182	8450-8456	higher	_	
39-183	8457-8467	university	_	
39-184	8468-8474	degree	_	
39-185	8474-8475	)	_	
39-186	8475-8476	.	_	

#Text=Intelligence was measured with the culture fair intelligence test.
40-1	8477-8489	Intelligence	_	
40-2	8490-8493	was	_	
40-3	8494-8502	measured	_	
40-4	8503-8507	with	_	
40-5	8508-8511	the	_	
40-6	8512-8519	culture	_	
40-7	8520-8524	fair	_	
40-8	8525-8537	intelligence	_	
40-9	8538-8542	test	_	
40-10	8542-8543	.	_	

#Text=Smoking: 0 = non-smoker, 1 = smoker.
41-1	8544-8551	Smoking	_	
41-2	8551-8552	:	_	
41-3	8553-8554	0	_	
41-4	8555-8556	=	_	
41-5	8557-8567	non-smoker	_	
41-6	8567-8568	,	_	
41-7	8569-8570	1	_	
41-8	8571-8572	=	_	
41-9	8573-8579	smoker	_	
41-10	8579-8580	.	_	

#Text=Substance use was measured on a 5-point scale (from 0 = never used to 5 = daily user).
42-1	8581-8590	Substance	_	
42-2	8591-8594	use	_	
42-3	8595-8598	was	_	
42-4	8599-8607	measured	_	
42-5	8608-8610	on	_	
42-6	8611-8612	a	_	
42-7	8613-8614	5	_	
42-8	8614-8615	-	_	
42-9	8615-8620	point	_	
42-10	8621-8626	scale	_	
42-11	8627-8628	(	_	
42-12	8628-8632	from	_	
42-13	8633-8634	0	_	
42-14	8635-8636	=	_	
42-15	8637-8642	never	_	
42-16	8643-8647	used	_	
42-17	8648-8650	to	_	
42-18	8651-8652	5	_	
42-19	8653-8654	=	_	
42-20	8655-8660	daily	_	
42-21	8661-8665	user	_	
42-22	8665-8666	)	_	
42-23	8666-8667	.	_	

#Text=Bold values indicate significant differences
#Text=Clinical assessment of the participants
#Text=Variable\tControls (n = 34)\tFEP (n = 13)\tGroup statistics\t\t\t \t\tMean\tSD\tMean\tSD\tt\tdf\tp\t \tPANSS positive\t0.97\t0.2\t2.2\t0.7\t10.1\t45\t < 0.001\t \tP1\t0.97\t0.2\t3.2\t1.6\t7.86\t45\t < 0.001\t \tP2\t0.97\t0.2\t1.3\t0.9\t2.22\t45\t < 0.001\t \tP3\t0.97\t0.2\t3.4\t1.6\t9.06\t45\t < 0.001\t \tSANS score\t0.09\t0.3\t0.3\t0.6\t1.6\t45\t0.116\t \tBDI\t3.4\t3.9\t27.8\t10.7\t11.1\t41\t < 0.001\t \t
#Text=FEP first episode psychosis patients.
43-1	8668-8672	Bold	_	
43-2	8673-8679	values	_	
43-3	8680-8688	indicate	_	
43-4	8689-8700	significant	_	
43-5	8701-8712	differences	_	
43-6	8713-8721	Clinical	_	
43-7	8722-8732	assessment	_	
43-8	8733-8735	of	_	
43-9	8736-8739	the	_	
43-10	8740-8752	participants	_	
43-11	8753-8761	Variable	_	
43-12	8762-8770	Controls	_	
43-13	8771-8772	(	_	
43-14	8772-8773	n	_	
43-15	8774-8775	=	_	
43-16	8776-8778	34	_	
43-17	8778-8779	)	_	
43-18	8780-8783	FEP	_	
43-19	8784-8785	(	_	
43-20	8785-8786	n	_	
43-21	8787-8788	=	_	
43-22	8789-8791	13	_	
43-23	8791-8792	)	_	
43-24	8793-8798	Group	_	
43-25	8799-8809	statistics	_	
43-26	8815-8819	Mean	_	
43-27	8820-8822	SD	_	
43-28	8823-8827	Mean	_	
43-29	8828-8830	SD	_	
43-30	8831-8832	t	_	
43-31	8833-8835	df	_	
43-32	8836-8837	p	_	
43-33	8840-8845	PANSS	_	
43-34	8846-8854	positive	_	
43-35	8855-8859	0.97	_	
43-36	8860-8863	0.2	_	
43-37	8864-8867	2.2	_	
43-38	8868-8871	0.7	_	
43-39	8872-8876	10.1	_	
43-40	8877-8879	45	_	
43-41	8881-8882	<	_	
43-42	8883-8888	0.001	_	
43-43	8891-8893	P1	_	
43-44	8894-8898	0.97	_	
43-45	8899-8902	0.2	_	
43-46	8903-8906	3.2	_	
43-47	8907-8910	1.6	_	
43-48	8911-8915	7.86	_	
43-49	8916-8918	45	_	
43-50	8920-8921	<	_	
43-51	8922-8927	0.001	_	
43-52	8930-8932	P2	_	
43-53	8933-8937	0.97	_	
43-54	8938-8941	0.2	_	
43-55	8942-8945	1.3	_	
43-56	8946-8949	0.9	_	
43-57	8950-8954	2.22	_	
43-58	8955-8957	45	_	
43-59	8959-8960	<	_	
43-60	8961-8966	0.001	_	
43-61	8969-8971	P3	_	
43-62	8972-8976	0.97	_	
43-63	8977-8980	0.2	_	
43-64	8981-8984	3.4	_	
43-65	8985-8988	1.6	_	
43-66	8989-8993	9.06	_	
43-67	8994-8996	45	_	
43-68	8998-8999	<	_	
43-69	9000-9005	0.001	_	
43-70	9008-9012	SANS	_	
43-71	9013-9018	score	_	
43-72	9019-9023	0.09	_	
43-73	9024-9027	0.3	_	
43-74	9028-9031	0.3	_	
43-75	9032-9035	0.6	_	
43-76	9036-9039	1.6	_	
43-77	9040-9042	45	_	
43-78	9043-9048	0.116	_	
43-79	9051-9054	BDI	_	
43-80	9055-9058	3.4	_	
43-81	9059-9062	3.9	_	
43-82	9063-9067	27.8	_	
43-83	9068-9072	10.7	_	
43-84	9073-9077	11.1	_	
43-85	9078-9080	41	_	
43-86	9082-9083	<	_	
43-87	9084-9089	0.001	_	
43-88	9093-9096	FEP	_	
43-89	9097-9102	first	_	
43-90	9103-9110	episode	_	
43-91	9111-9120	psychosis	_	
43-92	9121-9129	patients	_	
43-93	9129-9130	.	_	

#Text=BDI Beck’s depression inventory.
44-1	9131-9134	BDI	_	
44-2	9135-9139	Beck	_	
44-3	9139-9140	’	_	
44-4	9140-9141	s	_	
44-5	9142-9152	depression	_	
44-6	9153-9162	inventory	_	
44-7	9162-9163	.	_	

#Text=PANSS positive and negative syndrome scale for schizophrenia.
45-1	9164-9169	PANSS	http://maven.renci.org/NeuroBridge/neurobridge#PositiveandNegativeSyndromeScale	
45-2	9170-9178	positive	_	
45-3	9179-9182	and	_	
45-4	9183-9191	negative	_	
45-5	9192-9200	syndrome	_	
45-6	9201-9206	scale	_	
45-7	9207-9210	for	_	
45-8	9211-9224	schizophrenia	http://maven.renci.org/NeuroBridge/neurobridge#Schizophrenia	
45-9	9224-9225	.	_	

#Text=P1 delusions, P2 conceptual disorganisation (thought disorder), P3 hallucinatory behaviour.
46-1	9226-9228	P1	_	
46-2	9229-9238	delusions	_	
46-3	9238-9239	,	_	
46-4	9240-9242	P2	_	
46-5	9243-9253	conceptual	_	
46-6	9254-9269	disorganisation	_	
46-7	9270-9271	(	_	
46-8	9271-9278	thought	_	
46-9	9279-9287	disorder	_	
46-10	9287-9288	)	_	
46-11	9288-9289	,	_	
46-12	9290-9292	P3	_	
46-13	9293-9306	hallucinatory	_	
46-14	9307-9316	behaviour	_	
46-15	9316-9317	.	_	

#Text=SANS scale for assessment of negative symptoms.
47-1	9318-9322	SANS	http://maven.renci.org/NeuroBridge/neurobridge#ScaleforAssessmentofNegativeSymptoms	
47-2	9323-9328	scale	_	
47-3	9329-9332	for	_	
47-4	9333-9343	assessment	_	
47-5	9344-9346	of	_	
47-6	9347-9355	negative	_	
47-7	9356-9364	symptoms	_	
47-8	9364-9365	.	_	

#Text=Bold values indicate significant differences
#Text=We recruited 14 antipsychotic naive individuals with first-episode psychosis and active psychotic symptoms from the Cambridge, early intervention service for psychosis, CAMEO.
48-1	9366-9370	Bold	_	
48-2	9371-9377	values	_	
48-3	9378-9386	indicate	_	
48-4	9387-9398	significant	_	
48-5	9399-9410	differences	_	
48-6	9411-9413	We	http://maven.renci.org/NeuroBridge/neurobridge#RecruitmentProtocol[2]	
48-7	9414-9423	recruited	http://maven.renci.org/NeuroBridge/neurobridge#RecruitmentProtocol[2]	
48-8	9424-9426	14	http://maven.renci.org/NeuroBridge/neurobridge#RecruitmentProtocol[2]	
48-9	9427-9440	antipsychotic	http://maven.renci.org/NeuroBridge/neurobridge#RecruitmentProtocol[2]	
48-10	9441-9446	naive	http://maven.renci.org/NeuroBridge/neurobridge#RecruitmentProtocol[2]	
48-11	9447-9458	individuals	http://maven.renci.org/NeuroBridge/neurobridge#RecruitmentProtocol[2]	
48-12	9459-9463	with	http://maven.renci.org/NeuroBridge/neurobridge#RecruitmentProtocol[2]	
48-13	9464-9477	first-episode	http://maven.renci.org/NeuroBridge/neurobridge#RecruitmentProtocol[2]	
48-14	9478-9487	psychosis	http://maven.renci.org/NeuroBridge/neurobridge#RecruitmentProtocol[2]|http://maven.renci.org/NeuroBridge/neurobridge#PsychoticDisorder[3]	
48-15	9488-9491	and	http://maven.renci.org/NeuroBridge/neurobridge#RecruitmentProtocol[2]	
48-16	9492-9498	active	http://maven.renci.org/NeuroBridge/neurobridge#RecruitmentProtocol[2]	
48-17	9499-9508	psychotic	http://maven.renci.org/NeuroBridge/neurobridge#RecruitmentProtocol[2]	
48-18	9509-9517	symptoms	http://maven.renci.org/NeuroBridge/neurobridge#RecruitmentProtocol[2]	
48-19	9518-9522	from	http://maven.renci.org/NeuroBridge/neurobridge#RecruitmentProtocol[2]	
48-20	9523-9526	the	http://maven.renci.org/NeuroBridge/neurobridge#RecruitmentProtocol[2]	
48-21	9527-9536	Cambridge	http://maven.renci.org/NeuroBridge/neurobridge#RecruitmentProtocol[2]	
48-22	9536-9537	,	http://maven.renci.org/NeuroBridge/neurobridge#RecruitmentProtocol[2]	
48-23	9538-9543	early	http://maven.renci.org/NeuroBridge/neurobridge#RecruitmentProtocol[2]	
48-24	9544-9556	intervention	http://maven.renci.org/NeuroBridge/neurobridge#RecruitmentProtocol[2]	
48-25	9557-9564	service	http://maven.renci.org/NeuroBridge/neurobridge#RecruitmentProtocol[2]	
48-26	9565-9568	for	http://maven.renci.org/NeuroBridge/neurobridge#RecruitmentProtocol[2]	
48-27	9569-9578	psychosis	http://maven.renci.org/NeuroBridge/neurobridge#RecruitmentProtocol[2]	
48-28	9578-9579	,	http://maven.renci.org/NeuroBridge/neurobridge#RecruitmentProtocol[2]	
48-29	9580-9585	CAMEO	http://maven.renci.org/NeuroBridge/neurobridge#RecruitmentProtocol[2]	
48-30	9585-9586	.	_	

#Text=Other inclusion criteria were as follows: age 16–35 years, meeting ICD-10 criteria for a schizophrenia spectrum disorder (ICD-10: F20, F22, F23, F25, F28 and F29) or affective psychosis (ICD-10: F30.2, F31.2 and F32.3).
49-1	9587-9592	Other	http://maven.renci.org/NeuroBridge/neurobridge#RecruitmentProtocol[4]	
49-2	9593-9602	inclusion	http://maven.renci.org/NeuroBridge/neurobridge#RecruitmentProtocol[4]	
49-3	9603-9611	criteria	http://maven.renci.org/NeuroBridge/neurobridge#RecruitmentProtocol[4]	
49-4	9612-9616	were	http://maven.renci.org/NeuroBridge/neurobridge#RecruitmentProtocol[4]	
49-5	9617-9619	as	http://maven.renci.org/NeuroBridge/neurobridge#RecruitmentProtocol[4]	
49-6	9620-9627	follows	http://maven.renci.org/NeuroBridge/neurobridge#RecruitmentProtocol[4]	
49-7	9627-9628	:	http://maven.renci.org/NeuroBridge/neurobridge#RecruitmentProtocol[4]	
49-8	9629-9632	age	http://maven.renci.org/NeuroBridge/neurobridge#RecruitmentProtocol[4]	
49-9	9633-9635	16	http://maven.renci.org/NeuroBridge/neurobridge#RecruitmentProtocol[4]	
49-10	9635-9636	–	http://maven.renci.org/NeuroBridge/neurobridge#RecruitmentProtocol[4]	
49-11	9636-9638	35	http://maven.renci.org/NeuroBridge/neurobridge#RecruitmentProtocol[4]	
49-12	9639-9644	years	http://maven.renci.org/NeuroBridge/neurobridge#RecruitmentProtocol[4]	
49-13	9644-9645	,	http://maven.renci.org/NeuroBridge/neurobridge#RecruitmentProtocol[4]	
49-14	9646-9653	meeting	http://maven.renci.org/NeuroBridge/neurobridge#RecruitmentProtocol[4]	
49-15	9654-9657	ICD	http://maven.renci.org/NeuroBridge/neurobridge#RecruitmentProtocol[4]	
49-16	9657-9658	-	http://maven.renci.org/NeuroBridge/neurobridge#RecruitmentProtocol[4]	
49-17	9658-9660	10	http://maven.renci.org/NeuroBridge/neurobridge#RecruitmentProtocol[4]	
49-18	9661-9669	criteria	http://maven.renci.org/NeuroBridge/neurobridge#RecruitmentProtocol[4]	
49-19	9670-9673	for	http://maven.renci.org/NeuroBridge/neurobridge#RecruitmentProtocol[4]	
49-20	9674-9675	a	http://maven.renci.org/NeuroBridge/neurobridge#RecruitmentProtocol[4]	
49-21	9676-9689	schizophrenia	http://maven.renci.org/NeuroBridge/neurobridge#RecruitmentProtocol[4]|http://maven.renci.org/NeuroBridge/neurobridge#Schizophrenia[5]	
49-22	9690-9698	spectrum	http://maven.renci.org/NeuroBridge/neurobridge#RecruitmentProtocol[4]	
49-23	9699-9707	disorder	http://maven.renci.org/NeuroBridge/neurobridge#RecruitmentProtocol[4]	
49-24	9708-9709	(	http://maven.renci.org/NeuroBridge/neurobridge#RecruitmentProtocol[4]	
49-25	9709-9712	ICD	http://maven.renci.org/NeuroBridge/neurobridge#RecruitmentProtocol[4]	
49-26	9712-9713	-	http://maven.renci.org/NeuroBridge/neurobridge#RecruitmentProtocol[4]	
49-27	9713-9715	10	http://maven.renci.org/NeuroBridge/neurobridge#RecruitmentProtocol[4]	
49-28	9715-9716	:	http://maven.renci.org/NeuroBridge/neurobridge#RecruitmentProtocol[4]	
49-29	9717-9720	F20	http://maven.renci.org/NeuroBridge/neurobridge#RecruitmentProtocol[4]	
49-30	9720-9721	,	http://maven.renci.org/NeuroBridge/neurobridge#RecruitmentProtocol[4]	
49-31	9722-9725	F22	http://maven.renci.org/NeuroBridge/neurobridge#RecruitmentProtocol[4]	
49-32	9725-9726	,	http://maven.renci.org/NeuroBridge/neurobridge#RecruitmentProtocol[4]	
49-33	9727-9730	F23	http://maven.renci.org/NeuroBridge/neurobridge#RecruitmentProtocol[4]	
49-34	9730-9731	,	http://maven.renci.org/NeuroBridge/neurobridge#RecruitmentProtocol[4]	
49-35	9732-9735	F25	http://maven.renci.org/NeuroBridge/neurobridge#RecruitmentProtocol[4]	
49-36	9735-9736	,	http://maven.renci.org/NeuroBridge/neurobridge#RecruitmentProtocol[4]	
49-37	9737-9740	F28	http://maven.renci.org/NeuroBridge/neurobridge#RecruitmentProtocol[4]	
49-38	9741-9744	and	http://maven.renci.org/NeuroBridge/neurobridge#RecruitmentProtocol[4]	
49-39	9745-9748	F29	http://maven.renci.org/NeuroBridge/neurobridge#RecruitmentProtocol[4]	
49-40	9748-9749	)	http://maven.renci.org/NeuroBridge/neurobridge#RecruitmentProtocol[4]	
49-41	9750-9752	or	http://maven.renci.org/NeuroBridge/neurobridge#RecruitmentProtocol[4]	
49-42	9753-9762	affective	http://maven.renci.org/NeuroBridge/neurobridge#RecruitmentProtocol[4]	
49-43	9763-9772	psychosis	http://maven.renci.org/NeuroBridge/neurobridge#RecruitmentProtocol[4]	
49-44	9773-9774	(	http://maven.renci.org/NeuroBridge/neurobridge#RecruitmentProtocol[4]	
49-45	9774-9777	ICD	http://maven.renci.org/NeuroBridge/neurobridge#RecruitmentProtocol[4]	
49-46	9777-9778	-	http://maven.renci.org/NeuroBridge/neurobridge#RecruitmentProtocol[4]	
49-47	9778-9780	10	http://maven.renci.org/NeuroBridge/neurobridge#RecruitmentProtocol[4]	
49-48	9780-9781	:	http://maven.renci.org/NeuroBridge/neurobridge#RecruitmentProtocol[4]	
49-49	9782-9787	F30.2	http://maven.renci.org/NeuroBridge/neurobridge#RecruitmentProtocol[4]	
49-50	9787-9788	,	http://maven.renci.org/NeuroBridge/neurobridge#RecruitmentProtocol[4]	
49-51	9789-9794	F31.2	http://maven.renci.org/NeuroBridge/neurobridge#RecruitmentProtocol[4]	
49-52	9795-9798	and	http://maven.renci.org/NeuroBridge/neurobridge#RecruitmentProtocol[4]	
49-53	9799-9804	F32.3	http://maven.renci.org/NeuroBridge/neurobridge#RecruitmentProtocol[4]	
49-54	9804-9805	)	http://maven.renci.org/NeuroBridge/neurobridge#RecruitmentProtocol[4]	
49-55	9805-9806	.	http://maven.renci.org/NeuroBridge/neurobridge#RecruitmentProtocol[4]	

#Text=Age, gender and handedness matched healthy volunteers (n = 37) were recruited as control subjects.
50-1	9807-9810	Age	http://maven.renci.org/NeuroBridge/neurobridge#RecruitmentProtocol[6]	
50-2	9810-9811	,	http://maven.renci.org/NeuroBridge/neurobridge#RecruitmentProtocol[6]	
50-3	9812-9818	gender	http://maven.renci.org/NeuroBridge/neurobridge#RecruitmentProtocol[6]	
50-4	9819-9822	and	http://maven.renci.org/NeuroBridge/neurobridge#RecruitmentProtocol[6]	
50-5	9823-9833	handedness	http://maven.renci.org/NeuroBridge/neurobridge#RecruitmentProtocol[6]	
50-6	9834-9841	matched	http://maven.renci.org/NeuroBridge/neurobridge#RecruitmentProtocol[6]	
50-7	9842-9849	healthy	http://maven.renci.org/NeuroBridge/neurobridge#RecruitmentProtocol[6]|http://maven.renci.org/NeuroBridge/neurobridge#NoKnownDisorder[7]	
50-8	9850-9860	volunteers	http://maven.renci.org/NeuroBridge/neurobridge#RecruitmentProtocol[6]|http://maven.renci.org/NeuroBridge/neurobridge#NoKnownDisorder[7]	
50-9	9861-9862	(	http://maven.renci.org/NeuroBridge/neurobridge#RecruitmentProtocol[6]	
50-10	9862-9863	n	http://maven.renci.org/NeuroBridge/neurobridge#RecruitmentProtocol[6]	
50-11	9864-9865	=	http://maven.renci.org/NeuroBridge/neurobridge#RecruitmentProtocol[6]	
50-12	9866-9868	37	http://maven.renci.org/NeuroBridge/neurobridge#RecruitmentProtocol[6]	
50-13	9868-9869	)	http://maven.renci.org/NeuroBridge/neurobridge#RecruitmentProtocol[6]	
50-14	9870-9874	were	http://maven.renci.org/NeuroBridge/neurobridge#RecruitmentProtocol[6]	
50-15	9875-9884	recruited	http://maven.renci.org/NeuroBridge/neurobridge#RecruitmentProtocol[6]	
50-16	9885-9887	as	http://maven.renci.org/NeuroBridge/neurobridge#RecruitmentProtocol[6]	
50-17	9888-9895	control	http://maven.renci.org/NeuroBridge/neurobridge#RecruitmentProtocol[6]	
50-18	9896-9904	subjects	http://maven.renci.org/NeuroBridge/neurobridge#RecruitmentProtocol[6]	
50-19	9904-9905	.	http://maven.renci.org/NeuroBridge/neurobridge#RecruitmentProtocol[6]	

#Text=We recruited a higher number of controls than patients in order to improve statistical power, given the challenges in recruiting antipsychotic naïve individuals with active psychotic symptoms (yet still well enough to tolerate the MRI procedure) in their first episode of illness.
51-1	9906-9908	We	http://maven.renci.org/NeuroBridge/neurobridge#RecruitmentProtocol[8]	
51-2	9909-9918	recruited	http://maven.renci.org/NeuroBridge/neurobridge#RecruitmentProtocol[8]	
51-3	9919-9920	a	http://maven.renci.org/NeuroBridge/neurobridge#RecruitmentProtocol[8]	
51-4	9921-9927	higher	http://maven.renci.org/NeuroBridge/neurobridge#RecruitmentProtocol[8]	
51-5	9928-9934	number	http://maven.renci.org/NeuroBridge/neurobridge#RecruitmentProtocol[8]	
51-6	9935-9937	of	http://maven.renci.org/NeuroBridge/neurobridge#RecruitmentProtocol[8]	
51-7	9938-9946	controls	http://maven.renci.org/NeuroBridge/neurobridge#RecruitmentProtocol[8]	
51-8	9947-9951	than	http://maven.renci.org/NeuroBridge/neurobridge#RecruitmentProtocol[8]	
51-9	9952-9960	patients	http://maven.renci.org/NeuroBridge/neurobridge#RecruitmentProtocol[8]	
51-10	9961-9963	in	http://maven.renci.org/NeuroBridge/neurobridge#RecruitmentProtocol[8]	
51-11	9964-9969	order	http://maven.renci.org/NeuroBridge/neurobridge#RecruitmentProtocol[8]	
51-12	9970-9972	to	http://maven.renci.org/NeuroBridge/neurobridge#RecruitmentProtocol[8]	
51-13	9973-9980	improve	http://maven.renci.org/NeuroBridge/neurobridge#RecruitmentProtocol[8]	
51-14	9981-9992	statistical	http://maven.renci.org/NeuroBridge/neurobridge#RecruitmentProtocol[8]	
51-15	9993-9998	power	http://maven.renci.org/NeuroBridge/neurobridge#RecruitmentProtocol[8]	
51-16	9998-9999	,	http://maven.renci.org/NeuroBridge/neurobridge#RecruitmentProtocol[8]	
51-17	10000-10005	given	http://maven.renci.org/NeuroBridge/neurobridge#RecruitmentProtocol[8]	
51-18	10006-10009	the	http://maven.renci.org/NeuroBridge/neurobridge#RecruitmentProtocol[8]	
51-19	10010-10020	challenges	http://maven.renci.org/NeuroBridge/neurobridge#RecruitmentProtocol[8]	
51-20	10021-10023	in	http://maven.renci.org/NeuroBridge/neurobridge#RecruitmentProtocol[8]	
51-21	10024-10034	recruiting	http://maven.renci.org/NeuroBridge/neurobridge#RecruitmentProtocol[8]	
51-22	10035-10048	antipsychotic	http://maven.renci.org/NeuroBridge/neurobridge#RecruitmentProtocol[8]	
51-23	10049-10054	naïve	http://maven.renci.org/NeuroBridge/neurobridge#RecruitmentProtocol[8]	
51-24	10055-10066	individuals	http://maven.renci.org/NeuroBridge/neurobridge#RecruitmentProtocol[8]	
51-25	10067-10071	with	http://maven.renci.org/NeuroBridge/neurobridge#RecruitmentProtocol[8]	
51-26	10072-10078	active	http://maven.renci.org/NeuroBridge/neurobridge#RecruitmentProtocol[8]	
51-27	10079-10088	psychotic	http://maven.renci.org/NeuroBridge/neurobridge#RecruitmentProtocol[8]	
51-28	10089-10097	symptoms	http://maven.renci.org/NeuroBridge/neurobridge#RecruitmentProtocol[8]	
51-29	10098-10099	(	http://maven.renci.org/NeuroBridge/neurobridge#RecruitmentProtocol[8]	
51-30	10099-10102	yet	http://maven.renci.org/NeuroBridge/neurobridge#RecruitmentProtocol[8]	
51-31	10103-10108	still	http://maven.renci.org/NeuroBridge/neurobridge#RecruitmentProtocol[8]	
51-32	10109-10113	well	http://maven.renci.org/NeuroBridge/neurobridge#RecruitmentProtocol[8]	
51-33	10114-10120	enough	http://maven.renci.org/NeuroBridge/neurobridge#RecruitmentProtocol[8]	
51-34	10121-10123	to	http://maven.renci.org/NeuroBridge/neurobridge#RecruitmentProtocol[8]	
51-35	10124-10132	tolerate	http://maven.renci.org/NeuroBridge/neurobridge#RecruitmentProtocol[8]	
51-36	10133-10136	the	http://maven.renci.org/NeuroBridge/neurobridge#RecruitmentProtocol[8]	
51-37	10137-10140	MRI	http://maven.renci.org/NeuroBridge/neurobridge#RecruitmentProtocol[8]|http://maven.renci.org/NeuroBridge/neurobridge#MagneticResonanceImaging[9]	
51-38	10141-10150	procedure	http://maven.renci.org/NeuroBridge/neurobridge#RecruitmentProtocol[8]	
51-39	10150-10151	)	http://maven.renci.org/NeuroBridge/neurobridge#RecruitmentProtocol[8]	
51-40	10152-10154	in	http://maven.renci.org/NeuroBridge/neurobridge#RecruitmentProtocol[8]	
51-41	10155-10160	their	http://maven.renci.org/NeuroBridge/neurobridge#RecruitmentProtocol[8]	
51-42	10161-10166	first	http://maven.renci.org/NeuroBridge/neurobridge#RecruitmentProtocol[8]	
51-43	10167-10174	episode	http://maven.renci.org/NeuroBridge/neurobridge#RecruitmentProtocol[8]	
51-44	10175-10177	of	http://maven.renci.org/NeuroBridge/neurobridge#RecruitmentProtocol[8]	
51-45	10178-10185	illness	http://maven.renci.org/NeuroBridge/neurobridge#RecruitmentProtocol[8]	
51-46	10185-10186	.	_	

#Text=Demographic and clinical characteristics of those participants included in the final analysis are presented in Tables 1 and 2.
52-1	10187-10198	Demographic	_	
52-2	10199-10202	and	_	
52-3	10203-10211	clinical	_	
52-4	10212-10227	characteristics	_	
52-5	10228-10230	of	_	
52-6	10231-10236	those	_	
52-7	10237-10249	participants	_	
52-8	10250-10258	included	_	
52-9	10259-10261	in	_	
52-10	10262-10265	the	_	
52-11	10266-10271	final	_	
52-12	10272-10280	analysis	_	
52-13	10281-10284	are	_	
52-14	10285-10294	presented	_	
52-15	10295-10297	in	_	
52-16	10298-10304	Tables	_	
52-17	10305-10306	1	_	
52-18	10307-10310	and	_	
52-19	10311-10312	2	_	
52-20	10312-10313	.	_	

#Text=None of the healthy volunteers reported any personal or family history of severe neurological, psychiatric or medical disorders.
53-1	10314-10318	None	_	
53-2	10319-10321	of	_	
53-3	10322-10325	the	_	
53-4	10326-10333	healthy	http://maven.renci.org/NeuroBridge/neurobridge#NoKnownDisorder[10]	
53-5	10334-10344	volunteers	http://maven.renci.org/NeuroBridge/neurobridge#NoKnownDisorder[10]	
53-6	10345-10353	reported	_	
53-7	10354-10357	any	_	
53-8	10358-10366	personal	_	
53-9	10367-10369	or	_	
53-10	10370-10376	family	_	
53-11	10377-10384	history	_	
53-12	10385-10387	of	_	
53-13	10388-10394	severe	_	
53-14	10395-10407	neurological	_	
53-15	10407-10408	,	_	
53-16	10409-10420	psychiatric	_	
53-17	10421-10423	or	_	
53-18	10424-10431	medical	_	
53-19	10432-10441	disorders	_	
53-20	10441-10442	.	_	

#Text=All participants had normal or corrected-to-normal vision, and had no contraindications to MRI scanning.
54-1	10443-10446	All	_	
54-2	10447-10459	participants	_	
54-3	10460-10463	had	_	
54-4	10464-10470	normal	_	
54-5	10471-10473	or	_	
54-6	10474-10493	corrected-to-normal	_	
54-7	10494-10500	vision	_	
54-8	10500-10501	,	_	
54-9	10502-10505	and	_	
54-10	10506-10509	had	_	
54-11	10510-10512	no	_	
54-12	10513-10530	contraindications	_	
54-13	10531-10533	to	_	
54-14	10534-10537	MRI	http://maven.renci.org/NeuroBridge/neurobridge#MagneticResonanceImaging	
54-15	10538-10546	scanning	_	
54-16	10546-10547	.	_	

#Text=At the time of the study, none of the participants were taking antipsychotic medication or had drug or alcohol dependence.
55-1	10548-10550	At	_	
55-2	10551-10554	the	_	
55-3	10555-10559	time	_	
55-4	10560-10562	of	_	
55-5	10563-10566	the	_	
55-6	10567-10572	study	_	
55-7	10572-10573	,	_	
55-8	10574-10578	none	_	
55-9	10579-10581	of	_	
55-10	10582-10585	the	_	
55-11	10586-10598	participants	_	
55-12	10599-10603	were	_	
55-13	10604-10610	taking	_	
55-14	10611-10624	antipsychotic	_	
55-15	10625-10635	medication	_	
55-16	10636-10638	or	_	
55-17	10639-10642	had	_	
55-18	10643-10647	drug	_	
55-19	10648-10650	or	_	
55-20	10651-10658	alcohol	_	
55-21	10659-10669	dependence	_	
55-22	10669-10670	.	_	

#Text=Before scanning, each of the participants underwent a general interview and clinical assessment using the positive and negative symptom scale (PANSS), the scale for the assessment of negative symptoms (SANS) and the global assessment of functioning (GAF).
56-1	10671-10677	Before	_	
56-2	10678-10686	scanning	_	
56-3	10686-10687	,	_	
56-4	10688-10692	each	_	
56-5	10693-10695	of	_	
56-6	10696-10699	the	_	
56-7	10700-10712	participants	_	
56-8	10713-10722	underwent	_	
56-9	10723-10724	a	_	
56-10	10725-10732	general	_	
56-11	10733-10742	interview	_	
56-12	10743-10746	and	_	
56-13	10747-10755	clinical	_	
56-14	10756-10766	assessment	_	
56-15	10767-10772	using	_	
56-16	10773-10776	the	_	
56-17	10777-10785	positive	http://maven.renci.org/NeuroBridge/neurobridge#PositiveandNegativeSyndromeScale[11]	
56-18	10786-10789	and	http://maven.renci.org/NeuroBridge/neurobridge#PositiveandNegativeSyndromeScale[11]	
56-19	10790-10798	negative	http://maven.renci.org/NeuroBridge/neurobridge#PositiveandNegativeSyndromeScale[11]	
56-20	10799-10806	symptom	http://maven.renci.org/NeuroBridge/neurobridge#PositiveandNegativeSyndromeScale[11]	
56-21	10807-10812	scale	http://maven.renci.org/NeuroBridge/neurobridge#PositiveandNegativeSyndromeScale[11]	
56-22	10813-10814	(	http://maven.renci.org/NeuroBridge/neurobridge#PositiveandNegativeSyndromeScale[11]	
56-23	10814-10819	PANSS	http://maven.renci.org/NeuroBridge/neurobridge#PositiveandNegativeSyndromeScale[11]	
56-24	10819-10820	)	http://maven.renci.org/NeuroBridge/neurobridge#PositiveandNegativeSyndromeScale[11]	
56-25	10820-10821	,	_	
56-26	10822-10825	the	_	
56-27	10826-10831	scale	http://maven.renci.org/NeuroBridge/neurobridge#ScaleforAssessmentofNegativeSymptoms[12]	
56-28	10832-10835	for	http://maven.renci.org/NeuroBridge/neurobridge#ScaleforAssessmentofNegativeSymptoms[12]	
56-29	10836-10839	the	http://maven.renci.org/NeuroBridge/neurobridge#ScaleforAssessmentofNegativeSymptoms[12]	
56-30	10840-10850	assessment	http://maven.renci.org/NeuroBridge/neurobridge#ScaleforAssessmentofNegativeSymptoms[12]	
56-31	10851-10853	of	http://maven.renci.org/NeuroBridge/neurobridge#ScaleforAssessmentofNegativeSymptoms[12]	
56-32	10854-10862	negative	http://maven.renci.org/NeuroBridge/neurobridge#ScaleforAssessmentofNegativeSymptoms[12]	
56-33	10863-10871	symptoms	http://maven.renci.org/NeuroBridge/neurobridge#ScaleforAssessmentofNegativeSymptoms[12]	
56-34	10872-10873	(	http://maven.renci.org/NeuroBridge/neurobridge#ScaleforAssessmentofNegativeSymptoms[12]	
56-35	10873-10877	SANS	http://maven.renci.org/NeuroBridge/neurobridge#ScaleforAssessmentofNegativeSymptoms[12]	
56-36	10877-10878	)	http://maven.renci.org/NeuroBridge/neurobridge#ScaleforAssessmentofNegativeSymptoms[12]	
56-37	10879-10882	and	_	
56-38	10883-10886	the	_	
56-39	10887-10893	global	_	
56-40	10894-10904	assessment	_	
56-41	10905-10907	of	_	
56-42	10908-10919	functioning	_	
56-43	10920-10921	(	_	
56-44	10921-10924	GAF	_	
56-45	10924-10925	)	_	
56-46	10925-10926	.	_	

#Text=The Beck depression inventory (BDI) was used to assess depressive symptoms during the last two weeks.
57-1	10927-10930	The	_	
57-2	10931-10935	Beck	http://maven.renci.org/NeuroBridge/neurobridge#BeckDepressionInventory[13]	
57-3	10936-10946	depression	http://maven.renci.org/NeuroBridge/neurobridge#BeckDepressionInventory[13]	
57-4	10947-10956	inventory	http://maven.renci.org/NeuroBridge/neurobridge#BeckDepressionInventory[13]	
57-5	10957-10958	(	http://maven.renci.org/NeuroBridge/neurobridge#BeckDepressionInventory[13]	
57-6	10958-10961	BDI	http://maven.renci.org/NeuroBridge/neurobridge#BeckDepressionInventory[13]	
57-7	10961-10962	)	http://maven.renci.org/NeuroBridge/neurobridge#BeckDepressionInventory[13]	
57-8	10963-10966	was	_	
57-9	10967-10971	used	_	
57-10	10972-10974	to	_	
57-11	10975-10981	assess	_	
57-12	10982-10992	depressive	_	
57-13	10993-11001	symptoms	_	
57-14	11002-11008	during	_	
57-15	11009-11012	the	_	
57-16	11013-11017	last	_	
57-17	11018-11021	two	_	
57-18	11022-11027	weeks	_	
57-19	11027-11028	.	_	

#Text=IQ was estimated using the culture fair intelligence test.
58-1	11029-11031	IQ	_	
58-2	11032-11035	was	_	
58-3	11036-11045	estimated	_	
58-4	11046-11051	using	_	
58-5	11052-11055	the	_	
58-6	11056-11063	culture	_	
58-7	11064-11068	fair	_	
58-8	11069-11081	intelligence	_	
58-9	11082-11086	test	_	
58-10	11086-11087	.	_	

#Text=The study was approved by the Cambridgeshire 3 National Health Service research ethics committee.
59-1	11088-11091	The	http://maven.renci.org/NeuroBridge/neurobridge#RecruitmentProtocol[14]	
59-2	11092-11097	study	http://maven.renci.org/NeuroBridge/neurobridge#RecruitmentProtocol[14]	
59-3	11098-11101	was	http://maven.renci.org/NeuroBridge/neurobridge#RecruitmentProtocol[14]	
59-4	11102-11110	approved	http://maven.renci.org/NeuroBridge/neurobridge#RecruitmentProtocol[14]	
59-5	11111-11113	by	http://maven.renci.org/NeuroBridge/neurobridge#RecruitmentProtocol[14]	
59-6	11114-11117	the	http://maven.renci.org/NeuroBridge/neurobridge#RecruitmentProtocol[14]	
59-7	11118-11132	Cambridgeshire	http://maven.renci.org/NeuroBridge/neurobridge#RecruitmentProtocol[14]	
59-8	11133-11134	3	http://maven.renci.org/NeuroBridge/neurobridge#RecruitmentProtocol[14]	
59-9	11135-11143	National	http://maven.renci.org/NeuroBridge/neurobridge#RecruitmentProtocol[14]	
59-10	11144-11150	Health	http://maven.renci.org/NeuroBridge/neurobridge#RecruitmentProtocol[14]	
59-11	11151-11158	Service	http://maven.renci.org/NeuroBridge/neurobridge#RecruitmentProtocol[14]	
59-12	11159-11167	research	http://maven.renci.org/NeuroBridge/neurobridge#RecruitmentProtocol[14]	
59-13	11168-11174	ethics	http://maven.renci.org/NeuroBridge/neurobridge#RecruitmentProtocol[14]	
59-14	11175-11184	committee	http://maven.renci.org/NeuroBridge/neurobridge#RecruitmentProtocol[14]	
59-15	11184-11185	.	_	

#Text=All participants supplied written informed consent after they had read a complete description of the study.
60-1	11186-11189	All	http://maven.renci.org/NeuroBridge/neurobridge#RecruitmentProtocol[15]	
60-2	11190-11202	participants	http://maven.renci.org/NeuroBridge/neurobridge#RecruitmentProtocol[15]	
60-3	11203-11211	supplied	http://maven.renci.org/NeuroBridge/neurobridge#RecruitmentProtocol[15]	
60-4	11212-11219	written	http://maven.renci.org/NeuroBridge/neurobridge#RecruitmentProtocol[15]	
60-5	11220-11228	informed	http://maven.renci.org/NeuroBridge/neurobridge#RecruitmentProtocol[15]	
60-6	11229-11236	consent	http://maven.renci.org/NeuroBridge/neurobridge#RecruitmentProtocol[15]	
60-7	11237-11242	after	http://maven.renci.org/NeuroBridge/neurobridge#RecruitmentProtocol[15]	
60-8	11243-11247	they	http://maven.renci.org/NeuroBridge/neurobridge#RecruitmentProtocol[15]	
60-9	11248-11251	had	http://maven.renci.org/NeuroBridge/neurobridge#RecruitmentProtocol[15]	
60-10	11252-11256	read	http://maven.renci.org/NeuroBridge/neurobridge#RecruitmentProtocol[15]	
60-11	11257-11258	a	http://maven.renci.org/NeuroBridge/neurobridge#RecruitmentProtocol[15]	
60-12	11259-11267	complete	http://maven.renci.org/NeuroBridge/neurobridge#RecruitmentProtocol[15]	
60-13	11268-11279	description	http://maven.renci.org/NeuroBridge/neurobridge#RecruitmentProtocol[15]	
60-14	11280-11282	of	http://maven.renci.org/NeuroBridge/neurobridge#RecruitmentProtocol[15]	
60-15	11283-11286	the	http://maven.renci.org/NeuroBridge/neurobridge#RecruitmentProtocol[15]	
60-16	11287-11292	study	http://maven.renci.org/NeuroBridge/neurobridge#RecruitmentProtocol[15]	
60-17	11292-11293	.	http://maven.renci.org/NeuroBridge/neurobridge#RecruitmentProtocol[15]	

#Text=Novelty task
#Text=Visual oddball paradigm.
61-1	11294-11301	Novelty	_	
61-2	11302-11306	task	_	
61-3	11307-11313	Visual	_	
61-4	11314-11321	oddball	_	
61-5	11322-11330	paradigm	_	
61-6	11330-11331	.	_	

#Text=Participants are presented with a series of greyscale images of faces and outdoor scenes.
#Text=66.6% of those were ‘standard’ images.
62-1	11332-11344	Participants	_	
62-2	11345-11348	are	_	
62-3	11349-11358	presented	_	
62-4	11359-11363	with	_	
62-5	11364-11365	a	_	
62-6	11366-11372	series	_	
62-7	11373-11375	of	_	
62-8	11376-11385	greyscale	_	
62-9	11386-11392	images	_	
62-10	11393-11395	of	_	
62-11	11396-11401	faces	_	
62-12	11402-11405	and	_	
62-13	11406-11413	outdoor	_	
62-14	11414-11420	scenes	_	
62-15	11420-11421	.	_	
62-16	11422-11427	66.6%	_	
62-17	11428-11430	of	_	
62-18	11431-11436	those	_	
62-19	11437-11441	were	_	
62-20	11442-11443	‘	_	
62-21	11443-11451	standard	_	
62-22	11451-11452	’	_	
62-23	11453-11459	images	_	
62-24	11459-11460	.	_	

#Text=The remaining 33.4% consisted of four types of rare or contextually deviant events, which were randomly intermixed with the standard stimuli; each occurred with a probability of 8.3%.
63-1	11461-11464	The	_	
63-2	11465-11474	remaining	_	
63-3	11475-11480	33.4%	_	
63-4	11481-11490	consisted	_	
63-5	11491-11493	of	_	
63-6	11494-11498	four	_	
63-7	11499-11504	types	_	
63-8	11505-11507	of	_	
63-9	11508-11512	rare	_	
63-10	11513-11515	or	_	
63-11	11516-11528	contextually	_	
63-12	11529-11536	deviant	_	
63-13	11537-11543	events	_	
63-14	11543-11544	,	_	
63-15	11545-11550	which	_	
63-16	11551-11555	were	_	
63-17	11556-11564	randomly	_	
63-18	11565-11575	intermixed	_	
63-19	11576-11580	with	_	
63-20	11581-11584	the	_	
63-21	11585-11593	standard	_	
63-22	11594-11601	stimuli	_	
63-23	11601-11602	;	_	
63-24	11603-11607	each	_	
63-25	11608-11616	occurred	_	
63-26	11617-11621	with	_	
63-27	11622-11623	a	_	
63-28	11624-11635	probability	_	
63-29	11636-11638	of	_	
63-30	11639-11643	8.3%	_	
63-31	11643-11644	.	_	

#Text=These deviant events were: neutral stimuli that required a motor response (‘target oddball’); stimuli that evoked a negative emotional response (‘emotional oddball’, angry face or image of car crash); novel stimuli (‘novel oddball’, different neutral images that appear only once); and neutral stimuli (‘neutral oddball’, neutral image of face or scene)
#Text=We used a visual oddball paradigm in order to investigate four types of salience, which were novelty, negative emotional salience, targetness and rareness/deviance.
64-1	11645-11650	These	_	
64-2	11651-11658	deviant	_	
64-3	11659-11665	events	_	
64-4	11666-11670	were	_	
64-5	11670-11671	:	_	
64-6	11672-11679	neutral	_	
64-7	11680-11687	stimuli	_	
64-8	11688-11692	that	_	
64-9	11693-11701	required	_	
64-10	11702-11703	a	_	
64-11	11704-11709	motor	_	
64-12	11710-11718	response	_	
64-13	11719-11720	(	_	
64-14	11720-11721	‘	_	
64-15	11721-11727	target	_	
64-16	11728-11735	oddball	_	
64-17	11735-11736	’	_	
64-18	11736-11737	)	_	
64-19	11737-11738	;	_	
64-20	11739-11746	stimuli	_	
64-21	11747-11751	that	_	
64-22	11752-11758	evoked	_	
64-23	11759-11760	a	_	
64-24	11761-11769	negative	_	
64-25	11770-11779	emotional	_	
64-26	11780-11788	response	_	
64-27	11789-11790	(	_	
64-28	11790-11791	‘	_	
64-29	11791-11800	emotional	_	
64-30	11801-11808	oddball	_	
64-31	11808-11809	’	_	
64-32	11809-11810	,	_	
64-33	11811-11816	angry	_	
64-34	11817-11821	face	_	
64-35	11822-11824	or	_	
64-36	11825-11830	image	_	
64-37	11831-11833	of	_	
64-38	11834-11837	car	_	
64-39	11838-11843	crash	_	
64-40	11843-11844	)	_	
64-41	11844-11845	;	_	
64-42	11846-11851	novel	_	
64-43	11852-11859	stimuli	_	
64-44	11860-11861	(	_	
64-45	11861-11862	‘	_	
64-46	11862-11867	novel	_	
64-47	11868-11875	oddball	_	
64-48	11875-11876	’	_	
64-49	11876-11877	,	_	
64-50	11878-11887	different	_	
64-51	11888-11895	neutral	_	
64-52	11896-11902	images	_	
64-53	11903-11907	that	_	
64-54	11908-11914	appear	_	
64-55	11915-11919	only	_	
64-56	11920-11924	once	_	
64-57	11924-11925	)	_	
64-58	11925-11926	;	_	
64-59	11927-11930	and	_	
64-60	11931-11938	neutral	_	
64-61	11939-11946	stimuli	_	
64-62	11947-11948	(	_	
64-63	11948-11949	‘	_	
64-64	11949-11956	neutral	_	
64-65	11957-11964	oddball	_	
64-66	11964-11965	’	_	
64-67	11965-11966	,	_	
64-68	11967-11974	neutral	_	
64-69	11975-11980	image	_	
64-70	11981-11983	of	_	
64-71	11984-11988	face	_	
64-72	11989-11991	or	_	
64-73	11992-11997	scene	_	
64-74	11997-11998	)	_	
64-75	11999-12001	We	_	
64-76	12002-12006	used	_	
64-77	12007-12008	a	_	
64-78	12009-12015	visual	_	
64-79	12016-12023	oddball	_	
64-80	12024-12032	paradigm	_	
64-81	12033-12035	in	_	
64-82	12036-12041	order	_	
64-83	12042-12044	to	_	
64-84	12045-12056	investigate	_	
64-85	12057-12061	four	_	
64-86	12062-12067	types	_	
64-87	12068-12070	of	_	
64-88	12071-12079	salience	_	
64-89	12079-12080	,	_	
64-90	12081-12086	which	_	
64-91	12087-12091	were	_	
64-92	12092-12099	novelty	_	
64-93	12099-12100	,	_	
64-94	12101-12109	negative	_	
64-95	12110-12119	emotional	_	
64-96	12120-12128	salience	_	
64-97	12128-12129	,	_	
64-98	12130-12140	targetness	_	
64-99	12141-12144	and	_	
64-100	12145-12153	rareness	_	
64-101	12153-12154	/	_	
64-102	12154-12162	deviance	_	
64-103	12162-12163	.	_	

#Text=Participants were presented with a series of greyscale images of faces and outdoor scenes. 66.6% of those were used as ‘standard’ images, which were of neutral emotional valence.
65-1	12164-12176	Participants	_	
65-2	12177-12181	were	_	
65-3	12182-12191	presented	_	
65-4	12192-12196	with	_	
65-5	12197-12198	a	_	
65-6	12199-12205	series	_	
65-7	12206-12208	of	_	
65-8	12209-12218	greyscale	_	
65-9	12219-12225	images	_	
65-10	12226-12228	of	_	
65-11	12229-12234	faces	_	
65-12	12235-12238	and	_	
65-13	12239-12246	outdoor	_	
65-14	12247-12253	scenes	_	
65-15	12253-12254	.	_	
65-16	12255-12260	66.6%	_	
65-17	12261-12263	of	_	
65-18	12264-12269	those	_	
65-19	12270-12274	were	_	
65-20	12275-12279	used	_	
65-21	12280-12282	as	_	
65-22	12283-12284	‘	_	
65-23	12284-12292	standard	_	
65-24	12292-12293	’	_	
65-25	12294-12300	images	_	
65-26	12300-12301	,	_	
65-27	12302-12307	which	_	
65-28	12308-12312	were	_	
65-29	12313-12315	of	_	
65-30	12316-12323	neutral	_	
65-31	12324-12333	emotional	_	
65-32	12334-12341	valence	_	
65-33	12341-12342	.	_	

#Text=The four types of rare or contextually deviant events were randomly intermixed with these; each occurred with a probability of 8.3%.
66-1	12343-12346	The	_	
66-2	12347-12351	four	_	
66-3	12352-12357	types	_	
66-4	12358-12360	of	_	
66-5	12361-12365	rare	_	
66-6	12366-12368	or	_	
66-7	12369-12381	contextually	_	
66-8	12382-12389	deviant	_	
66-9	12390-12396	events	_	
66-10	12397-12401	were	_	
66-11	12402-12410	randomly	_	
66-12	12411-12421	intermixed	_	
66-13	12422-12426	with	_	
66-14	12427-12432	these	_	
66-15	12432-12433	;	_	
66-16	12434-12438	each	_	
66-17	12439-12447	occurred	_	
66-18	12448-12452	with	_	
66-19	12453-12454	a	_	
66-20	12455-12466	probability	_	
66-21	12467-12469	of	_	
66-22	12470-12474	8.3%	_	
66-23	12474-12475	.	_	

#Text=These deviant events were: neutral stimuli that required a motor response (‘target oddball’); stimuli that evoked a negative emotional response (‘emotional oddball’, angry face or image of car crash); novel stimuli (‘novel oddball’, different neutral images that appear only once); and neutral stimuli (‘neutral oddball’, neutral image of face or scene) (Fig. 1).
67-1	12476-12481	These	_	
67-2	12482-12489	deviant	_	
67-3	12490-12496	events	_	
67-4	12497-12501	were	_	
67-5	12501-12502	:	_	
67-6	12503-12510	neutral	_	
67-7	12511-12518	stimuli	_	
67-8	12519-12523	that	_	
67-9	12524-12532	required	_	
67-10	12533-12534	a	_	
67-11	12535-12540	motor	_	
67-12	12541-12549	response	_	
67-13	12550-12551	(	_	
67-14	12551-12552	‘	_	
67-15	12552-12558	target	_	
67-16	12559-12566	oddball	_	
67-17	12566-12567	’	_	
67-18	12567-12568	)	_	
67-19	12568-12569	;	_	
67-20	12570-12577	stimuli	_	
67-21	12578-12582	that	_	
67-22	12583-12589	evoked	_	
67-23	12590-12591	a	_	
67-24	12592-12600	negative	_	
67-25	12601-12610	emotional	_	
67-26	12611-12619	response	_	
67-27	12620-12621	(	_	
67-28	12621-12622	‘	_	
67-29	12622-12631	emotional	_	
67-30	12632-12639	oddball	_	
67-31	12639-12640	’	_	
67-32	12640-12641	,	_	
67-33	12642-12647	angry	_	
67-34	12648-12652	face	_	
67-35	12653-12655	or	_	
67-36	12656-12661	image	_	
67-37	12662-12664	of	_	
67-38	12665-12668	car	_	
67-39	12669-12674	crash	_	
67-40	12674-12675	)	_	
67-41	12675-12676	;	_	
67-42	12677-12682	novel	_	
67-43	12683-12690	stimuli	_	
67-44	12691-12692	(	_	
67-45	12692-12693	‘	_	
67-46	12693-12698	novel	_	
67-47	12699-12706	oddball	_	
67-48	12706-12707	’	_	
67-49	12707-12708	,	_	
67-50	12709-12718	different	_	
67-51	12719-12726	neutral	_	
67-52	12727-12733	images	_	
67-53	12734-12738	that	_	
67-54	12739-12745	appear	_	
67-55	12746-12750	only	_	
67-56	12751-12755	once	_	
67-57	12755-12756	)	_	
67-58	12756-12757	;	_	
67-59	12758-12761	and	_	
67-60	12762-12769	neutral	_	
67-61	12770-12777	stimuli	_	
67-62	12778-12779	(	_	
67-63	12779-12780	‘	_	
67-64	12780-12787	neutral	_	
67-65	12788-12795	oddball	_	
67-66	12795-12796	’	_	
67-67	12796-12797	,	_	
67-68	12798-12805	neutral	_	
67-69	12806-12811	image	_	
67-70	12812-12814	of	_	
67-71	12815-12819	face	_	
67-72	12820-12822	or	_	
67-73	12823-12828	scene	_	
67-74	12828-12829	)	_	
67-75	12830-12831	(	_	
67-76	12831-12834	Fig	_	
67-77	12834-12835	.	_	
67-78	12836-12837	1	_	
67-79	12837-12838	)	_	
67-80	12838-12839	.	_	

#Text=All participants completed four blocks with 60 trials each, resulting in a total of 240 trials (160 standard trials, and 20 oddball trials each of target, neutral, emotional and novel stimuli).
68-1	12840-12843	All	_	
68-2	12844-12856	participants	_	
68-3	12857-12866	completed	_	
68-4	12867-12871	four	_	
68-5	12872-12878	blocks	_	
68-6	12879-12883	with	_	
68-7	12884-12886	60	_	
68-8	12887-12893	trials	_	
68-9	12894-12898	each	_	
68-10	12898-12899	,	_	
68-11	12900-12909	resulting	_	
68-12	12910-12912	in	_	
68-13	12913-12914	a	_	
68-14	12915-12920	total	_	
68-15	12921-12923	of	_	
68-16	12924-12927	240	_	
68-17	12928-12934	trials	_	
68-18	12935-12936	(	_	
68-19	12936-12939	160	_	
68-20	12940-12948	standard	_	
68-21	12949-12955	trials	_	
68-22	12955-12956	,	_	
68-23	12957-12960	and	_	
68-24	12961-12963	20	_	
68-25	12964-12971	oddball	_	
68-26	12972-12978	trials	_	
68-27	12979-12983	each	_	
68-28	12984-12986	of	_	
68-29	12987-12993	target	_	
68-30	12993-12994	,	_	
68-31	12995-13002	neutral	_	
68-32	13002-13003	,	_	
68-33	13004-13013	emotional	_	
68-34	13014-13017	and	_	
68-35	13018-13023	novel	_	
68-36	13024-13031	stimuli	_	
68-37	13031-13032	)	_	
68-38	13032-13033	.	_	

#Text=The task contained 50% faces and 50% outdoor scenes, this allowed prevention of category-specific habituation.
69-1	13034-13037	The	_	
69-2	13038-13042	task	_	
69-3	13043-13052	contained	_	
69-4	13053-13056	50%	_	
69-5	13057-13062	faces	_	
69-6	13063-13066	and	_	
69-7	13067-13070	50%	_	
69-8	13071-13078	outdoor	_	
69-9	13079-13085	scenes	_	
69-10	13085-13086	,	_	
69-11	13087-13091	this	_	
69-12	13092-13099	allowed	_	
69-13	13100-13110	prevention	_	
69-14	13111-13113	of	_	
69-15	13114-13131	category-specific	_	
69-16	13132-13143	habituation	_	
69-17	13143-13144	.	_	

#Text=These categories were chosen instead of abstract images to make stimulus exploration biologically relevant.
70-1	13145-13150	These	_	
70-2	13151-13161	categories	_	
70-3	13162-13166	were	_	
70-4	13167-13173	chosen	_	
70-5	13174-13181	instead	_	
70-6	13182-13184	of	_	
70-7	13185-13193	abstract	_	
70-8	13194-13200	images	_	
70-9	13201-13203	to	_	
70-10	13204-13208	make	_	
70-11	13209-13217	stimulus	_	
70-12	13218-13229	exploration	_	
70-13	13230-13242	biologically	_	
70-14	13243-13251	relevant	_	
70-15	13251-13252	.	_	

#Text=Participants were introduced to the target stimulus prior to the experimental session for 4.5 s, and they were required to make a simple button press with their right index finger in response to each of its subsequent appearances during the experiment within the fMRI-scanner.
71-1	13253-13265	Participants	_	
71-2	13266-13270	were	_	
71-3	13271-13281	introduced	_	
71-4	13282-13284	to	_	
71-5	13285-13288	the	_	
71-6	13289-13295	target	_	
71-7	13296-13304	stimulus	_	
71-8	13305-13310	prior	_	
71-9	13311-13313	to	_	
71-10	13314-13317	the	_	
71-11	13318-13330	experimental	_	
71-12	13331-13338	session	_	
71-13	13339-13342	for	_	
71-14	13343-13346	4.5	_	
71-15	13347-13348	s	_	
71-16	13348-13349	,	_	
71-17	13350-13353	and	_	
71-18	13354-13358	they	_	
71-19	13359-13363	were	_	
71-20	13364-13372	required	_	
71-21	13373-13375	to	_	
71-22	13376-13380	make	_	
71-23	13381-13382	a	_	
71-24	13383-13389	simple	_	
71-25	13390-13396	button	_	
71-26	13397-13402	press	_	
71-27	13403-13407	with	_	
71-28	13408-13413	their	_	
71-29	13414-13419	right	_	
71-30	13420-13425	index	_	
71-31	13426-13432	finger	_	
71-32	13433-13435	in	_	
71-33	13436-13444	response	_	
71-34	13445-13447	to	_	
71-35	13448-13452	each	_	
71-36	13453-13455	of	_	
71-37	13456-13459	its	_	
71-38	13460-13470	subsequent	_	
71-39	13471-13482	appearances	_	
71-40	13483-13489	during	_	
71-41	13490-13493	the	_	
71-42	13494-13504	experiment	_	
71-43	13505-13511	within	_	
71-44	13512-13515	the	_	
71-45	13516-13528	fMRI-scanner	_	
71-46	13528-13529	.	_	

#Text=No motor responses were associated with any of the other stimulus types.
72-1	13530-13532	No	_	
72-2	13533-13538	motor	_	
72-3	13539-13548	responses	_	
72-4	13549-13553	were	_	
72-5	13554-13564	associated	_	
72-6	13565-13569	with	_	
72-7	13570-13573	any	_	
72-8	13574-13576	of	_	
72-9	13577-13580	the	_	
72-10	13581-13586	other	_	
72-11	13587-13595	stimulus	_	
72-12	13596-13601	types	_	
72-13	13601-13602	.	_	

#Text=During the fMRI-experiment, the pictures were presented for 500 ms followed by a white fixation cross on a grey background (grey value = 127) using an inter-stimulus interval (ISI) of 2.7 s.
73-1	13603-13609	During	_	
73-2	13610-13613	the	_	
73-3	13614-13629	fMRI-experiment	_	
73-4	13629-13630	,	_	
73-5	13631-13634	the	_	
73-6	13635-13643	pictures	_	
73-7	13644-13648	were	_	
73-8	13649-13658	presented	_	
73-9	13659-13662	for	_	
73-10	13663-13666	500	_	
73-11	13667-13669	ms	_	
73-12	13670-13678	followed	_	
73-13	13679-13681	by	_	
73-14	13682-13683	a	_	
73-15	13684-13689	white	_	
73-16	13690-13698	fixation	_	
73-17	13699-13704	cross	_	
73-18	13705-13707	on	_	
73-19	13708-13709	a	_	
73-20	13710-13714	grey	_	
73-21	13715-13725	background	_	
73-22	13726-13727	(	_	
73-23	13727-13731	grey	_	
73-24	13732-13737	value	_	
73-25	13738-13739	=	_	
73-26	13740-13743	127	_	
73-27	13743-13744	)	_	
73-28	13745-13750	using	_	
73-29	13751-13753	an	_	
73-30	13754-13768	inter-stimulus	_	
73-31	13769-13777	interval	_	
73-32	13778-13779	(	_	
73-33	13779-13782	ISI	_	
73-34	13782-13783	)	_	
73-35	13784-13786	of	_	
73-36	13787-13790	2.7	_	
73-37	13791-13792	s	_	
73-38	13792-13793	.	_	

#Text=ISI was jittered with ±300 ms (uniformly distributed).
74-1	13794-13797	ISI	_	
74-2	13798-13801	was	_	
74-3	13802-13810	jittered	_	
74-4	13811-13815	with	_	
74-5	13816-13817	±	_	
74-6	13817-13820	300	_	
74-7	13821-13823	ms	_	
74-8	13824-13825	(	_	
74-9	13825-13834	uniformly	_	
74-10	13835-13846	distributed	_	
74-11	13846-13847	)	_	
74-12	13847-13848	.	_	

#Text=The order of stimuli was optimised for efficiency with regard to estimating stimulus-related haemodynamic responses.
75-1	13849-13852	The	_	
75-2	13853-13858	order	_	
75-3	13859-13861	of	_	
75-4	13862-13869	stimuli	_	
75-5	13870-13873	was	_	
75-6	13874-13883	optimised	_	
75-7	13884-13887	for	_	
75-8	13888-13898	efficiency	_	
75-9	13899-13903	with	_	
75-10	13904-13910	regard	_	
75-11	13911-13913	to	_	
75-12	13914-13924	estimating	_	
75-13	13925-13941	stimulus-related	_	
75-14	13942-13954	haemodynamic	_	
75-15	13955-13964	responses	_	
75-16	13964-13965	.	_	

#Text=All of the stimuli were taken from Bunzeck and Düzel.
76-1	13966-13969	All	_	
76-2	13970-13972	of	_	
76-3	13973-13976	the	_	
76-4	13977-13984	stimuli	_	
76-5	13985-13989	were	_	
76-6	13990-13995	taken	_	
76-7	13996-14000	from	_	
76-8	14001-14008	Bunzeck	_	
76-9	14009-14012	and	_	
76-10	14013-14018	Düzel	_	
76-11	14018-14019	.	_	

#Text=The scalp hair and ears of faces were removed artificially; the outdoor scenes did not include faces.
77-1	14020-14023	The	_	
77-2	14024-14029	scalp	_	
77-3	14030-14034	hair	_	
77-4	14035-14038	and	_	
77-5	14039-14043	ears	_	
77-6	14044-14046	of	_	
77-7	14047-14052	faces	_	
77-8	14053-14057	were	_	
77-9	14058-14065	removed	_	
77-10	14066-14078	artificially	_	
77-11	14078-14079	;	_	
77-12	14080-14083	the	_	
77-13	14084-14091	outdoor	_	
77-14	14092-14098	scenes	_	
77-15	14099-14102	did	_	
77-16	14103-14106	not	_	
77-17	14107-14114	include	_	
77-18	14115-14120	faces	_	
77-19	14120-14121	.	_	

#Text=All pictures were grey scaled and normalised to a mean grey value of 127 (SD 75).
78-1	14122-14125	All	_	
78-2	14126-14134	pictures	_	
78-3	14135-14139	were	_	
78-4	14140-14144	grey	_	
78-5	14145-14151	scaled	_	
78-6	14152-14155	and	_	
78-7	14156-14166	normalised	_	
78-8	14167-14169	to	_	
78-9	14170-14171	a	_	
78-10	14172-14176	mean	_	
78-11	14177-14181	grey	_	
78-12	14182-14187	value	_	
78-13	14188-14190	of	_	
78-14	14191-14194	127	_	
78-15	14195-14196	(	_	
78-16	14196-14198	SD	_	
78-17	14199-14201	75	_	
78-18	14201-14202	)	_	
78-19	14202-14203	.	_	

#Text=The pictures were projected on to the centre of a screen, and the participants watched them through a mirror mounted on the head coil, subtending a visual angle of about 8°.
79-1	14204-14207	The	_	
79-2	14208-14216	pictures	_	
79-3	14217-14221	were	_	
79-4	14222-14231	projected	_	
79-5	14232-14234	on	_	
79-6	14235-14237	to	_	
79-7	14238-14241	the	_	
79-8	14242-14248	centre	_	
79-9	14249-14251	of	_	
79-10	14252-14253	a	_	
79-11	14254-14260	screen	_	
79-12	14260-14261	,	_	
79-13	14262-14265	and	_	
79-14	14266-14269	the	_	
79-15	14270-14282	participants	_	
79-16	14283-14290	watched	_	
79-17	14291-14295	them	_	
79-18	14296-14303	through	_	
79-19	14304-14305	a	_	
79-20	14306-14312	mirror	_	
79-21	14313-14320	mounted	_	
79-22	14321-14323	on	_	
79-23	14324-14327	the	_	
79-24	14328-14332	head	_	
79-25	14333-14337	coil	_	
79-26	14337-14338	,	_	
79-27	14339-14349	subtending	_	
79-28	14350-14351	a	_	
79-29	14352-14358	visual	_	
79-30	14359-14364	angle	_	
79-31	14365-14367	of	_	
79-32	14368-14373	about	_	
79-33	14374-14375	8	_	
79-34	14375-14376	°	_	
79-35	14376-14377	.	_	

#Text=The negative emotional scene depicted a negatively rated car accident (without any people).
80-1	14378-14381	The	_	
80-2	14382-14390	negative	_	
80-3	14391-14400	emotional	_	
80-4	14401-14406	scene	_	
80-5	14407-14415	depicted	_	
80-6	14416-14417	a	_	
80-7	14418-14428	negatively	_	
80-8	14429-14434	rated	_	
80-9	14435-14438	car	_	
80-10	14439-14447	accident	_	
80-11	14448-14449	(	_	
80-12	14449-14456	without	_	
80-13	14457-14460	any	_	
80-14	14461-14467	people	_	
80-15	14467-14468	)	_	
80-16	14468-14469	.	_	

#Text=The contrast between stimuli allowed us to examine brain responses to the pure stimulus novelty (‘novel’ vs.
81-1	14470-14473	The	_	
81-2	14474-14482	contrast	_	
81-3	14483-14490	between	_	
81-4	14491-14498	stimuli	_	
81-5	14499-14506	allowed	_	
81-6	14507-14509	us	_	
81-7	14510-14512	to	_	
81-8	14513-14520	examine	_	
81-9	14521-14526	brain	_	
81-10	14527-14536	responses	_	
81-11	14537-14539	to	_	
81-12	14540-14543	the	_	
81-13	14544-14548	pure	_	
81-14	14549-14557	stimulus	_	
81-15	14558-14565	novelty	_	
81-16	14566-14567	(	_	
81-17	14567-14568	‘	_	
81-18	14568-14573	novel	_	
81-19	14573-14574	’	_	
81-20	14575-14577	vs	_	
81-21	14577-14578	.	_	

#Text=‘neutral’), targetness (‘target’ vs.
82-1	14579-14580	‘	_	
82-2	14580-14587	neutral	_	
82-3	14587-14588	’	_	
82-4	14588-14589	)	_	
82-5	14589-14590	,	_	
82-6	14591-14601	targetness	_	
82-7	14602-14603	(	_	
82-8	14603-14604	‘	_	
82-9	14604-14610	target	_	
82-10	14610-14611	’	_	
82-11	14612-14614	vs	_	
82-12	14614-14615	.	_	

#Text=‘neutral’), negative emotional valence (‘emotional’ vs.
83-1	14616-14617	‘	_	
83-2	14617-14624	neutral	_	
83-3	14624-14625	’	_	
83-4	14625-14626	)	_	
83-5	14626-14627	,	_	
83-6	14628-14636	negative	_	
83-7	14637-14646	emotional	_	
83-8	14647-14654	valence	_	
83-9	14655-14656	(	_	
83-10	14656-14657	‘	_	
83-11	14657-14666	emotional	_	
83-12	14666-14667	’	_	
83-13	14668-14670	vs	_	
83-14	14670-14671	.	_	

#Text=‘neutral’) and rareness/deviance per se (‘neutral’ vs.
84-1	14672-14673	‘	_	
84-2	14673-14680	neutral	_	
84-3	14680-14681	’	_	
84-4	14681-14682	)	_	
84-5	14683-14686	and	_	
84-6	14687-14695	rareness	_	
84-7	14695-14696	/	_	
84-8	14696-14704	deviance	_	
84-9	14705-14708	per	_	
84-10	14709-14711	se	_	
84-11	14712-14713	(	_	
84-12	14713-14714	‘	_	
84-13	14714-14721	neutral	_	
84-14	14721-14722	’	_	
84-15	14723-14725	vs	_	
84-16	14725-14726	.	_	

#Text=‘standard’) (Fig. 1).
85-1	14727-14728	‘	_	
85-2	14728-14736	standard	_	
85-3	14736-14737	’	_	
85-4	14737-14738	)	_	
85-5	14739-14740	(	_	
85-6	14740-14743	Fig	_	
85-7	14743-14744	.	_	
85-8	14745-14746	1	_	
85-9	14746-14747	)	_	
85-10	14747-14748	.	_	

#Text=By contrasting the specific salient oddball events with the neutral oddball events, and including a separate, additional, “rareness/deviance” contrast (that corresponds to a classical pure oddball effect), we can differentiate activation to the various forms of salience under study.
86-1	14749-14751	By	_	
86-2	14752-14763	contrasting	_	
86-3	14764-14767	the	_	
86-4	14768-14776	specific	_	
86-5	14777-14784	salient	_	
86-6	14785-14792	oddball	_	
86-7	14793-14799	events	_	
86-8	14800-14804	with	_	
86-9	14805-14808	the	_	
86-10	14809-14816	neutral	_	
86-11	14817-14824	oddball	_	
86-12	14825-14831	events	_	
86-13	14831-14832	,	_	
86-14	14833-14836	and	_	
86-15	14837-14846	including	_	
86-16	14847-14848	a	_	
86-17	14849-14857	separate	_	
86-18	14857-14858	,	_	
86-19	14859-14869	additional	_	
86-20	14869-14870	,	_	
86-21	14871-14872	“	_	
86-22	14872-14880	rareness	_	
86-23	14880-14881	/	_	
86-24	14881-14889	deviance	_	
86-25	14889-14890	”	_	
86-26	14891-14899	contrast	_	
86-27	14900-14901	(	_	
86-28	14901-14905	that	_	
86-29	14906-14917	corresponds	_	
86-30	14918-14920	to	_	
86-31	14921-14922	a	_	
86-32	14923-14932	classical	_	
86-33	14933-14937	pure	_	
86-34	14938-14945	oddball	_	
86-35	14946-14952	effect	_	
86-36	14952-14953	)	_	
86-37	14953-14954	,	_	
86-38	14955-14957	we	_	
86-39	14958-14961	can	_	
86-40	14962-14975	differentiate	_	
86-41	14976-14986	activation	_	
86-42	14987-14989	to	_	
86-43	14990-14993	the	_	
86-44	14994-15001	various	_	
86-45	15002-15007	forms	_	
86-46	15008-15010	of	_	
86-47	15011-15019	salience	_	
86-48	15020-15025	under	_	
86-49	15026-15031	study	_	
86-50	15031-15032	.	_	

#Text=Irrespective of whether participants were left or right handed, they used their right hand to press the buttons on the button box for the target picture.
87-1	15033-15045	Irrespective	_	
87-2	15046-15048	of	_	
87-3	15049-15056	whether	_	
87-4	15057-15069	participants	_	
87-5	15070-15074	were	_	
87-6	15075-15079	left	_	
87-7	15080-15082	or	_	
87-8	15083-15088	right	_	
87-9	15089-15095	handed	_	
87-10	15095-15096	,	_	
87-11	15097-15101	they	_	
87-12	15102-15106	used	_	
87-13	15107-15112	their	_	
87-14	15113-15118	right	_	
87-15	15119-15123	hand	_	
87-16	15124-15126	to	_	
87-17	15127-15132	press	_	
87-18	15133-15136	the	_	
87-19	15137-15144	buttons	_	
87-20	15145-15147	on	_	
87-21	15148-15151	the	_	
87-22	15152-15158	button	_	
87-23	15159-15162	box	_	
87-24	15163-15166	for	_	
87-25	15167-15170	the	_	
87-26	15171-15177	target	_	
87-27	15178-15185	picture	_	
87-28	15185-15186	.	_	

#Text=Behaviour analysis
#Text=An analysis of variance (ANOVA) was used to investigate group differences in pressing the buttons in response to the target stimuli and assessing reaction times.
88-1	15187-15196	Behaviour	_	
88-2	15197-15205	analysis	_	
88-3	15206-15208	An	_	
88-4	15209-15217	analysis	_	
88-5	15218-15220	of	_	
88-6	15221-15229	variance	_	
88-7	15230-15231	(	_	
88-8	15231-15236	ANOVA	_	
88-9	15236-15237	)	_	
88-10	15238-15241	was	_	
88-11	15242-15246	used	_	
88-12	15247-15249	to	_	
88-13	15250-15261	investigate	_	
88-14	15262-15267	group	_	
88-15	15268-15279	differences	_	
88-16	15280-15282	in	_	
88-17	15283-15291	pressing	_	
88-18	15292-15295	the	_	
88-19	15296-15303	buttons	_	
88-20	15304-15306	in	_	
88-21	15307-15315	response	_	
88-22	15316-15318	to	_	
88-23	15319-15322	the	_	
88-24	15323-15329	target	_	
88-25	15330-15337	stimuli	_	
88-26	15338-15341	and	_	
88-27	15342-15351	assessing	_	
88-28	15352-15360	reaction	_	
88-29	15361-15366	times	_	
88-30	15366-15367	.	_	

#Text=All runs in which participants missed more than five button presses were excluded.
89-1	15368-15371	All	_	
89-2	15372-15376	runs	_	
89-3	15377-15379	in	_	
89-4	15380-15385	which	_	
89-5	15386-15398	participants	_	
89-6	15399-15405	missed	_	
89-7	15406-15410	more	_	
89-8	15411-15415	than	_	
89-9	15416-15420	five	_	
89-10	15421-15427	button	_	
89-11	15428-15435	presses	_	
89-12	15436-15440	were	_	
89-13	15441-15449	excluded	_	
89-14	15449-15450	.	_	

#Text=Behavioural data were analysed using SPSS 21 (IBM Corp.).
#Text=fMRI data acquisition and analysis
#Text=A Siemens Magnetom Trio Tim syngo MR B17 operating at 3T was used to collect imaging data.
90-1	15451-15462	Behavioural	_	
90-2	15463-15467	data	_	
90-3	15468-15472	were	_	
90-4	15473-15481	analysed	_	
90-5	15482-15487	using	_	
90-6	15488-15492	SPSS	_	
90-7	15493-15495	21	_	
90-8	15496-15497	(	_	
90-9	15497-15500	IBM	_	
90-10	15501-15505	Corp	_	
90-11	15505-15506	.	_	
90-12	15506-15507	)	_	
90-13	15507-15508	.	_	
90-14	15509-15513	fMRI	_	
90-15	15514-15518	data	_	
90-16	15519-15530	acquisition	_	
90-17	15531-15534	and	_	
90-18	15535-15543	analysis	_	
90-19	15544-15545	A	_	
90-20	15546-15553	Siemens	_	
90-21	15554-15562	Magnetom	_	
90-22	15563-15567	Trio	_	
90-23	15568-15571	Tim	_	
90-24	15572-15577	syngo	_	
90-25	15578-15580	MR	_	
90-26	15581-15584	B17	_	
90-27	15585-15594	operating	_	
90-28	15595-15597	at	_	
90-29	15598-15600	3T	_	
90-30	15601-15604	was	_	
90-31	15605-15609	used	_	
90-32	15610-15612	to	_	
90-33	15613-15620	collect	_	
90-34	15621-15628	imaging	_	
90-35	15629-15633	data	_	
90-36	15633-15634	.	_	

#Text=Gradient-echo echo-planar T2*-weighted images depicting BOLD contrast were acquired from 35 non-contiguous oblique axial plane slices of 2 mm thickness to minimise signal drop-out in the ventral regions.
91-1	15635-15648	Gradient-echo	_	
91-2	15649-15660	echo-planar	_	
91-3	15661-15663	T2	_	
91-4	15663-15664	*	_	
91-5	15664-15665	-	_	
91-6	15665-15673	weighted	_	
91-7	15674-15680	images	_	
91-8	15681-15690	depicting	_	
91-9	15691-15695	BOLD	_	
91-10	15696-15704	contrast	_	
91-11	15705-15709	were	_	
91-12	15710-15718	acquired	_	
91-13	15719-15723	from	_	
91-14	15724-15726	35	_	
91-15	15727-15741	non-contiguous	_	
91-16	15742-15749	oblique	_	
91-17	15750-15755	axial	_	
91-18	15756-15761	plane	_	
91-19	15762-15768	slices	_	
91-20	15769-15771	of	_	
91-21	15772-15773	2	_	
91-22	15774-15776	mm	_	
91-23	15777-15786	thickness	_	
91-24	15787-15789	to	_	
91-25	15790-15798	minimise	_	
91-26	15799-15805	signal	_	
91-27	15806-15814	drop-out	_	
91-28	15815-15817	in	_	
91-29	15818-15821	the	_	
91-30	15822-15829	ventral	_	
91-31	15830-15837	regions	_	
91-32	15837-15838	.	_	

#Text=We did not retrieve images of the whole brain; the superior part of the cortex was not imaged.
92-1	15839-15841	We	_	
92-2	15842-15845	did	_	
92-3	15846-15849	not	_	
92-4	15850-15858	retrieve	_	
92-5	15859-15865	images	_	
92-6	15866-15868	of	_	
92-7	15869-15872	the	_	
92-8	15873-15878	whole	_	
92-9	15879-15884	brain	_	
92-10	15884-15885	;	_	
92-11	15886-15889	the	_	
92-12	15890-15898	superior	_	
92-13	15899-15903	part	_	
92-14	15904-15906	of	_	
92-15	15907-15910	the	_	
92-16	15911-15917	cortex	_	
92-17	15918-15921	was	_	
92-18	15922-15925	not	_	
92-19	15926-15932	imaged	_	
92-20	15932-15933	.	_	

#Text=The relaxation time was 1620 ms, echo time was 30 ms, flip angle was 65°, in-plane resolution was 3 × 3 × 3 mm, matrix size was 64 × 64, field of view was 192 × 192 mm, and bandwidth was 2442 Hz/px.
93-1	15934-15937	The	_	
93-2	15938-15948	relaxation	_	
93-3	15949-15953	time	_	
93-4	15954-15957	was	_	
93-5	15958-15962	1620	_	
93-6	15963-15965	ms	_	
93-7	15965-15966	,	_	
93-8	15967-15971	echo	_	
93-9	15972-15976	time	_	
93-10	15977-15980	was	_	
93-11	15981-15983	30	_	
93-12	15984-15986	ms	_	
93-13	15986-15987	,	_	
93-14	15988-15992	flip	_	
93-15	15993-15998	angle	_	
93-16	15999-16002	was	_	
93-17	16003-16005	65	_	
93-18	16005-16006	°	_	
93-19	16006-16007	,	_	
93-20	16008-16016	in-plane	_	
93-21	16017-16027	resolution	_	
93-22	16028-16031	was	_	
93-23	16032-16033	3	_	
93-24	16034-16035	×	_	
93-25	16036-16037	3	_	
93-26	16038-16039	×	_	
93-27	16040-16041	3	_	
93-28	16042-16044	mm	_	
93-29	16044-16045	,	_	
93-30	16046-16052	matrix	_	
93-31	16053-16057	size	_	
93-32	16058-16061	was	_	
93-33	16062-16064	64	_	
93-34	16065-16066	×	_	
93-35	16067-16069	64	_	
93-36	16069-16070	,	_	
93-37	16071-16076	field	_	
93-38	16077-16079	of	_	
93-39	16080-16084	view	_	
93-40	16085-16088	was	_	
93-41	16089-16092	192	_	
93-42	16093-16094	×	_	
93-43	16095-16098	192	_	
93-44	16099-16101	mm	_	
93-45	16101-16102	,	_	
93-46	16103-16106	and	_	
93-47	16107-16116	bandwidth	_	
93-48	16117-16120	was	_	
93-49	16121-16125	2442	_	
93-50	16126-16128	Hz	_	
93-51	16128-16129	/	_	
93-52	16129-16131	px	_	
93-53	16131-16132	.	_	

#Text=A total of 437 volumes per participant were acquired (35 slices each of 2 mm thickness, inter-slice gap 1 mm).
94-1	16133-16134	A	_	
94-2	16135-16140	total	_	
94-3	16141-16143	of	_	
94-4	16144-16147	437	_	
94-5	16148-16155	volumes	_	
94-6	16156-16159	per	_	
94-7	16160-16171	participant	_	
94-8	16172-16176	were	_	
94-9	16177-16185	acquired	_	
94-10	16186-16187	(	_	
94-11	16187-16189	35	_	
94-12	16190-16196	slices	_	
94-13	16197-16201	each	_	
94-14	16202-16204	of	_	
94-15	16205-16206	2	_	
94-16	16207-16209	mm	_	
94-17	16210-16219	thickness	_	
94-18	16219-16220	,	_	
94-19	16221-16232	inter-slice	_	
94-20	16233-16236	gap	_	
94-21	16237-16238	1	_	
94-22	16239-16241	mm	_	
94-23	16241-16242	)	_	
94-24	16242-16243	.	_	

#Text=The first five volumes were discarded to allow for T1 equilibration effects.
95-1	16244-16247	The	_	
95-2	16248-16253	first	_	
95-3	16254-16258	five	_	
95-4	16259-16266	volumes	_	
95-5	16267-16271	were	_	
95-6	16272-16281	discarded	_	
95-7	16282-16284	to	_	
95-8	16285-16290	allow	_	
95-9	16291-16294	for	_	
95-10	16295-16297	T1	_	
95-11	16298-16311	equilibration	_	
95-12	16312-16319	effects	_	
95-13	16319-16320	.	_	

#Text=Group effects in primary and secondary region of interest (ROI) analysis of activation associated with novelty processing (novel oddballs vs. neutral oddballs).
#Text=a Primary ROI (colour coding pink): SN/VTA, maximal difference at x = 0, y = −20, z = −6.
96-1	16321-16326	Group	_	
96-2	16327-16334	effects	_	
96-3	16335-16337	in	_	
96-4	16338-16345	primary	_	
96-5	16346-16349	and	_	
96-6	16350-16359	secondary	_	
96-7	16360-16366	region	_	
96-8	16367-16369	of	_	
96-9	16370-16378	interest	_	
96-10	16379-16380	(	_	
96-11	16380-16383	ROI	_	
96-12	16383-16384	)	_	
96-13	16385-16393	analysis	_	
96-14	16394-16396	of	_	
96-15	16397-16407	activation	_	
96-16	16408-16418	associated	_	
96-17	16419-16423	with	_	
96-18	16424-16431	novelty	_	
96-19	16432-16442	processing	_	
96-20	16443-16444	(	_	
96-21	16444-16449	novel	_	
96-22	16450-16458	oddballs	_	
96-23	16459-16461	vs	_	
96-24	16461-16462	.	_	
96-25	16463-16470	neutral	_	
96-26	16471-16479	oddballs	_	
96-27	16479-16480	)	_	
96-28	16480-16481	.	_	
96-29	16482-16483	a	_	
96-30	16484-16491	Primary	_	
96-31	16492-16495	ROI	_	
96-32	16496-16497	(	_	
96-33	16497-16503	colour	_	
96-34	16504-16510	coding	_	
96-35	16511-16515	pink	_	
96-36	16515-16516	)	_	
96-37	16516-16517	:	_	
96-38	16518-16520	SN	_	
96-39	16520-16521	/	_	
96-40	16521-16524	VTA	_	
96-41	16524-16525	,	_	
96-42	16526-16533	maximal	_	
96-43	16534-16544	difference	_	
96-44	16545-16547	at	_	
96-45	16548-16549	x	_	
96-46	16550-16551	=	_	
96-47	16552-16553	0	_	
96-48	16553-16554	,	_	
96-49	16555-16556	y	_	
96-50	16557-16558	=	_	
96-51	16559-16560	−	_	
96-52	16560-16562	20	_	
96-53	16562-16563	,	_	
96-54	16564-16565	z	_	
96-55	16566-16567	=	_	
96-56	16568-16569	−	_	
96-57	16569-16570	6	_	
96-58	16570-16571	.	_	

#Text=Secondary ROI (colour coding green), striatum, two clusters maximal difference at x = 8, y = −2, z = 14 and x = −8, y = −2, z = 12 (p < 0.05 FWE corrected). b Bar chart shows the mean contrast (COPEs, FSL) values to group, extracted from significant clusters determined by FSL randomise ANOVA results of primary and secondary ROI analysis.
97-1	16572-16581	Secondary	_	
97-2	16582-16585	ROI	_	
97-3	16586-16587	(	_	
97-4	16587-16593	colour	_	
97-5	16594-16600	coding	_	
97-6	16601-16606	green	_	
97-7	16606-16607	)	_	
97-8	16607-16608	,	_	
97-9	16609-16617	striatum	_	
97-10	16617-16618	,	_	
97-11	16619-16622	two	_	
97-12	16623-16631	clusters	_	
97-13	16632-16639	maximal	_	
97-14	16640-16650	difference	_	
97-15	16651-16653	at	_	
97-16	16654-16655	x	_	
97-17	16656-16657	=	_	
97-18	16658-16659	8	_	
97-19	16659-16660	,	_	
97-20	16661-16662	y	_	
97-21	16663-16664	=	_	
97-22	16665-16666	−	_	
97-23	16666-16667	2	_	
97-24	16667-16668	,	_	
97-25	16669-16670	z	_	
97-26	16671-16672	=	_	
97-27	16673-16675	14	_	
97-28	16676-16679	and	_	
97-29	16680-16681	x	_	
97-30	16682-16683	=	_	
97-31	16684-16685	−	_	
97-32	16685-16686	8	_	
97-33	16686-16687	,	_	
97-34	16688-16689	y	_	
97-35	16690-16691	=	_	
97-36	16692-16693	−	_	
97-37	16693-16694	2	_	
97-38	16694-16695	,	_	
97-39	16696-16697	z	_	
97-40	16698-16699	=	_	
97-41	16700-16702	12	_	
97-42	16703-16704	(	_	
97-43	16704-16705	p	_	
97-44	16706-16707	<	_	
97-45	16708-16712	0.05	_	
97-46	16713-16716	FWE	_	
97-47	16717-16726	corrected	_	
97-48	16726-16727	)	_	
97-49	16727-16728	.	_	
97-50	16729-16730	b	_	
97-51	16731-16734	Bar	_	
97-52	16735-16740	chart	_	
97-53	16741-16746	shows	_	
97-54	16747-16750	the	_	
97-55	16751-16755	mean	_	
97-56	16756-16764	contrast	_	
97-57	16765-16766	(	_	
97-58	16766-16771	COPEs	_	
97-59	16771-16772	,	_	
97-60	16773-16776	FSL	_	
97-61	16776-16777	)	_	
97-62	16778-16784	values	_	
97-63	16785-16787	to	_	
97-64	16788-16793	group	_	
97-65	16793-16794	,	_	
97-66	16795-16804	extracted	_	
97-67	16805-16809	from	_	
97-68	16810-16821	significant	_	
97-69	16822-16830	clusters	_	
97-70	16831-16841	determined	_	
97-71	16842-16844	by	_	
97-72	16845-16848	FSL	_	
97-73	16849-16858	randomise	_	
97-74	16859-16864	ANOVA	_	
97-75	16865-16872	results	_	
97-76	16873-16875	of	_	
97-77	16876-16883	primary	_	
97-78	16884-16887	and	_	
97-79	16888-16897	secondary	_	
97-80	16898-16901	ROI	_	
97-81	16902-16910	analysis	_	
97-82	16910-16911	.	_	

#Text=Multiple significant clusters are combined.
98-1	16912-16920	Multiple	_	
98-2	16921-16932	significant	_	
98-3	16933-16941	clusters	_	
98-4	16942-16945	are	_	
98-5	16946-16954	combined	_	
98-6	16954-16955	.	_	

#Text=Error bars show ±1 SE
#Text=Group effects in primary and secondary region of interest (ROI) analysis of activation associated with negative emotional salience processing (emotional oddballs vs. neutral oddballs).
#Text=a Primary ROI (colour coding pink): SN/VTA, four clusters maximal differences at x = −12, y = −16, z = −6; x = 0, y = −20 z = −4; x = −10, y = −22, z = −20; and x = −12, y = −26, z = −20, and amygdala maximal differences at x = 22, y = 0, z = −14.
99-1	16956-16961	Error	_	
99-2	16962-16966	bars	_	
99-3	16967-16971	show	_	
99-4	16972-16973	±	_	
99-5	16973-16974	1	_	
99-6	16975-16977	SE	_	
99-7	16978-16983	Group	_	
99-8	16984-16991	effects	_	
99-9	16992-16994	in	_	
99-10	16995-17002	primary	_	
99-11	17003-17006	and	_	
99-12	17007-17016	secondary	_	
99-13	17017-17023	region	_	
99-14	17024-17026	of	_	
99-15	17027-17035	interest	_	
99-16	17036-17037	(	_	
99-17	17037-17040	ROI	_	
99-18	17040-17041	)	_	
99-19	17042-17050	analysis	_	
99-20	17051-17053	of	_	
99-21	17054-17064	activation	_	
99-22	17065-17075	associated	_	
99-23	17076-17080	with	_	
99-24	17081-17089	negative	_	
99-25	17090-17099	emotional	_	
99-26	17100-17108	salience	_	
99-27	17109-17119	processing	_	
99-28	17120-17121	(	_	
99-29	17121-17130	emotional	_	
99-30	17131-17139	oddballs	_	
99-31	17140-17142	vs	_	
99-32	17142-17143	.	_	
99-33	17144-17151	neutral	_	
99-34	17152-17160	oddballs	_	
99-35	17160-17161	)	_	
99-36	17161-17162	.	_	
99-37	17163-17164	a	_	
99-38	17165-17172	Primary	_	
99-39	17173-17176	ROI	_	
99-40	17177-17178	(	_	
99-41	17178-17184	colour	_	
99-42	17185-17191	coding	_	
99-43	17192-17196	pink	_	
99-44	17196-17197	)	_	
99-45	17197-17198	:	_	
99-46	17199-17201	SN	_	
99-47	17201-17202	/	_	
99-48	17202-17205	VTA	_	
99-49	17205-17206	,	_	
99-50	17207-17211	four	_	
99-51	17212-17220	clusters	_	
99-52	17221-17228	maximal	_	
99-53	17229-17240	differences	_	
99-54	17241-17243	at	_	
99-55	17244-17245	x	_	
99-56	17246-17247	=	_	
99-57	17248-17249	−	_	
99-58	17249-17251	12	_	
99-59	17251-17252	,	_	
99-60	17253-17254	y	_	
99-61	17255-17256	=	_	
99-62	17257-17258	−	_	
99-63	17258-17260	16	_	
99-64	17260-17261	,	_	
99-65	17262-17263	z	_	
99-66	17264-17265	=	_	
99-67	17266-17267	−	_	
99-68	17267-17268	6	_	
99-69	17268-17269	;	_	
99-70	17270-17271	x	_	
99-71	17272-17273	=	_	
99-72	17274-17275	0	_	
99-73	17275-17276	,	_	
99-74	17277-17278	y	_	
99-75	17279-17280	=	_	
99-76	17281-17282	−	_	
99-77	17282-17284	20	_	
99-78	17285-17286	z	_	
99-79	17287-17288	=	_	
99-80	17289-17290	−	_	
99-81	17290-17291	4	_	
99-82	17291-17292	;	_	
99-83	17293-17294	x	_	
99-84	17295-17296	=	_	
99-85	17297-17298	−	_	
99-86	17298-17300	10	_	
99-87	17300-17301	,	_	
99-88	17302-17303	y	_	
99-89	17304-17305	=	_	
99-90	17306-17307	−	_	
99-91	17307-17309	22	_	
99-92	17309-17310	,	_	
99-93	17311-17312	z	_	
99-94	17313-17314	=	_	
99-95	17315-17316	−	_	
99-96	17316-17318	20	_	
99-97	17318-17319	;	_	
99-98	17320-17323	and	_	
99-99	17324-17325	x	_	
99-100	17326-17327	=	_	
99-101	17328-17329	−	_	
99-102	17329-17331	12	_	
99-103	17331-17332	,	_	
99-104	17333-17334	y	_	
99-105	17335-17336	=	_	
99-106	17337-17338	−	_	
99-107	17338-17340	26	_	
99-108	17340-17341	,	_	
99-109	17342-17343	z	_	
99-110	17344-17345	=	_	
99-111	17346-17347	−	_	
99-112	17347-17349	20	_	
99-113	17349-17350	,	_	
99-114	17351-17354	and	_	
99-115	17355-17363	amygdala	_	
99-116	17364-17371	maximal	_	
99-117	17372-17383	differences	_	
99-118	17384-17386	at	_	
99-119	17387-17388	x	_	
99-120	17389-17390	=	_	
99-121	17391-17393	22	_	
99-122	17393-17394	,	_	
99-123	17395-17396	y	_	
99-124	17397-17398	=	_	
99-125	17399-17400	0	_	
99-126	17400-17401	,	_	
99-127	17402-17403	z	_	
99-128	17404-17405	=	_	
99-129	17406-17407	−	_	
99-130	17407-17409	14	_	
99-131	17409-17410	.	_	

#Text=Secondary ROI (colour coding green), striatum, four clusters, maximal differences at x = 12, y = 14, z = 12; x = −10, y = −6, z = −16; x = −12, y = 6, z = −14 and x = −14, y = 22, z = −2 (p < 0.05 FWE corrected). b Bar chart shows the mean contrast (COPEs, FSL) values to group, extracted from significant clusters determined by FSL randomise ANOVA results of primary and secondary ROI analysis.
100-1	17411-17420	Secondary	_	
100-2	17421-17424	ROI	_	
100-3	17425-17426	(	_	
100-4	17426-17432	colour	_	
100-5	17433-17439	coding	_	
100-6	17440-17445	green	_	
100-7	17445-17446	)	_	
100-8	17446-17447	,	_	
100-9	17448-17456	striatum	_	
100-10	17456-17457	,	_	
100-11	17458-17462	four	_	
100-12	17463-17471	clusters	_	
100-13	17471-17472	,	_	
100-14	17473-17480	maximal	_	
100-15	17481-17492	differences	_	
100-16	17493-17495	at	_	
100-17	17496-17497	x	_	
100-18	17498-17499	=	_	
100-19	17500-17502	12	_	
100-20	17502-17503	,	_	
100-21	17504-17505	y	_	
100-22	17506-17507	=	_	
100-23	17508-17510	14	_	
100-24	17510-17511	,	_	
100-25	17512-17513	z	_	
100-26	17514-17515	=	_	
100-27	17516-17518	12	_	
100-28	17518-17519	;	_	
100-29	17520-17521	x	_	
100-30	17522-17523	=	_	
100-31	17524-17525	−	_	
100-32	17525-17527	10	_	
100-33	17527-17528	,	_	
100-34	17529-17530	y	_	
100-35	17531-17532	=	_	
100-36	17533-17534	−	_	
100-37	17534-17535	6	_	
100-38	17535-17536	,	_	
100-39	17537-17538	z	_	
100-40	17539-17540	=	_	
100-41	17541-17542	−	_	
100-42	17542-17544	16	_	
100-43	17544-17545	;	_	
100-44	17546-17547	x	_	
100-45	17548-17549	=	_	
100-46	17550-17551	−	_	
100-47	17551-17553	12	_	
100-48	17553-17554	,	_	
100-49	17555-17556	y	_	
100-50	17557-17558	=	_	
100-51	17559-17560	6	_	
100-52	17560-17561	,	_	
100-53	17562-17563	z	_	
100-54	17564-17565	=	_	
100-55	17566-17567	−	_	
100-56	17567-17569	14	_	
100-57	17570-17573	and	_	
100-58	17574-17575	x	_	
100-59	17576-17577	=	_	
100-60	17578-17579	−	_	
100-61	17579-17581	14	_	
100-62	17581-17582	,	_	
100-63	17583-17584	y	_	
100-64	17585-17586	=	_	
100-65	17587-17589	22	_	
100-66	17589-17590	,	_	
100-67	17591-17592	z	_	
100-68	17593-17594	=	_	
100-69	17595-17596	−	_	
100-70	17596-17597	2	_	
100-71	17598-17599	(	_	
100-72	17599-17600	p	_	
100-73	17601-17602	<	_	
100-74	17603-17607	0.05	_	
100-75	17608-17611	FWE	_	
100-76	17612-17621	corrected	_	
100-77	17621-17622	)	_	
100-78	17622-17623	.	_	
100-79	17624-17625	b	_	
100-80	17626-17629	Bar	_	
100-81	17630-17635	chart	_	
100-82	17636-17641	shows	_	
100-83	17642-17645	the	_	
100-84	17646-17650	mean	_	
100-85	17651-17659	contrast	_	
100-86	17660-17661	(	_	
100-87	17661-17666	COPEs	_	
100-88	17666-17667	,	_	
100-89	17668-17671	FSL	_	
100-90	17671-17672	)	_	
100-91	17673-17679	values	_	
100-92	17680-17682	to	_	
100-93	17683-17688	group	_	
100-94	17688-17689	,	_	
100-95	17690-17699	extracted	_	
100-96	17700-17704	from	_	
100-97	17705-17716	significant	_	
100-98	17717-17725	clusters	_	
100-99	17726-17736	determined	_	
100-100	17737-17739	by	_	
100-101	17740-17743	FSL	_	
100-102	17744-17753	randomise	_	
100-103	17754-17759	ANOVA	_	
100-104	17760-17767	results	_	
100-105	17768-17770	of	_	
100-106	17771-17778	primary	_	
100-107	17779-17782	and	_	
100-108	17783-17792	secondary	_	
100-109	17793-17796	ROI	_	
100-110	17797-17805	analysis	_	
100-111	17805-17806	.	_	

#Text=Multiple significant clusters are combined.
101-1	17807-17815	Multiple	_	
101-2	17816-17827	significant	_	
101-3	17828-17836	clusters	_	
101-4	17837-17840	are	_	
101-5	17841-17849	combined	_	
101-6	17849-17850	.	_	

#Text=Error bars show ±1 SE
#Text=The data were analysed using FSL software (FMRIB’s Software Library, www.fmrib.ox.ac.uk/fsl) version five.
102-1	17851-17856	Error	_	
102-2	17857-17861	bars	_	
102-3	17862-17866	show	_	
102-4	17867-17868	±	_	
102-5	17868-17869	1	_	
102-6	17870-17872	SE	_	
102-7	17873-17876	The	_	
102-8	17877-17881	data	_	
102-9	17882-17886	were	_	
102-10	17887-17895	analysed	_	
102-11	17896-17901	using	_	
102-12	17902-17905	FSL	_	
102-13	17906-17914	software	_	
102-14	17915-17916	(	_	
102-15	17916-17921	FMRIB	_	
102-16	17921-17922	’	_	
102-17	17922-17923	s	_	
102-18	17924-17932	Software	_	
102-19	17933-17940	Library	_	
102-20	17940-17941	,	_	
102-21	17942-17960	www.fmrib.ox.ac.uk	_	
102-22	17960-17961	/	_	
102-23	17961-17964	fsl	_	
102-24	17964-17965	)	_	
102-25	17966-17973	version	_	
102-26	17974-17978	five	_	
102-27	17978-17979	.	_	

#Text=Participants’ data (first-level analysis) were processed using the FMRI Expert Analysis Tool (FEAT).
103-1	17980-17992	Participants	_	
103-2	17992-17993	’	_	
103-3	17994-17998	data	_	
103-4	17999-18000	(	_	
103-5	18000-18011	first-level	_	
103-6	18012-18020	analysis	_	
103-7	18020-18021	)	_	
103-8	18022-18026	were	_	
103-9	18027-18036	processed	_	
103-10	18037-18042	using	_	
103-11	18043-18046	the	_	
103-12	18047-18051	FMRI	_	
103-13	18052-18058	Expert	_	
103-14	18059-18067	Analysis	_	
103-15	18068-18072	Tool	_	
103-16	18073-18074	(	_	
103-17	18074-18078	FEAT	_	
103-18	18078-18079	)	_	
103-19	18079-18080	.	_	

#Text=Functional images were realigned, motion corrected (MCFLIRT) and spatially smoothed with a 4 mm full-width half-maximum Gaussian kernel.
104-1	18081-18091	Functional	_	
104-2	18092-18098	images	_	
104-3	18099-18103	were	_	
104-4	18104-18113	realigned	_	
104-5	18113-18114	,	_	
104-6	18115-18121	motion	_	
104-7	18122-18131	corrected	_	
104-8	18132-18133	(	_	
104-9	18133-18140	MCFLIRT	_	
104-10	18140-18141	)	_	
104-11	18142-18145	and	_	
104-12	18146-18155	spatially	_	
104-13	18156-18164	smoothed	_	
104-14	18165-18169	with	_	
104-15	18170-18171	a	_	
104-16	18172-18173	4	_	
104-17	18174-18176	mm	_	
104-18	18177-18187	full-width	_	
104-19	18188-18200	half-maximum	_	
104-20	18201-18209	Gaussian	_	
104-21	18210-18216	kernel	_	
104-22	18216-18217	.	_	

#Text=A high-pass filter was applied (120 s cut-off).
105-1	18218-18219	A	_	
105-2	18220-18229	high-pass	_	
105-3	18230-18236	filter	_	
105-4	18237-18240	was	_	
105-5	18241-18248	applied	_	
105-6	18249-18250	(	_	
105-7	18250-18253	120	_	
105-8	18254-18255	s	_	
105-9	18256-18263	cut-off	_	
105-10	18263-18264	)	_	
105-11	18264-18265	.	_	

#Text=All images were registered to the whole-brain echo-planar image (EPI) (i.e., functional image with the whole-brain field of view), and then to the structural image of the corresponding participant (MPRAGE) and normalised to an MNI template, using linear registration with FSL FLIRT.
106-1	18266-18269	All	_	
106-2	18270-18276	images	_	
106-3	18277-18281	were	_	
106-4	18282-18292	registered	_	
106-5	18293-18295	to	_	
106-6	18296-18299	the	_	
106-7	18300-18311	whole-brain	_	
106-8	18312-18323	echo-planar	_	
106-9	18324-18329	image	_	
106-10	18330-18331	(	_	
106-11	18331-18334	EPI	_	
106-12	18334-18335	)	_	
106-13	18336-18337	(	_	
106-14	18337-18340	i.e	_	
106-15	18340-18341	.	_	
106-16	18341-18342	,	_	
106-17	18343-18353	functional	_	
106-18	18354-18359	image	_	
106-19	18360-18364	with	_	
106-20	18365-18368	the	_	
106-21	18369-18380	whole-brain	_	
106-22	18381-18386	field	_	
106-23	18387-18389	of	_	
106-24	18390-18394	view	_	
106-25	18394-18395	)	_	
106-26	18395-18396	,	_	
106-27	18397-18400	and	_	
106-28	18401-18405	then	_	
106-29	18406-18408	to	_	
106-30	18409-18412	the	_	
106-31	18413-18423	structural	_	
106-32	18424-18429	image	_	
106-33	18430-18432	of	_	
106-34	18433-18436	the	_	
106-35	18437-18450	corresponding	_	
106-36	18451-18462	participant	_	
106-37	18463-18464	(	_	
106-38	18464-18470	MPRAGE	_	
106-39	18470-18471	)	_	
106-40	18472-18475	and	_	
106-41	18476-18486	normalised	_	
106-42	18487-18489	to	_	
106-43	18490-18492	an	_	
106-44	18493-18496	MNI	_	
106-45	18497-18505	template	_	
106-46	18505-18506	,	_	
106-47	18507-18512	using	_	
106-48	18513-18519	linear	_	
106-49	18520-18532	registration	_	
106-50	18533-18537	with	_	
106-51	18538-18541	FSL	_	
106-52	18542-18547	FLIRT	_	
106-53	18547-18548	.	_	

#Text=The five explanatory variables (EVs) that we used were the onset times of the standard, target, emotional, novel and neutral pictures.
107-1	18549-18552	The	_	
107-2	18553-18557	five	_	
107-3	18558-18569	explanatory	_	
107-4	18570-18579	variables	_	
107-5	18580-18581	(	_	
107-6	18581-18584	EVs	_	
107-7	18584-18585	)	_	
107-8	18586-18590	that	_	
107-9	18591-18593	we	_	
107-10	18594-18598	used	_	
107-11	18599-18603	were	_	
107-12	18604-18607	the	_	
107-13	18608-18613	onset	_	
107-14	18614-18619	times	_	
107-15	18620-18622	of	_	
107-16	18623-18626	the	_	
107-17	18627-18635	standard	_	
107-18	18635-18636	,	_	
107-19	18637-18643	target	_	
107-20	18643-18644	,	_	
107-21	18645-18654	emotional	_	
107-22	18654-18655	,	_	
107-23	18656-18661	novel	_	
107-24	18662-18665	and	_	
107-25	18666-18673	neutral	_	
107-26	18674-18682	pictures	_	
107-27	18682-18683	.	_	

#Text=They were modelled as 1 s events and convolved with a canonical double-gamma response function.
108-1	18684-18688	They	_	
108-2	18689-18693	were	_	
108-3	18694-18702	modelled	_	
108-4	18703-18705	as	_	
108-5	18706-18707	1	_	
108-6	18708-18709	s	_	
108-7	18710-18716	events	_	
108-8	18717-18720	and	_	
108-9	18721-18730	convolved	_	
108-10	18731-18735	with	_	
108-11	18736-18737	a	_	
108-12	18738-18747	canonical	_	
108-13	18748-18760	double-gamma	_	
108-14	18761-18769	response	_	
108-15	18770-18778	function	_	
108-16	18778-18779	.	_	

#Text=We added a temporal derivative to the model to take into account possible variations in the haemodynamic response function.
109-1	18780-18782	We	_	
109-2	18783-18788	added	_	
109-3	18789-18790	a	_	
109-4	18791-18799	temporal	_	
109-5	18800-18810	derivative	_	
109-6	18811-18813	to	_	
109-7	18814-18817	the	_	
109-8	18818-18823	model	_	
109-9	18824-18826	to	_	
109-10	18827-18831	take	_	
109-11	18832-18836	into	_	
109-12	18837-18844	account	_	
109-13	18845-18853	possible	_	
109-14	18854-18864	variations	_	
109-15	18865-18867	in	_	
109-16	18868-18871	the	_	
109-17	18872-18884	haemodynamic	_	
109-18	18885-18893	response	_	
109-19	18894-18902	function	_	
109-20	18902-18903	.	_	

#Text=To capture residual movement-related artefacts, six covariates were used as regressors of no interest (three rigid-body translations and three rotations resulting from realignment).
110-1	18904-18906	To	_	
110-2	18907-18914	capture	_	
110-3	18915-18923	residual	_	
110-4	18924-18940	movement-related	_	
110-5	18941-18950	artefacts	_	
110-6	18950-18951	,	_	
110-7	18952-18955	six	_	
110-8	18956-18966	covariates	_	
110-9	18967-18971	were	_	
110-10	18972-18976	used	_	
110-11	18977-18979	as	_	
110-12	18980-18990	regressors	_	
110-13	18991-18993	of	_	
110-14	18994-18996	no	_	
110-15	18997-19005	interest	_	
110-16	19006-19007	(	_	
110-17	19007-19012	three	_	
110-18	19013-19023	rigid-body	_	
110-19	19024-19036	translations	_	
110-20	19037-19040	and	_	
110-21	19041-19046	three	_	
110-22	19047-19056	rotations	_	
110-23	19057-19066	resulting	_	
110-24	19067-19071	from	_	
110-25	19072-19083	realignment	_	
110-26	19083-19084	)	_	
110-27	19084-19085	.	_	

#Text=We used four contrasts: target–neutral, emotion–neutral, novel–neutral, and neutral–standard.
111-1	19086-19088	We	_	
111-2	19089-19093	used	_	
111-3	19094-19098	four	_	
111-4	19099-19108	contrasts	_	
111-5	19108-19109	:	_	
111-6	19110-19124	target–neutral	_	
111-7	19124-19125	,	_	
111-8	19126-19141	emotion–neutral	_	
111-9	19141-19142	,	_	
111-10	19143-19156	novel–neutral	_	
111-11	19156-19157	,	_	
111-12	19158-19161	and	_	
111-13	19162-19178	neutral–standard	_	
111-14	19178-19179	.	_	

#Text=In the “second-level” analysis, we averaged the four blocks of the task for each participant using FEAT with Fixed Effects.
112-1	19180-19182	In	_	
112-2	19183-19186	the	_	
112-3	19187-19188	“	_	
112-4	19188-19200	second-level	_	
112-5	19200-19201	”	_	
112-6	19202-19210	analysis	_	
112-7	19210-19211	,	_	
112-8	19212-19214	we	_	
112-9	19215-19223	averaged	_	
112-10	19224-19227	the	_	
112-11	19228-19232	four	_	
112-12	19233-19239	blocks	_	
112-13	19240-19242	of	_	
112-14	19243-19246	the	_	
112-15	19247-19251	task	_	
112-16	19252-19255	for	_	
112-17	19256-19260	each	_	
112-18	19261-19272	participant	_	
112-19	19273-19278	using	_	
112-20	19279-19283	FEAT	_	
112-21	19284-19288	with	_	
112-22	19289-19294	Fixed	_	
112-23	19295-19302	Effects	_	
112-24	19302-19303	.	_	

#Text=For estimation of group comparison (higher level, or “third level”) statistics, we used permutation testing utilising the FSL randomise tool, with threshold-free-cluster enhancement, which enhances cluster-like structures but remains fundamentally a voxel-wise statistical testing method.
113-1	19304-19307	For	_	
113-2	19308-19318	estimation	_	
113-3	19319-19321	of	_	
113-4	19322-19327	group	_	
113-5	19328-19338	comparison	_	
113-6	19339-19340	(	_	
113-7	19340-19346	higher	_	
113-8	19347-19352	level	_	
113-9	19352-19353	,	_	
113-10	19354-19356	or	_	
113-11	19357-19358	“	_	
113-12	19358-19363	third	_	
113-13	19364-19369	level	_	
113-14	19369-19370	”	_	
113-15	19370-19371	)	_	
113-16	19372-19382	statistics	_	
113-17	19382-19383	,	_	
113-18	19384-19386	we	_	
113-19	19387-19391	used	_	
113-20	19392-19403	permutation	_	
113-21	19404-19411	testing	_	
113-22	19412-19421	utilising	_	
113-23	19422-19425	the	_	
113-24	19426-19429	FSL	_	
113-25	19430-19439	randomise	_	
113-26	19440-19444	tool	_	
113-27	19444-19445	,	_	
113-28	19446-19450	with	_	
113-29	19451-19473	threshold-free-cluster	_	
113-30	19474-19485	enhancement	_	
113-31	19485-19486	,	_	
113-32	19487-19492	which	_	
113-33	19493-19501	enhances	_	
113-34	19502-19514	cluster-like	_	
113-35	19515-19525	structures	_	
113-36	19526-19529	but	_	
113-37	19530-19537	remains	_	
113-38	19538-19551	fundamentally	_	
113-39	19552-19553	a	_	
113-40	19554-19564	voxel-wise	_	
113-41	19565-19576	statistical	_	
113-42	19577-19584	testing	_	
113-43	19585-19591	method	_	
113-44	19591-19592	.	_	

#Text=We used 5000 permutations and we report results at p = 0.05 or less, family-wise error corrected for multiple comparisons, using the variance smoothing option (3 mm) as recommended for experiments with small to modest sample sizes, as is common in fMRI research.
114-1	19593-19595	We	_	
114-2	19596-19600	used	_	
114-3	19601-19605	5000	_	
114-4	19606-19618	permutations	_	
114-5	19619-19622	and	_	
114-6	19623-19625	we	_	
114-7	19626-19632	report	_	
114-8	19633-19640	results	_	
114-9	19641-19643	at	_	
114-10	19644-19645	p	_	
114-11	19646-19647	=	_	
114-12	19648-19652	0.05	_	
114-13	19653-19655	or	_	
114-14	19656-19660	less	_	
114-15	19660-19661	,	_	
114-16	19662-19673	family-wise	_	
114-17	19674-19679	error	_	
114-18	19680-19689	corrected	_	
114-19	19690-19693	for	_	
114-20	19694-19702	multiple	_	
114-21	19703-19714	comparisons	_	
114-22	19714-19715	,	_	
114-23	19716-19721	using	_	
114-24	19722-19725	the	_	
114-25	19726-19734	variance	_	
114-26	19735-19744	smoothing	_	
114-27	19745-19751	option	_	
114-28	19752-19753	(	_	
114-29	19753-19754	3	_	
114-30	19755-19757	mm	_	
114-31	19757-19758	)	_	
114-32	19759-19761	as	_	
114-33	19762-19773	recommended	_	
114-34	19774-19777	for	_	
114-35	19778-19789	experiments	_	
114-36	19790-19794	with	_	
114-37	19795-19800	small	_	
114-38	19801-19803	to	_	
114-39	19804-19810	modest	_	
114-40	19811-19817	sample	_	
114-41	19818-19823	sizes	_	
114-42	19823-19824	,	_	
114-43	19825-19827	as	_	
114-44	19828-19830	is	_	
114-45	19831-19837	common	_	
114-46	19838-19840	in	_	
114-47	19841-19845	fMRI	_	
114-48	19846-19854	research	_	
114-49	19854-19855	.	_	

#Text=For illustrative purposes only, we then extracted contrast values (contrast of parameter estimates, or COPEs in FSL) for each individual from voxels in which significant group differences were found (See bar chart in Figs. 2b and 3b).
115-1	19856-19859	For	_	
115-2	19860-19872	illustrative	_	
115-3	19873-19881	purposes	_	
115-4	19882-19886	only	_	
115-5	19886-19887	,	_	
115-6	19888-19890	we	_	
115-7	19891-19895	then	_	
115-8	19896-19905	extracted	_	
115-9	19906-19914	contrast	_	
115-10	19915-19921	values	_	
115-11	19922-19923	(	_	
115-12	19923-19931	contrast	_	
115-13	19932-19934	of	_	
115-14	19935-19944	parameter	_	
115-15	19945-19954	estimates	_	
115-16	19954-19955	,	_	
115-17	19956-19958	or	_	
115-18	19959-19964	COPEs	_	
115-19	19965-19967	in	_	
115-20	19968-19971	FSL	_	
115-21	19971-19972	)	_	
115-22	19973-19976	for	_	
115-23	19977-19981	each	_	
115-24	19982-19992	individual	_	
115-25	19993-19997	from	_	
115-26	19998-20004	voxels	_	
115-27	20005-20007	in	_	
115-28	20008-20013	which	_	
115-29	20014-20025	significant	_	
115-30	20026-20031	group	_	
115-31	20032-20043	differences	_	
115-32	20044-20048	were	_	
115-33	20049-20054	found	_	
115-34	20055-20056	(	_	
115-35	20056-20059	See	_	
115-36	20060-20063	bar	_	
115-37	20064-20069	chart	_	
115-38	20070-20072	in	_	
115-39	20073-20077	Figs	_	
115-40	20077-20078	.	_	
115-41	20079-20081	2b	_	
115-42	20082-20085	and	_	
115-43	20086-20088	3b	_	
115-44	20088-20089	)	_	
115-45	20089-20090	.	_	

#Text=Our main analysis was based on a region of interest (ROI) approach as follows.
116-1	20091-20094	Our	_	
116-2	20095-20099	main	_	
116-3	20100-20108	analysis	_	
116-4	20109-20112	was	_	
116-5	20113-20118	based	_	
116-6	20119-20121	on	_	
116-7	20122-20123	a	_	
116-8	20124-20130	region	_	
116-9	20131-20133	of	_	
116-10	20134-20142	interest	_	
116-11	20143-20144	(	_	
116-12	20144-20147	ROI	_	
116-13	20147-20148	)	_	
116-14	20149-20157	approach	_	
116-15	20158-20160	as	_	
116-16	20161-20168	follows	_	
116-17	20168-20169	.	_	

#Text=For all types of salience, our primary hypothesis involved the dopaminergic SN/VTA, which was used as our primary ROI.
117-1	20170-20173	For	_	
117-2	20174-20177	all	_	
117-3	20178-20183	types	_	
117-4	20184-20186	of	_	
117-5	20187-20195	salience	_	
117-6	20195-20196	,	_	
117-7	20197-20200	our	_	
117-8	20201-20208	primary	_	
117-9	20209-20219	hypothesis	_	
117-10	20220-20228	involved	_	
117-11	20229-20232	the	_	
117-12	20233-20245	dopaminergic	_	
117-13	20246-20248	SN	_	
117-14	20248-20249	/	_	
117-15	20249-20252	VTA	_	
117-16	20252-20253	,	_	
117-17	20254-20259	which	_	
117-18	20260-20263	was	_	
117-19	20264-20268	used	_	
117-20	20269-20271	as	_	
117-21	20272-20275	our	_	
117-22	20276-20283	primary	_	
117-23	20284-20287	ROI	_	
117-24	20287-20288	.	_	

#Text=It was generated using the probabilistic atlas of Murty and colleagues, in which traditional anatomical segmentation was replicated using a seed-based functional connectivity approach and which provides a mask that consists of the SN and VTA, also used in our previous work.
118-1	20289-20291	It	_	
118-2	20292-20295	was	_	
118-3	20296-20305	generated	_	
118-4	20306-20311	using	_	
118-5	20312-20315	the	_	
118-6	20316-20329	probabilistic	_	
118-7	20330-20335	atlas	_	
118-8	20336-20338	of	_	
118-9	20339-20344	Murty	_	
118-10	20345-20348	and	_	
118-11	20349-20359	colleagues	_	
118-12	20359-20360	,	_	
118-13	20361-20363	in	_	
118-14	20364-20369	which	_	
118-15	20370-20381	traditional	_	
118-16	20382-20392	anatomical	_	
118-17	20393-20405	segmentation	_	
118-18	20406-20409	was	_	
118-19	20410-20420	replicated	_	
118-20	20421-20426	using	_	
118-21	20427-20428	a	_	
118-22	20429-20439	seed-based	_	
118-23	20440-20450	functional	_	
118-24	20451-20463	connectivity	_	
118-25	20464-20472	approach	_	
118-26	20473-20476	and	_	
118-27	20477-20482	which	_	
118-28	20483-20491	provides	_	
118-29	20492-20493	a	_	
118-30	20494-20498	mask	_	
118-31	20499-20503	that	_	
118-32	20504-20512	consists	_	
118-33	20513-20515	of	_	
118-34	20516-20519	the	_	
118-35	20520-20522	SN	_	
118-36	20523-20526	and	_	
118-37	20527-20530	VTA	_	
118-38	20530-20531	,	_	
118-39	20532-20536	also	_	
118-40	20537-20541	used	_	
118-41	20542-20544	in	_	
118-42	20545-20548	our	_	
118-43	20549-20557	previous	_	
118-44	20558-20562	work	_	
118-45	20562-20563	.	_	

#Text=Furthermore, for each contrast we defined a secondary analysis, with either one region, or two non-adjacent regions combined in a single mask.
119-1	20564-20575	Furthermore	_	
119-2	20575-20576	,	_	
119-3	20577-20580	for	_	
119-4	20581-20585	each	_	
119-5	20586-20594	contrast	_	
119-6	20595-20597	we	_	
119-7	20598-20605	defined	_	
119-8	20606-20607	a	_	
119-9	20608-20617	secondary	_	
119-10	20618-20626	analysis	_	
119-11	20626-20627	,	_	
119-12	20628-20632	with	_	
119-13	20633-20639	either	_	
119-14	20640-20643	one	_	
119-15	20644-20650	region	_	
119-16	20650-20651	,	_	
119-17	20652-20654	or	_	
119-18	20655-20658	two	_	
119-19	20659-20671	non-adjacent	_	
119-20	20672-20679	regions	_	
119-21	20680-20688	combined	_	
119-22	20689-20691	in	_	
119-23	20692-20693	a	_	
119-24	20694-20700	single	_	
119-25	20701-20705	mask	_	
119-26	20705-20706	.	_	

#Text=For novelty, we used a secondary region of interest mask composed of the striatum (using a hand-drawn mask, encompassing both associative and limbic striatum, but not sensorimotor striatum, based on operational criteria) and the right lateral frontal cortex (utilising a sphere, 10 mm, centred at x = 50, y = 30, z = 28, based on our previous work).
120-1	20707-20710	For	_	
120-2	20711-20718	novelty	_	
120-3	20718-20719	,	_	
120-4	20720-20722	we	_	
120-5	20723-20727	used	_	
120-6	20728-20729	a	_	
120-7	20730-20739	secondary	_	
120-8	20740-20746	region	_	
120-9	20747-20749	of	_	
120-10	20750-20758	interest	_	
120-11	20759-20763	mask	_	
120-12	20764-20772	composed	_	
120-13	20773-20775	of	_	
120-14	20776-20779	the	_	
120-15	20780-20788	striatum	_	
120-16	20789-20790	(	_	
120-17	20790-20795	using	_	
120-18	20796-20797	a	_	
120-19	20798-20808	hand-drawn	_	
120-20	20809-20813	mask	_	
120-21	20813-20814	,	_	
120-22	20815-20827	encompassing	_	
120-23	20828-20832	both	_	
120-24	20833-20844	associative	_	
120-25	20845-20848	and	_	
120-26	20849-20855	limbic	_	
120-27	20856-20864	striatum	_	
120-28	20864-20865	,	_	
120-29	20866-20869	but	_	
120-30	20870-20873	not	_	
120-31	20874-20886	sensorimotor	_	
120-32	20887-20895	striatum	_	
120-33	20895-20896	,	_	
120-34	20897-20902	based	_	
120-35	20903-20905	on	_	
120-36	20906-20917	operational	_	
120-37	20918-20926	criteria	_	
120-38	20926-20927	)	_	
120-39	20928-20931	and	_	
120-40	20932-20935	the	_	
120-41	20936-20941	right	_	
120-42	20942-20949	lateral	_	
120-43	20950-20957	frontal	_	
120-44	20958-20964	cortex	_	
120-45	20965-20966	(	_	
120-46	20966-20975	utilising	_	
120-47	20976-20977	a	_	
120-48	20978-20984	sphere	_	
120-49	20984-20985	,	_	
120-50	20986-20988	10	_	
120-51	20989-20991	mm	_	
120-52	20991-20992	,	_	
120-53	20993-21000	centred	_	
120-54	21001-21003	at	_	
120-55	21004-21005	x	_	
120-56	21006-21007	=	_	
120-57	21008-21010	50	_	
120-58	21010-21011	,	_	
120-59	21012-21013	y	_	
120-60	21014-21015	=	_	
120-61	21016-21018	30	_	
120-62	21018-21019	,	_	
120-63	21020-21021	z	_	
120-64	21022-21023	=	_	
120-65	21024-21026	28	_	
120-66	21026-21027	,	_	
120-67	21028-21033	based	_	
120-68	21034-21036	on	_	
120-69	21037-21040	our	_	
120-70	21041-21049	previous	_	
120-71	21050-21054	work	_	
120-72	21054-21055	)	_	
120-73	21055-21056	.	_	

#Text=For negative emotional salience, our secondary region of interest mask was composed of the striatum and the amygdala (anatomically derived mask using the Harvard-Oxford subcortical structural atlas supplied with FSL).
121-1	21057-21060	For	_	
121-2	21061-21069	negative	_	
121-3	21070-21079	emotional	_	
121-4	21080-21088	salience	_	
121-5	21088-21089	,	_	
121-6	21090-21093	our	_	
121-7	21094-21103	secondary	_	
121-8	21104-21110	region	_	
121-9	21111-21113	of	_	
121-10	21114-21122	interest	_	
121-11	21123-21127	mask	_	
121-12	21128-21131	was	_	
121-13	21132-21140	composed	_	
121-14	21141-21143	of	_	
121-15	21144-21147	the	_	
121-16	21148-21156	striatum	_	
121-17	21157-21160	and	_	
121-18	21161-21164	the	_	
121-19	21165-21173	amygdala	_	
121-20	21174-21175	(	_	
121-21	21175-21187	anatomically	_	
121-22	21188-21195	derived	_	
121-23	21196-21200	mask	_	
121-24	21201-21206	using	_	
121-25	21207-21210	the	_	
121-26	21211-21225	Harvard-Oxford	_	
121-27	21226-21237	subcortical	_	
121-28	21238-21248	structural	_	
121-29	21249-21254	atlas	_	
121-30	21255-21263	supplied	_	
121-31	21264-21268	with	_	
121-32	21269-21272	FSL	_	
121-33	21272-21273	)	_	
121-34	21273-21274	.	_	

#Text=For targetness and rareness, we used the striatum as our secondary ROI.
122-1	21275-21278	For	_	
122-2	21279-21289	targetness	_	
122-3	21290-21293	and	_	
122-4	21294-21302	rareness	_	
122-5	21302-21303	,	_	
122-6	21304-21306	we	_	
122-7	21307-21311	used	_	
122-8	21312-21315	the	_	
122-9	21316-21324	striatum	_	
122-10	21325-21327	as	_	
122-11	21328-21331	our	_	
122-12	21332-21341	secondary	_	
122-13	21342-21345	ROI	_	
122-14	21345-21346	.	_	

#Text=Parameter estimates for the events that contribute to the contrasts of interest are presented in the supplementary materials (Supplementary Figures 5–8, and 11) for all conditions in primary and secondary ROIs.
123-1	21347-21356	Parameter	_	
123-2	21357-21366	estimates	_	
123-3	21367-21370	for	_	
123-4	21371-21374	the	_	
123-5	21375-21381	events	_	
123-6	21382-21386	that	_	
123-7	21387-21397	contribute	_	
123-8	21398-21400	to	_	
123-9	21401-21404	the	_	
123-10	21405-21414	contrasts	_	
123-11	21415-21417	of	_	
123-12	21418-21426	interest	_	
123-13	21427-21430	are	_	
123-14	21431-21440	presented	_	
123-15	21441-21443	in	_	
123-16	21444-21447	the	_	
123-17	21448-21461	supplementary	_	
123-18	21462-21471	materials	_	
123-19	21472-21473	(	_	
123-20	21473-21486	Supplementary	_	
123-21	21487-21494	Figures	_	
123-22	21495-21496	5	_	
123-23	21496-21497	–	_	
123-24	21497-21498	8	_	
123-25	21498-21499	,	_	
123-26	21500-21503	and	_	
123-27	21504-21506	11	_	
123-28	21506-21507	)	_	
123-29	21508-21511	for	_	
123-30	21512-21515	all	_	
123-31	21516-21526	conditions	_	
123-32	21527-21529	in	_	
123-33	21530-21537	primary	_	
123-34	21538-21541	and	_	
123-35	21542-21551	secondary	_	
123-36	21552-21556	ROIs	_	
123-37	21556-21557	.	_	

#Text=The parameter estimates indicate the potential drivers of the COPE (contrast of parameter estimates) effect.
124-1	21558-21561	The	_	
124-2	21562-21571	parameter	_	
124-3	21572-21581	estimates	_	
124-4	21582-21590	indicate	_	
124-5	21591-21594	the	_	
124-6	21595-21604	potential	_	
124-7	21605-21612	drivers	_	
124-8	21613-21615	of	_	
124-9	21616-21619	the	_	
124-10	21620-21624	COPE	_	
124-11	21625-21626	(	_	
124-12	21626-21634	contrast	_	
124-13	21635-21637	of	_	
124-14	21638-21647	parameter	_	
124-15	21648-21657	estimates	_	
124-16	21657-21658	)	_	
124-17	21659-21665	effect	_	
124-18	21665-21666	.	_	

#Text=For completeness, the same analysis as described above has been conducted on controls only and is presented in the supplements (Supplementary Figure 9, Supplementary Table 3 and 4).
125-1	21667-21670	For	_	
125-2	21671-21683	completeness	_	
125-3	21683-21684	,	_	
125-4	21685-21688	the	_	
125-5	21689-21693	same	_	
125-6	21694-21702	analysis	_	
125-7	21703-21705	as	_	
125-8	21706-21715	described	_	
125-9	21716-21721	above	_	
125-10	21722-21725	has	_	
125-11	21726-21730	been	_	
125-12	21731-21740	conducted	_	
125-13	21741-21743	on	_	
125-14	21744-21752	controls	_	
125-15	21753-21757	only	_	
125-16	21758-21761	and	_	
125-17	21762-21764	is	_	
125-18	21765-21774	presented	_	
125-19	21775-21777	in	_	
125-20	21778-21781	the	_	
125-21	21782-21793	supplements	_	
125-22	21794-21795	(	_	
125-23	21795-21808	Supplementary	_	
125-24	21809-21815	Figure	_	
125-25	21816-21817	9	_	
125-26	21817-21818	,	_	
125-27	21819-21832	Supplementary	_	
125-28	21833-21838	Table	_	
125-29	21839-21840	3	_	
125-30	21841-21844	and	_	
125-31	21845-21846	4	_	
125-32	21846-21847	)	_	
125-33	21847-21848	.	_	

#Text=Movement differences during fMRI scan
#Text=As the task was relatively long (46 min) and mostly passive (button presses were only required in 20 out of the total of 240 trials), we split the task into four blocks of 11.5 min.
126-1	21849-21857	Movement	_	
126-2	21858-21869	differences	_	
126-3	21870-21876	during	_	
126-4	21877-21881	fMRI	_	
126-5	21882-21886	scan	_	
126-6	21887-21889	As	_	
126-7	21890-21893	the	_	
126-8	21894-21898	task	_	
126-9	21899-21902	was	_	
126-10	21903-21913	relatively	_	
126-11	21914-21918	long	_	
126-12	21919-21920	(	_	
126-13	21920-21922	46	_	
126-14	21923-21926	min	_	
126-15	21926-21927	)	_	
126-16	21928-21931	and	_	
126-17	21932-21938	mostly	_	
126-18	21939-21946	passive	_	
126-19	21947-21948	(	_	
126-20	21948-21954	button	_	
126-21	21955-21962	presses	_	
126-22	21963-21967	were	_	
126-23	21968-21972	only	_	
126-24	21973-21981	required	_	
126-25	21982-21984	in	_	
126-26	21985-21987	20	_	
126-27	21988-21991	out	_	
126-28	21992-21994	of	_	
126-29	21995-21998	the	_	
126-30	21999-22004	total	_	
126-31	22005-22007	of	_	
126-32	22008-22011	240	_	
126-33	22012-22018	trials	_	
126-34	22018-22019	)	_	
126-35	22019-22020	,	_	
126-36	22021-22023	we	_	
126-37	22024-22029	split	_	
126-38	22030-22033	the	_	
126-39	22034-22038	task	_	
126-40	22039-22043	into	_	
126-41	22044-22048	four	_	
126-42	22049-22055	blocks	_	
126-43	22056-22058	of	_	
126-44	22059-22063	11.5	_	
126-45	22064-22067	min	_	
126-46	22067-22068	.	_	

#Text=Still many participants, independent of group, exhibited movements, possibly due to tiredness.
127-1	22069-22074	Still	_	
127-2	22075-22079	many	_	
127-3	22080-22092	participants	_	
127-4	22092-22093	,	_	
127-5	22094-22105	independent	_	
127-6	22106-22108	of	_	
127-7	22109-22114	group	_	
127-8	22114-22115	,	_	
127-9	22116-22125	exhibited	_	
127-10	22126-22135	movements	_	
127-11	22135-22136	,	_	
127-12	22137-22145	possibly	_	
127-13	22146-22149	due	_	
127-14	22150-22152	to	_	
127-15	22153-22162	tiredness	_	
127-16	22162-22163	.	_	

#Text=We, therefore, excluded those blocks in which movement exceeded 3 mm on average or 10 mm maximum.
128-1	22164-22166	We	_	
128-2	22166-22167	,	_	
128-3	22168-22177	therefore	_	
128-4	22177-22178	,	_	
128-5	22179-22187	excluded	_	
128-6	22188-22193	those	_	
128-7	22194-22200	blocks	_	
128-8	22201-22203	in	_	
128-9	22204-22209	which	_	
128-10	22210-22218	movement	_	
128-11	22219-22227	exceeded	_	
128-12	22228-22229	3	_	
128-13	22230-22232	mm	_	
128-14	22233-22235	on	_	
128-15	22236-22243	average	_	
128-16	22244-22246	or	_	
128-17	22247-22249	10	_	
128-18	22250-22252	mm	_	
128-19	22253-22260	maximum	_	
128-20	22260-22261	.	_	

#Text=In total, we identified 14 runs that fulfilled the movement exclusion criterion.
129-1	22262-22264	In	_	
129-2	22265-22270	total	_	
129-3	22270-22271	,	_	
129-4	22272-22274	we	_	
129-5	22275-22285	identified	_	
129-6	22286-22288	14	_	
129-7	22289-22293	runs	_	
129-8	22294-22298	that	_	
129-9	22299-22308	fulfilled	_	
129-10	22309-22312	the	_	
129-11	22313-22321	movement	_	
129-12	22322-22331	exclusion	_	
129-13	22332-22341	criterion	_	
129-14	22341-22342	.	_	

#Text=Of those 14 runs, 10 were either from testing block 3 or 4, 2 were from testing block 2 and 2 were from testing block 1.
130-1	22343-22345	Of	_	
130-2	22346-22351	those	_	
130-3	22352-22354	14	_	
130-4	22355-22359	runs	_	
130-5	22359-22360	,	_	
130-6	22361-22363	10	_	
130-7	22364-22368	were	_	
130-8	22369-22375	either	_	
130-9	22376-22380	from	_	
130-10	22381-22388	testing	_	
130-11	22389-22394	block	_	
130-12	22395-22396	3	_	
130-13	22397-22399	or	_	
130-14	22400-22401	4	_	
130-15	22401-22402	,	_	
130-16	22403-22404	2	_	
130-17	22405-22409	were	_	
130-18	22410-22414	from	_	
130-19	22415-22422	testing	_	
130-20	22423-22428	block	_	
130-21	22429-22430	2	_	
130-22	22431-22434	and	_	
130-23	22435-22436	2	_	
130-24	22437-22441	were	_	
130-25	22442-22446	from	_	
130-26	22447-22454	testing	_	
130-27	22455-22460	block	_	
130-28	22461-22462	1	_	
130-29	22462-22463	.	_	

#Text=Additionally, three runs had to be interrupted and were therefore not completed by the participants.
131-1	22464-22476	Additionally	_	
131-2	22476-22477	,	_	
131-3	22478-22483	three	_	
131-4	22484-22488	runs	_	
131-5	22489-22492	had	_	
131-6	22493-22495	to	_	
131-7	22496-22498	be	_	
131-8	22499-22510	interrupted	_	
131-9	22511-22514	and	_	
131-10	22515-22519	were	_	
131-11	22520-22529	therefore	_	
131-12	22530-22533	not	_	
131-13	22534-22543	completed	_	
131-14	22544-22546	by	_	
131-15	22547-22550	the	_	
131-16	22551-22563	participants	_	
131-17	22563-22564	.	_	

#Text=If for a single participant only one or two runs remained for analysis, we excluded this participant entirely.
132-1	22565-22567	If	_	
132-2	22568-22571	for	_	
132-3	22572-22573	a	_	
132-4	22574-22580	single	_	
132-5	22581-22592	participant	_	
132-6	22593-22597	only	_	
132-7	22598-22601	one	_	
132-8	22602-22604	or	_	
132-9	22605-22608	two	_	
132-10	22609-22613	runs	_	
132-11	22614-22622	remained	_	
132-12	22623-22626	for	_	
132-13	22627-22635	analysis	_	
132-14	22635-22636	,	_	
132-15	22637-22639	we	_	
132-16	22640-22648	excluded	_	
132-17	22649-22653	this	_	
132-18	22654-22665	participant	_	
132-19	22666-22674	entirely	_	
132-20	22674-22675	.	_	

#Text=Based on these criterions, we excluded three controls and one psychosis patient entirely, as well as one run in five psychosis patients and one run in three controls.
133-1	22676-22681	Based	_	
133-2	22682-22684	on	_	
133-3	22685-22690	these	_	
133-4	22691-22701	criterions	_	
133-5	22701-22702	,	_	
133-6	22703-22705	we	_	
133-7	22706-22714	excluded	_	
133-8	22715-22720	three	_	
133-9	22721-22729	controls	_	
133-10	22730-22733	and	_	
133-11	22734-22737	one	_	
133-12	22738-22747	psychosis	_	
133-13	22748-22755	patient	_	
133-14	22756-22764	entirely	_	
133-15	22764-22765	,	_	
133-16	22766-22768	as	_	
133-17	22769-22773	well	_	
133-18	22774-22776	as	_	
133-19	22777-22780	one	_	
133-20	22781-22784	run	_	
133-21	22785-22787	in	_	
133-22	22788-22792	five	_	
133-23	22793-22802	psychosis	_	
133-24	22803-22811	patients	_	
133-25	22812-22815	and	_	
133-26	22816-22819	one	_	
133-27	22820-22823	run	_	
133-28	22824-22826	in	_	
133-29	22827-22832	three	_	
133-30	22833-22841	controls	_	
133-31	22841-22842	.	_	

#Text=We excluded those four individuals from all analyses within this study.
134-1	22843-22845	We	_	
134-2	22846-22854	excluded	_	
134-3	22855-22860	those	_	
134-4	22861-22865	four	_	
134-5	22866-22877	individuals	_	
134-6	22878-22882	from	_	
134-7	22883-22886	all	_	
134-8	22887-22895	analyses	_	
134-9	22896-22902	within	_	
134-10	22903-22907	this	_	
134-11	22908-22913	study	_	
134-12	22913-22914	.	_	

#Text=In the remaining sample, we compared the two groups in two separate repeated measure ANOVAs across the four testing blocks, one for movement means and one for maximum (Supplementary Figure 1 and 2).
135-1	22915-22917	In	_	
135-2	22918-22921	the	_	
135-3	22922-22931	remaining	_	
135-4	22932-22938	sample	_	
135-5	22938-22939	,	_	
135-6	22940-22942	we	_	
135-7	22943-22951	compared	_	
135-8	22952-22955	the	_	
135-9	22956-22959	two	_	
135-10	22960-22966	groups	_	
135-11	22967-22969	in	_	
135-12	22970-22973	two	_	
135-13	22974-22982	separate	_	
135-14	22983-22991	repeated	_	
135-15	22992-22999	measure	_	
135-16	23000-23006	ANOVAs	_	
135-17	23007-23013	across	_	
135-18	23014-23017	the	_	
135-19	23018-23022	four	_	
135-20	23023-23030	testing	_	
135-21	23031-23037	blocks	_	
135-22	23037-23038	,	_	
135-23	23039-23042	one	_	
135-24	23043-23046	for	_	
135-25	23047-23055	movement	_	
135-26	23056-23061	means	_	
135-27	23062-23065	and	_	
135-28	23066-23069	one	_	
135-29	23070-23073	for	_	
135-30	23074-23081	maximum	_	
135-31	23082-23083	(	_	
135-32	23083-23096	Supplementary	_	
135-33	23097-23103	Figure	_	
135-34	23104-23105	1	_	
135-35	23106-23109	and	_	
135-36	23110-23111	2	_	
135-37	23111-23112	)	_	
135-38	23112-23113	.	_	

#Text=We did not find any significant group, run or interactions effect, neither for mean movement nor for maximum movement (all p > 0.1).
136-1	23114-23116	We	_	
136-2	23117-23120	did	_	
136-3	23121-23124	not	_	
136-4	23125-23129	find	_	
136-5	23130-23133	any	_	
136-6	23134-23145	significant	_	
136-7	23146-23151	group	_	
136-8	23151-23152	,	_	
136-9	23153-23156	run	_	
136-10	23157-23159	or	_	
136-11	23160-23172	interactions	_	
136-12	23173-23179	effect	_	
136-13	23179-23180	,	_	
136-14	23181-23188	neither	_	
136-15	23189-23192	for	_	
136-16	23193-23197	mean	_	
136-17	23198-23206	movement	_	
136-18	23207-23210	nor	_	
136-19	23211-23214	for	_	
136-20	23215-23222	maximum	_	
136-21	23223-23231	movement	_	
136-22	23232-23233	(	_	
136-23	23233-23236	all	_	
136-24	23237-23238	p	_	
136-25	23239-23240	>	_	
136-26	23241-23244	0.1	_	
136-27	23244-23245	)	_	
136-28	23245-23246	.	_	

#Text=Results
#Text=Demographic and questionnaire results
#Text=The demographic and rating results are summarised in Tables 1 and 2.
137-1	23247-23254	Results	_	
137-2	23255-23266	Demographic	_	
137-3	23267-23270	and	_	
137-4	23271-23284	questionnaire	_	
137-5	23285-23292	results	_	
137-6	23293-23296	The	_	
137-7	23297-23308	demographic	_	
137-8	23309-23312	and	_	
137-9	23313-23319	rating	_	
137-10	23320-23327	results	_	
137-11	23328-23331	are	_	
137-12	23332-23342	summarised	_	
137-13	23343-23345	in	_	
137-14	23346-23352	Tables	_	
137-15	23353-23354	1	_	
137-16	23355-23358	and	_	
137-17	23359-23360	2	_	
137-18	23360-23361	.	_	

#Text=There were significant differences in IQ between controls and patients (p = 0.02).
138-1	23362-23367	There	_	
138-2	23368-23372	were	_	
138-3	23373-23384	significant	_	
138-4	23385-23396	differences	_	
138-5	23397-23399	in	_	
138-6	23400-23402	IQ	_	
138-7	23403-23410	between	_	
138-8	23411-23419	controls	_	
138-9	23420-23423	and	_	
138-10	23424-23432	patients	_	
138-11	23433-23434	(	_	
138-12	23434-23435	p	_	
138-13	23436-23437	=	_	
138-14	23438-23442	0.02	_	
138-15	23442-23443	)	_	
138-16	23443-23444	.	_	

#Text=More importantly, however, the groups were matched in maternal education, which was similar across both groups (p = 0.36).
139-1	23445-23449	More	_	
139-2	23450-23461	importantly	_	
139-3	23461-23462	,	_	
139-4	23463-23470	however	_	
139-5	23470-23471	,	_	
139-6	23472-23475	the	_	
139-7	23476-23482	groups	_	
139-8	23483-23487	were	_	
139-9	23488-23495	matched	_	
139-10	23496-23498	in	_	
139-11	23499-23507	maternal	_	
139-12	23508-23517	education	_	
139-13	23517-23518	,	_	
139-14	23519-23524	which	_	
139-15	23525-23528	was	_	
139-16	23529-23536	similar	_	
139-17	23537-23543	across	_	
139-18	23544-23548	both	_	
139-19	23549-23555	groups	_	
139-20	23556-23557	(	_	
139-21	23557-23558	p	_	
139-22	23559-23560	=	_	
139-23	23561-23565	0.36	_	
139-24	23565-23566	)	_	
139-25	23566-23567	.	_	

#Text=Alcohol consumption was significantly lower in psychosis patients compared to controls (p = 0.002).
140-1	23568-23575	Alcohol	_	
140-2	23576-23587	consumption	_	
140-3	23588-23591	was	_	
140-4	23592-23605	significantly	_	
140-5	23606-23611	lower	_	
140-6	23612-23614	in	_	
140-7	23615-23624	psychosis	_	
140-8	23625-23633	patients	_	
140-9	23634-23642	compared	_	
140-10	23643-23645	to	_	
140-11	23646-23654	controls	_	
140-12	23655-23656	(	_	
140-13	23656-23657	p	_	
140-14	23658-23659	=	_	
140-15	23660-23665	0.002	_	
140-16	23665-23666	)	_	
140-17	23666-23667	.	_	

#Text=Behavioural responses to pictures and reaction times
#Text=In order to maintain engagement with task, participants were required to press a button in response to the target picture.
141-1	23668-23679	Behavioural	_	
141-2	23680-23689	responses	_	
141-3	23690-23692	to	_	
141-4	23693-23701	pictures	_	
141-5	23702-23705	and	_	
141-6	23706-23714	reaction	_	
141-7	23715-23720	times	_	
141-8	23721-23723	In	_	
141-9	23724-23729	order	_	
141-10	23730-23732	to	_	
141-11	23733-23741	maintain	_	
141-12	23742-23752	engagement	_	
141-13	23753-23757	with	_	
141-14	23758-23762	task	_	
141-15	23762-23763	,	_	
141-16	23764-23776	participants	_	
141-17	23777-23781	were	_	
141-18	23782-23790	required	_	
141-19	23791-23793	to	_	
141-20	23794-23799	press	_	
141-21	23800-23801	a	_	
141-22	23802-23808	button	_	
141-23	23809-23811	in	_	
141-24	23812-23820	response	_	
141-25	23821-23823	to	_	
141-26	23824-23827	the	_	
141-27	23828-23834	target	_	
141-28	23835-23842	picture	_	
141-29	23842-23843	.	_	

#Text=Due to technical problems, button presses were not recorded for eight controls, and one psychosis patient.
142-1	23844-23847	Due	_	
142-2	23848-23850	to	_	
142-3	23851-23860	technical	_	
142-4	23861-23869	problems	_	
142-5	23869-23870	,	_	
142-6	23871-23877	button	_	
142-7	23878-23885	presses	_	
142-8	23886-23890	were	_	
142-9	23891-23894	not	_	
142-10	23895-23903	recorded	_	
142-11	23904-23907	for	_	
142-12	23908-23913	eight	_	
142-13	23914-23922	controls	_	
142-14	23922-23923	,	_	
142-15	23924-23927	and	_	
142-16	23928-23931	one	_	
142-17	23932-23941	psychosis	_	
142-18	23942-23949	patient	_	
142-19	23949-23950	.	_	

#Text=Analysing the number of missed button presses and reaction times of the remaining participants across the four testing blocks (Supplementary Table 1), we did not find any significant effects for group, testing block or any interactions (all p > 0.3).
143-1	23951-23960	Analysing	_	
143-2	23961-23964	the	_	
143-3	23965-23971	number	_	
143-4	23972-23974	of	_	
143-5	23975-23981	missed	_	
143-6	23982-23988	button	_	
143-7	23989-23996	presses	_	
143-8	23997-24000	and	_	
143-9	24001-24009	reaction	_	
143-10	24010-24015	times	_	
143-11	24016-24018	of	_	
143-12	24019-24022	the	_	
143-13	24023-24032	remaining	_	
143-14	24033-24045	participants	_	
143-15	24046-24052	across	_	
143-16	24053-24056	the	_	
143-17	24057-24061	four	_	
143-18	24062-24069	testing	_	
143-19	24070-24076	blocks	_	
143-20	24077-24078	(	_	
143-21	24078-24091	Supplementary	_	
143-22	24092-24097	Table	_	
143-23	24098-24099	1	_	
143-24	24099-24100	)	_	
143-25	24100-24101	,	_	
143-26	24102-24104	we	_	
143-27	24105-24108	did	_	
143-28	24109-24112	not	_	
143-29	24113-24117	find	_	
143-30	24118-24121	any	_	
143-31	24122-24133	significant	_	
143-32	24134-24141	effects	_	
143-33	24142-24145	for	_	
143-34	24146-24151	group	_	
143-35	24151-24152	,	_	
143-36	24153-24160	testing	_	
143-37	24161-24166	block	_	
143-38	24167-24169	or	_	
143-39	24170-24173	any	_	
143-40	24174-24186	interactions	_	
143-41	24187-24188	(	_	
143-42	24188-24191	all	_	
143-43	24192-24193	p	_	
143-44	24194-24195	>	_	
143-45	24196-24199	0.3	_	
143-46	24199-24200	)	_	
143-47	24200-24201	.	_	

#Text=On average, participants missed to press the button on one target trial (mean: 1.0 SE ± 0.2) and generally required approximately 550 ms (SE ± 0.02) to make a response, which is consistent with previous findings.
144-1	24202-24204	On	_	
144-2	24205-24212	average	_	
144-3	24212-24213	,	_	
144-4	24214-24226	participants	_	
144-5	24227-24233	missed	_	
144-6	24234-24236	to	_	
144-7	24237-24242	press	_	
144-8	24243-24246	the	_	
144-9	24247-24253	button	_	
144-10	24254-24256	on	_	
144-11	24257-24260	one	_	
144-12	24261-24267	target	_	
144-13	24268-24273	trial	_	
144-14	24274-24275	(	_	
144-15	24275-24279	mean	_	
144-16	24279-24280	:	_	
144-17	24281-24284	1.0	_	
144-18	24285-24287	SE	_	
144-19	24288-24289	±	_	
144-20	24290-24293	0.2	_	
144-21	24293-24294	)	_	
144-22	24295-24298	and	_	
144-23	24299-24308	generally	_	
144-24	24309-24317	required	_	
144-25	24318-24331	approximately	_	
144-26	24332-24335	550	_	
144-27	24336-24338	ms	_	
144-28	24339-24340	(	_	
144-29	24340-24342	SE	_	
144-30	24343-24344	±	_	
144-31	24345-24349	0.02	_	
144-32	24349-24350	)	_	
144-33	24351-24353	to	_	
144-34	24354-24358	make	_	
144-35	24359-24360	a	_	
144-36	24361-24369	response	_	
144-37	24369-24370	,	_	
144-38	24371-24376	which	_	
144-39	24377-24379	is	_	
144-40	24380-24390	consistent	_	
144-41	24391-24395	with	_	
144-42	24396-24404	previous	_	
144-43	24405-24413	findings	_	
144-44	24413-24414	.	_	

#Text=Due to the high performance across all groups, we included the data of the nine participants without recorded button presses in all further analyses, in order to increase statistical power.
145-1	24415-24418	Due	_	
145-2	24419-24421	to	_	
145-3	24422-24425	the	_	
145-4	24426-24430	high	_	
145-5	24431-24442	performance	_	
145-6	24443-24449	across	_	
145-7	24450-24453	all	_	
145-8	24454-24460	groups	_	
145-9	24460-24461	,	_	
145-10	24462-24464	we	_	
145-11	24465-24473	included	_	
145-12	24474-24477	the	_	
145-13	24478-24482	data	_	
145-14	24483-24485	of	_	
145-15	24486-24489	the	_	
145-16	24490-24494	nine	_	
145-17	24495-24507	participants	_	
145-18	24508-24515	without	_	
145-19	24516-24524	recorded	_	
145-20	24525-24531	button	_	
145-21	24532-24539	presses	_	
145-22	24540-24542	in	_	
145-23	24543-24546	all	_	
145-24	24547-24554	further	_	
145-25	24555-24563	analyses	_	
145-26	24563-24564	,	_	
145-27	24565-24567	in	_	
145-28	24568-24573	order	_	
145-29	24574-24576	to	_	
145-30	24577-24585	increase	_	
145-31	24586-24597	statistical	_	
145-32	24598-24603	power	_	
145-33	24603-24604	.	_	

#Text=We also repeated the analysis after excluding those participants.
146-1	24605-24607	We	_	
146-2	24608-24612	also	_	
146-3	24613-24621	repeated	_	
146-4	24622-24625	the	_	
146-5	24626-24634	analysis	_	
146-6	24635-24640	after	_	
146-7	24641-24650	excluding	_	
146-8	24651-24656	those	_	
146-9	24657-24669	participants	_	
146-10	24669-24670	.	_	

#Text=The results were very similar.
#Text=fMRI results
#Text=Novelty (novel–neutral oddballs)
#Text=In our primary ROI, the SN/VTA, psychosis patients showed a significant reduction of activation compared to the controls (t = 4.39, p = 0.015 FWE corrected, 10 voxels; maximal difference at x = 0, y = −20, z = −6).
147-1	24671-24674	The	_	
147-2	24675-24682	results	_	
147-3	24683-24687	were	_	
147-4	24688-24692	very	_	
147-5	24693-24700	similar	_	
147-6	24700-24701	.	_	
147-7	24702-24706	fMRI	_	
147-8	24707-24714	results	_	
147-9	24715-24722	Novelty	_	
147-10	24723-24724	(	_	
147-11	24724-24737	novel–neutral	_	
147-12	24738-24746	oddballs	_	
147-13	24746-24747	)	_	
147-14	24748-24750	In	_	
147-15	24751-24754	our	_	
147-16	24755-24762	primary	_	
147-17	24763-24766	ROI	_	
147-18	24766-24767	,	_	
147-19	24768-24771	the	_	
147-20	24772-24774	SN	_	
147-21	24774-24775	/	_	
147-22	24775-24778	VTA	_	
147-23	24778-24779	,	_	
147-24	24780-24789	psychosis	_	
147-25	24790-24798	patients	_	
147-26	24799-24805	showed	_	
147-27	24806-24807	a	_	
147-28	24808-24819	significant	_	
147-29	24820-24829	reduction	_	
147-30	24830-24832	of	_	
147-31	24833-24843	activation	_	
147-32	24844-24852	compared	_	
147-33	24853-24855	to	_	
147-34	24856-24859	the	_	
147-35	24860-24868	controls	_	
147-36	24869-24870	(	_	
147-37	24870-24871	t	_	
147-38	24872-24873	=	_	
147-39	24874-24878	4.39	_	
147-40	24878-24879	,	_	
147-41	24880-24881	p	_	
147-42	24882-24883	=	_	
147-43	24884-24889	0.015	_	
147-44	24890-24893	FWE	_	
147-45	24894-24903	corrected	_	
147-46	24903-24904	,	_	
147-47	24905-24907	10	_	
147-48	24908-24914	voxels	_	
147-49	24914-24915	;	_	
147-50	24916-24923	maximal	_	
147-51	24924-24934	difference	_	
147-52	24935-24937	at	_	
147-53	24938-24939	x	_	
147-54	24940-24941	=	_	
147-55	24942-24943	0	_	
147-56	24943-24944	,	_	
147-57	24945-24946	y	_	
147-58	24947-24948	=	_	
147-59	24949-24950	−	_	
147-60	24950-24952	20	_	
147-61	24952-24953	,	_	
147-62	24954-24955	z	_	
147-63	24956-24957	=	_	
147-64	24958-24959	−	_	
147-65	24959-24960	6	_	
147-66	24960-24961	)	_	
147-67	24961-24962	.	_	

#Text=See Fig. 2a, b.
148-1	24963-24966	See	_	
148-2	24967-24970	Fig	_	
148-3	24970-24971	.	_	
148-4	24972-24974	2a	_	
148-5	24974-24975	,	_	
148-6	24976-24977	b	_	
148-7	24977-24978	.	_	

#Text=In our secondary ROI, composed of the striatum and the DLPFC, we found two significant clusters, both within the striatum, that showed reduced activation for psychosis patients (cluster 1: t = 4.51, p = 0.03 FWE corrected, 18 voxels; maximal difference at x = 8, y = −2, z = 14; cluster 2: t = 3.66, p = 0.008 FWE corrected, 10 voxels; maximal difference at x = −8, y = −2, z = 12).
149-1	24979-24981	In	_	
149-2	24982-24985	our	_	
149-3	24986-24995	secondary	_	
149-4	24996-24999	ROI	_	
149-5	24999-25000	,	_	
149-6	25001-25009	composed	_	
149-7	25010-25012	of	_	
149-8	25013-25016	the	_	
149-9	25017-25025	striatum	_	
149-10	25026-25029	and	_	
149-11	25030-25033	the	_	
149-12	25034-25039	DLPFC	_	
149-13	25039-25040	,	_	
149-14	25041-25043	we	_	
149-15	25044-25049	found	_	
149-16	25050-25053	two	_	
149-17	25054-25065	significant	_	
149-18	25066-25074	clusters	_	
149-19	25074-25075	,	_	
149-20	25076-25080	both	_	
149-21	25081-25087	within	_	
149-22	25088-25091	the	_	
149-23	25092-25100	striatum	_	
149-24	25100-25101	,	_	
149-25	25102-25106	that	_	
149-26	25107-25113	showed	_	
149-27	25114-25121	reduced	_	
149-28	25122-25132	activation	_	
149-29	25133-25136	for	_	
149-30	25137-25146	psychosis	_	
149-31	25147-25155	patients	_	
149-32	25156-25157	(	_	
149-33	25157-25164	cluster	_	
149-34	25165-25166	1	_	
149-35	25166-25167	:	_	
149-36	25168-25169	t	_	
149-37	25170-25171	=	_	
149-38	25172-25176	4.51	_	
149-39	25176-25177	,	_	
149-40	25178-25179	p	_	
149-41	25180-25181	=	_	
149-42	25182-25186	0.03	_	
149-43	25187-25190	FWE	_	
149-44	25191-25200	corrected	_	
149-45	25200-25201	,	_	
149-46	25202-25204	18	_	
149-47	25205-25211	voxels	_	
149-48	25211-25212	;	_	
149-49	25213-25220	maximal	_	
149-50	25221-25231	difference	_	
149-51	25232-25234	at	_	
149-52	25235-25236	x	_	
149-53	25237-25238	=	_	
149-54	25239-25240	8	_	
149-55	25240-25241	,	_	
149-56	25242-25243	y	_	
149-57	25244-25245	=	_	
149-58	25246-25247	−	_	
149-59	25247-25248	2	_	
149-60	25248-25249	,	_	
149-61	25250-25251	z	_	
149-62	25252-25253	=	_	
149-63	25254-25256	14	_	
149-64	25256-25257	;	_	
149-65	25258-25265	cluster	_	
149-66	25266-25267	2	_	
149-67	25267-25268	:	_	
149-68	25269-25270	t	_	
149-69	25271-25272	=	_	
149-70	25273-25277	3.66	_	
149-71	25277-25278	,	_	
149-72	25279-25280	p	_	
149-73	25281-25282	=	_	
149-74	25283-25288	0.008	_	
149-75	25289-25292	FWE	_	
149-76	25293-25302	corrected	_	
149-77	25302-25303	,	_	
149-78	25304-25306	10	_	
149-79	25307-25313	voxels	_	
149-80	25313-25314	;	_	
149-81	25315-25322	maximal	_	
149-82	25323-25333	difference	_	
149-83	25334-25336	at	_	
149-84	25337-25338	x	_	
149-85	25339-25340	=	_	
149-86	25341-25342	−	_	
149-87	25342-25343	8	_	
149-88	25343-25344	,	_	
149-89	25345-25346	y	_	
149-90	25347-25348	=	_	
149-91	25349-25350	−	_	
149-92	25350-25351	2	_	
149-93	25351-25352	,	_	
149-94	25353-25354	z	_	
149-95	25355-25356	=	_	
149-96	25357-25359	12	_	
149-97	25359-25360	)	_	
149-98	25360-25361	.	_	

#Text=See Fig. 2a, b.
#Text=fMRI Activations from FSL randomise whole brain analysis
#Text=Anatomical structure\tHemisphere\tCluster size (voxel)\tP value (TFCE)\tt value\tPeak MNI-coordinates\t \tX\ty\tz\t \tNovel–neutral oddball (novelty)\t \tCerebellum CrusI\tL\t221\t0.041\t4.27\t−24\t−90\t−20\t \tOccipital pole, lingual gyrus\tL/R\t69\t0.048\t2.73\t4\t−94\t−4\t \tOccipital pole and cortex\tL\t23\t0.049\t3.6\t−26\t−96\t−4\t \tCerebellum CrusI,II\tR\t19\t0.049\t3.85\t46\t−50\t−38\t \tCerebellum CrusI\tL\t10\t0.048\t4.81\t−50\t−68\t−32\t \tCerebellum CrusI\tR\t10\t0.049\t4.07\t52\t−60\t−28\t \tOccipital pole and cortex\tL\t2\t0.05\t3.77\t−8\t−96\t−6\t \tOccipital cortex, inferior\tL\t1\t0.05\t3.81\t−48\t−82\t4\t \tEmotional–neutral oddball (negative emotional salience)\t \tLingual gyrus, intracalcarine cortex\tR\t11327\t0.02\t3.82\t6\t−86\t−2\t \tParahippocampus, putamen, nucleus accumbens\tL\t321\t0.041\t4.01\t−10\t2\t−20\t \tOccipital cortex, inferior\tR\t73\t0.045\t3.39\t44\t−72\t10\t \tAmygdala\tL\t15\t0.046\t3.5\t−26\t−2\t−12\t \tCerebellum CrusI and occipital cortex inferior\tL\t14\t0.048\t2.95\t−46\t−76\t−26\t \tCerebellum lobe X and VIIIb\tR\t11\t0.048\t3.14\t16\t−40\t−46\t \tSN/VTA\tL\t10\t0.048\t2.51\t−12\t−16\t−6\t \tFrontal operculum cortex\tL\t9\t0.047\t2.04\t−40\t16\t4\t \tACC\tR/L\t9\t0.048\t3.19\t2\t16\t18\t \tParahippocampal gyrus\tL\t4\t0.047\t3.43\t−14\t−14\t−24\t \tACC\tL\t1\t0.05\t2.72\t−8\t6\t36\t \tTarget–neutral oddball (targetness)\t \tn.s.
150-1	25362-25365	See	_	
150-2	25366-25369	Fig	_	
150-3	25369-25370	.	_	
150-4	25371-25373	2a	_	
150-5	25373-25374	,	_	
150-6	25375-25376	b	_	
150-7	25376-25377	.	_	
150-8	25378-25382	fMRI	_	
150-9	25383-25394	Activations	_	
150-10	25395-25399	from	_	
150-11	25400-25403	FSL	_	
150-12	25404-25413	randomise	_	
150-13	25414-25419	whole	_	
150-14	25420-25425	brain	_	
150-15	25426-25434	analysis	_	
150-16	25435-25445	Anatomical	_	
150-17	25446-25455	structure	_	
150-18	25456-25466	Hemisphere	_	
150-19	25467-25474	Cluster	_	
150-20	25475-25479	size	_	
150-21	25480-25481	(	_	
150-22	25481-25486	voxel	_	
150-23	25486-25487	)	_	
150-24	25488-25489	P	_	
150-25	25490-25495	value	_	
150-26	25496-25497	(	_	
150-27	25497-25501	TFCE	_	
150-28	25501-25502	)	_	
150-29	25503-25504	t	_	
150-30	25505-25510	value	_	
150-31	25511-25515	Peak	_	
150-32	25516-25531	MNI-coordinates	_	
150-33	25534-25535	X	_	
150-34	25536-25537	y	_	
150-35	25538-25539	z	_	
150-36	25542-25555	Novel–neutral	_	
150-37	25556-25563	oddball	_	
150-38	25564-25565	(	_	
150-39	25565-25572	novelty	_	
150-40	25572-25573	)	_	
150-41	25576-25586	Cerebellum	_	
150-42	25587-25592	CrusI	_	
150-43	25593-25594	L	_	
150-44	25595-25598	221	_	
150-45	25599-25604	0.041	_	
150-46	25605-25609	4.27	_	
150-47	25610-25611	−	_	
150-48	25611-25613	24	_	
150-49	25614-25615	−	_	
150-50	25615-25617	90	_	
150-51	25618-25619	−	_	
150-52	25619-25621	20	_	
150-53	25624-25633	Occipital	_	
150-54	25634-25638	pole	_	
150-55	25638-25639	,	_	
150-56	25640-25647	lingual	_	
150-57	25648-25653	gyrus	_	
150-58	25654-25655	L	_	
150-59	25655-25656	/	_	
150-60	25656-25657	R	_	
150-61	25658-25660	69	_	
150-62	25661-25666	0.048	_	
150-63	25667-25671	2.73	_	
150-64	25672-25673	4	_	
150-65	25674-25675	−	_	
150-66	25675-25677	94	_	
150-67	25678-25679	−	_	
150-68	25679-25680	4	_	
150-69	25683-25692	Occipital	_	
150-70	25693-25697	pole	_	
150-71	25698-25701	and	_	
150-72	25702-25708	cortex	_	
150-73	25709-25710	L	_	
150-74	25711-25713	23	_	
150-75	25714-25719	0.049	_	
150-76	25720-25723	3.6	_	
150-77	25724-25725	−	_	
150-78	25725-25727	26	_	
150-79	25728-25729	−	_	
150-80	25729-25731	96	_	
150-81	25732-25733	−	_	
150-82	25733-25734	4	_	
150-83	25737-25747	Cerebellum	_	
150-84	25748-25753	CrusI	_	
150-85	25753-25754	,	_	
150-86	25754-25756	II	_	
150-87	25757-25758	R	_	
150-88	25759-25761	19	_	
150-89	25762-25767	0.049	_	
150-90	25768-25772	3.85	_	
150-91	25773-25775	46	_	
150-92	25776-25777	−	_	
150-93	25777-25779	50	_	
150-94	25780-25781	−	_	
150-95	25781-25783	38	_	
150-96	25786-25796	Cerebellum	_	
150-97	25797-25802	CrusI	_	
150-98	25803-25804	L	_	
150-99	25805-25807	10	_	
150-100	25808-25813	0.048	_	
150-101	25814-25818	4.81	_	
150-102	25819-25820	−	_	
150-103	25820-25822	50	_	
150-104	25823-25824	−	_	
150-105	25824-25826	68	_	
150-106	25827-25828	−	_	
150-107	25828-25830	32	_	
150-108	25833-25843	Cerebellum	_	
150-109	25844-25849	CrusI	_	
150-110	25850-25851	R	_	
150-111	25852-25854	10	_	
150-112	25855-25860	0.049	_	
150-113	25861-25865	4.07	_	
150-114	25866-25868	52	_	
150-115	25869-25870	−	_	
150-116	25870-25872	60	_	
150-117	25873-25874	−	_	
150-118	25874-25876	28	_	
150-119	25879-25888	Occipital	_	
150-120	25889-25893	pole	_	
150-121	25894-25897	and	_	
150-122	25898-25904	cortex	_	
150-123	25905-25906	L	_	
150-124	25907-25908	2	_	
150-125	25909-25913	0.05	_	
150-126	25914-25918	3.77	_	
150-127	25919-25920	−	_	
150-128	25920-25921	8	_	
150-129	25922-25923	−	_	
150-130	25923-25925	96	_	
150-131	25926-25927	−	_	
150-132	25927-25928	6	_	
150-133	25931-25940	Occipital	_	
150-134	25941-25947	cortex	_	
150-135	25947-25948	,	_	
150-136	25949-25957	inferior	_	
150-137	25958-25959	L	_	
150-138	25960-25961	1	_	
150-139	25962-25966	0.05	_	
150-140	25967-25971	3.81	_	
150-141	25972-25973	−	_	
150-142	25973-25975	48	_	
150-143	25976-25977	−	_	
150-144	25977-25979	82	_	
150-145	25980-25981	4	_	
150-146	25984-26001	Emotional–neutral	_	
150-147	26002-26009	oddball	_	
150-148	26010-26011	(	_	
150-149	26011-26019	negative	_	
150-150	26020-26029	emotional	_	
150-151	26030-26038	salience	_	
150-152	26038-26039	)	_	
150-153	26042-26049	Lingual	_	
150-154	26050-26055	gyrus	_	
150-155	26055-26056	,	_	
150-156	26057-26071	intracalcarine	_	
150-157	26072-26078	cortex	_	
150-158	26079-26080	R	_	
150-159	26081-26086	11327	_	
150-160	26087-26091	0.02	_	
150-161	26092-26096	3.82	_	
150-162	26097-26098	6	_	
150-163	26099-26100	−	_	
150-164	26100-26102	86	_	
150-165	26103-26104	−	_	
150-166	26104-26105	2	_	
150-167	26108-26123	Parahippocampus	_	
150-168	26123-26124	,	_	
150-169	26125-26132	putamen	_	
150-170	26132-26133	,	_	
150-171	26134-26141	nucleus	_	
150-172	26142-26151	accumbens	_	
150-173	26152-26153	L	_	
150-174	26154-26157	321	_	
150-175	26158-26163	0.041	_	
150-176	26164-26168	4.01	_	
150-177	26169-26170	−	_	
150-178	26170-26172	10	_	
150-179	26173-26174	2	_	
150-180	26175-26176	−	_	
150-181	26176-26178	20	_	
150-182	26181-26190	Occipital	_	
150-183	26191-26197	cortex	_	
150-184	26197-26198	,	_	
150-185	26199-26207	inferior	_	
150-186	26208-26209	R	_	
150-187	26210-26212	73	_	
150-188	26213-26218	0.045	_	
150-189	26219-26223	3.39	_	
150-190	26224-26226	44	_	
150-191	26227-26228	−	_	
150-192	26228-26230	72	_	
150-193	26231-26233	10	_	
150-194	26236-26244	Amygdala	_	
150-195	26245-26246	L	_	
150-196	26247-26249	15	_	
150-197	26250-26255	0.046	_	
150-198	26256-26259	3.5	_	
150-199	26260-26261	−	_	
150-200	26261-26263	26	_	
150-201	26264-26265	−	_	
150-202	26265-26266	2	_	
150-203	26267-26268	−	_	
150-204	26268-26270	12	_	
150-205	26273-26283	Cerebellum	_	
150-206	26284-26289	CrusI	_	
150-207	26290-26293	and	_	
150-208	26294-26303	occipital	_	
150-209	26304-26310	cortex	_	
150-210	26311-26319	inferior	_	
150-211	26320-26321	L	_	
150-212	26322-26324	14	_	
150-213	26325-26330	0.048	_	
150-214	26331-26335	2.95	_	
150-215	26336-26337	−	_	
150-216	26337-26339	46	_	
150-217	26340-26341	−	_	
150-218	26341-26343	76	_	
150-219	26344-26345	−	_	
150-220	26345-26347	26	_	
150-221	26350-26360	Cerebellum	_	
150-222	26361-26365	lobe	_	
150-223	26366-26367	X	_	
150-224	26368-26371	and	_	
150-225	26372-26377	VIIIb	_	
150-226	26378-26379	R	_	
150-227	26380-26382	11	_	
150-228	26383-26388	0.048	_	
150-229	26389-26393	3.14	_	
150-230	26394-26396	16	_	
150-231	26397-26398	−	_	
150-232	26398-26400	40	_	
150-233	26401-26402	−	_	
150-234	26402-26404	46	_	
150-235	26407-26409	SN	_	
150-236	26409-26410	/	_	
150-237	26410-26413	VTA	_	
150-238	26414-26415	L	_	
150-239	26416-26418	10	_	
150-240	26419-26424	0.048	_	
150-241	26425-26429	2.51	_	
150-242	26430-26431	−	_	
150-243	26431-26433	12	_	
150-244	26434-26435	−	_	
150-245	26435-26437	16	_	
150-246	26438-26439	−	_	
150-247	26439-26440	6	_	
150-248	26443-26450	Frontal	_	
150-249	26451-26460	operculum	_	
150-250	26461-26467	cortex	_	
150-251	26468-26469	L	_	
150-252	26470-26471	9	_	
150-253	26472-26477	0.047	_	
150-254	26478-26482	2.04	_	
150-255	26483-26484	−	_	
150-256	26484-26486	40	_	
150-257	26487-26489	16	_	
150-258	26490-26491	4	_	
150-259	26494-26497	ACC	_	
150-260	26498-26499	R	_	
150-261	26499-26500	/	_	
150-262	26500-26501	L	_	
150-263	26502-26503	9	_	
150-264	26504-26509	0.048	_	
150-265	26510-26514	3.19	_	
150-266	26515-26516	2	_	
150-267	26517-26519	16	_	
150-268	26520-26522	18	_	
150-269	26525-26540	Parahippocampal	_	
150-270	26541-26546	gyrus	_	
150-271	26547-26548	L	_	
150-272	26549-26550	4	_	
150-273	26551-26556	0.047	_	
150-274	26557-26561	3.43	_	
150-275	26562-26563	−	_	
150-276	26563-26565	14	_	
150-277	26566-26567	−	_	
150-278	26567-26569	14	_	
150-279	26570-26571	−	_	
150-280	26571-26573	24	_	
150-281	26576-26579	ACC	_	
150-282	26580-26581	L	_	
150-283	26582-26583	1	_	
150-284	26584-26588	0.05	_	
150-285	26589-26593	2.72	_	
150-286	26594-26595	−	_	
150-287	26595-26596	8	_	
150-288	26597-26598	6	_	
150-289	26599-26601	36	_	
150-290	26604-26618	Target–neutral	_	
150-291	26619-26626	oddball	_	
150-292	26627-26628	(	_	
150-293	26628-26638	targetness	_	
150-294	26638-26639	)	_	
150-295	26642-26645	n.s	_	
150-296	26645-26646	.	_	

#Text=Neutral–Standard oddball (rareness)\t \tn.s.
151-1	26649-26665	Neutral–Standard	_	
151-2	26666-26673	oddball	_	
151-3	26674-26675	(	_	
151-4	26675-26683	rareness	_	
151-5	26683-26684	)	_	
151-6	26687-26690	n.s	_	
151-7	26690-26691	.	_	

#Text=Summary of fMRI results for significant clusters at the whole-brain level, using FSL randomise, variance smoothing: 3 mm, 5000 permutations, and threshold free cluster enhancement (TFCE).
152-1	26695-26702	Summary	_	
152-2	26703-26705	of	_	
152-3	26706-26710	fMRI	_	
152-4	26711-26718	results	_	
152-5	26719-26722	for	_	
152-6	26723-26734	significant	_	
152-7	26735-26743	clusters	_	
152-8	26744-26746	at	_	
152-9	26747-26750	the	_	
152-10	26751-26762	whole-brain	_	
152-11	26763-26768	level	_	
152-12	26768-26769	,	_	
152-13	26770-26775	using	_	
152-14	26776-26779	FSL	_	
152-15	26780-26789	randomise	_	
152-16	26789-26790	,	_	
152-17	26791-26799	variance	_	
152-18	26800-26809	smoothing	_	
152-19	26809-26810	:	_	
152-20	26811-26812	3	_	
152-21	26813-26815	mm	_	
152-22	26815-26816	,	_	
152-23	26817-26821	5000	_	
152-24	26822-26834	permutations	_	
152-25	26834-26835	,	_	
152-26	26836-26839	and	_	
152-27	26840-26849	threshold	_	
152-28	26850-26854	free	_	
152-29	26855-26862	cluster	_	
152-30	26863-26874	enhancement	_	
152-31	26875-26876	(	_	
152-32	26876-26880	TFCE	_	
152-33	26880-26881	)	_	
152-34	26881-26882	.	_	

#Text=Bold values indicate significant differences. n.s. not significant
#Text=On whole brain analysis using randomise, psychosis patients showed a significant reduction of activation in the occipital lobe, including the lingual gyrus and fusiform gyrus, and the cerebellum (Table 3 and Supplementary material).
153-1	26883-26887	Bold	_	
153-2	26888-26894	values	_	
153-3	26895-26903	indicate	_	
153-4	26904-26915	significant	_	
153-5	26916-26927	differences	_	
153-6	26927-26928	.	_	
153-7	26929-26932	n.s	_	
153-8	26932-26933	.	_	
153-9	26934-26937	not	_	
153-10	26938-26949	significant	_	
153-11	26950-26952	On	_	
153-12	26953-26958	whole	_	
153-13	26959-26964	brain	_	
153-14	26965-26973	analysis	_	
153-15	26974-26979	using	_	
153-16	26980-26989	randomise	_	
153-17	26989-26990	,	_	
153-18	26991-27000	psychosis	_	
153-19	27001-27009	patients	_	
153-20	27010-27016	showed	_	
153-21	27017-27018	a	_	
153-22	27019-27030	significant	_	
153-23	27031-27040	reduction	_	
153-24	27041-27043	of	_	
153-25	27044-27054	activation	_	
153-26	27055-27057	in	_	
153-27	27058-27061	the	_	
153-28	27062-27071	occipital	_	
153-29	27072-27076	lobe	_	
153-30	27076-27077	,	_	
153-31	27078-27087	including	_	
153-32	27088-27091	the	_	
153-33	27092-27099	lingual	_	
153-34	27100-27105	gyrus	_	
153-35	27106-27109	and	_	
153-36	27110-27118	fusiform	_	
153-37	27119-27124	gyrus	_	
153-38	27124-27125	,	_	
153-39	27126-27129	and	_	
153-40	27130-27133	the	_	
153-41	27134-27144	cerebellum	_	
153-42	27145-27146	(	_	
153-43	27146-27151	Table	_	
153-44	27152-27153	3	_	
153-45	27154-27157	and	_	
153-46	27158-27171	Supplementary	_	
153-47	27172-27180	material	_	
153-48	27180-27181	)	_	
153-49	27181-27182	.	_	

#Text=Negative emotional salience (emotion–neutral oddballs)
#Text=In our primary ROI, the SN/VTA, we found two clusters in which psychosis patients show significantly reduced activation(cluster 1: t = 3.45, p = 0.025 FWE corrected, 50 voxels; maximal difference at x = −12, y = −16, z = −6; cluster 2: t = 4.37, p = 0.02 FWE corrected, 22 voxels; maximal difference at x = 0, y = −20, z = −4).
154-1	27183-27191	Negative	_	
154-2	27192-27201	emotional	_	
154-3	27202-27210	salience	_	
154-4	27211-27212	(	_	
154-5	27212-27227	emotion–neutral	_	
154-6	27228-27236	oddballs	_	
154-7	27236-27237	)	_	
154-8	27238-27240	In	_	
154-9	27241-27244	our	_	
154-10	27245-27252	primary	_	
154-11	27253-27256	ROI	_	
154-12	27256-27257	,	_	
154-13	27258-27261	the	_	
154-14	27262-27264	SN	_	
154-15	27264-27265	/	_	
154-16	27265-27268	VTA	_	
154-17	27268-27269	,	_	
154-18	27270-27272	we	_	
154-19	27273-27278	found	_	
154-20	27279-27282	two	_	
154-21	27283-27291	clusters	_	
154-22	27292-27294	in	_	
154-23	27295-27300	which	_	
154-24	27301-27310	psychosis	_	
154-25	27311-27319	patients	_	
154-26	27320-27324	show	_	
154-27	27325-27338	significantly	_	
154-28	27339-27346	reduced	_	
154-29	27347-27357	activation	_	
154-30	27357-27358	(	_	
154-31	27358-27365	cluster	_	
154-32	27366-27367	1	_	
154-33	27367-27368	:	_	
154-34	27369-27370	t	_	
154-35	27371-27372	=	_	
154-36	27373-27377	3.45	_	
154-37	27377-27378	,	_	
154-38	27379-27380	p	_	
154-39	27381-27382	=	_	
154-40	27383-27388	0.025	_	
154-41	27389-27392	FWE	_	
154-42	27393-27402	corrected	_	
154-43	27402-27403	,	_	
154-44	27404-27406	50	_	
154-45	27407-27413	voxels	_	
154-46	27413-27414	;	_	
154-47	27415-27422	maximal	_	
154-48	27423-27433	difference	_	
154-49	27434-27436	at	_	
154-50	27437-27438	x	_	
154-51	27439-27440	=	_	
154-52	27441-27442	−	_	
154-53	27442-27444	12	_	
154-54	27444-27445	,	_	
154-55	27446-27447	y	_	
154-56	27448-27449	=	_	
154-57	27450-27451	−	_	
154-58	27451-27453	16	_	
154-59	27453-27454	,	_	
154-60	27455-27456	z	_	
154-61	27457-27458	=	_	
154-62	27459-27460	−	_	
154-63	27460-27461	6	_	
154-64	27461-27462	;	_	
154-65	27463-27470	cluster	_	
154-66	27471-27472	2	_	
154-67	27472-27473	:	_	
154-68	27474-27475	t	_	
154-69	27476-27477	=	_	
154-70	27478-27482	4.37	_	
154-71	27482-27483	,	_	
154-72	27484-27485	p	_	
154-73	27486-27487	=	_	
154-74	27488-27492	0.02	_	
154-75	27493-27496	FWE	_	
154-76	27497-27506	corrected	_	
154-77	27506-27507	,	_	
154-78	27508-27510	22	_	
154-79	27511-27517	voxels	_	
154-80	27517-27518	;	_	
154-81	27519-27526	maximal	_	
154-82	27527-27537	difference	_	
154-83	27538-27540	at	_	
154-84	27541-27542	x	_	
154-85	27543-27544	=	_	
154-86	27545-27546	0	_	
154-87	27546-27547	,	_	
154-88	27548-27549	y	_	
154-89	27550-27551	=	_	
154-90	27552-27553	−	_	
154-91	27553-27555	20	_	
154-92	27555-27556	,	_	
154-93	27557-27558	z	_	
154-94	27559-27560	=	_	
154-95	27561-27562	−	_	
154-96	27562-27563	4	_	
154-97	27563-27564	)	_	
154-98	27564-27565	.	_	

#Text=See Fig. 3a, b.
155-1	27566-27569	See	_	
155-2	27570-27573	Fig	_	
155-3	27573-27574	.	_	
155-4	27575-27577	3a	_	
155-5	27577-27578	,	_	
155-6	27579-27580	b	_	
155-7	27580-27581	.	_	

#Text=In our secondary ROI, composed of the striatum and the amygdala, psychosis patients showed a significant reduction of activation compared to the controls in four clusters within the striatum (cluster 1: t = 4.69, p = 0.002 FWE corrected, 1141 voxels; maximal difference at x = 12, y = 14, z = 12; cluster 2: t = 4.11, p = 0.008 FWE corrected, 320 voxels; maximal difference at x = −8, y = −6, z = −16; cluster 3: t = 3.53, p = 0.019 FWE corrected, 309 voxels; maximal difference at x = −12, y = 6, z = −14; cluster 4: t = 2.58, p = 0.048 FWE corrected, 5 voxels; maximal difference at x = −14, y = 22, z = −2).
156-1	27582-27584	In	_	
156-2	27585-27588	our	_	
156-3	27589-27598	secondary	_	
156-4	27599-27602	ROI	_	
156-5	27602-27603	,	_	
156-6	27604-27612	composed	_	
156-7	27613-27615	of	_	
156-8	27616-27619	the	_	
156-9	27620-27628	striatum	_	
156-10	27629-27632	and	_	
156-11	27633-27636	the	_	
156-12	27637-27645	amygdala	_	
156-13	27645-27646	,	_	
156-14	27647-27656	psychosis	_	
156-15	27657-27665	patients	_	
156-16	27666-27672	showed	_	
156-17	27673-27674	a	_	
156-18	27675-27686	significant	_	
156-19	27687-27696	reduction	_	
156-20	27697-27699	of	_	
156-21	27700-27710	activation	_	
156-22	27711-27719	compared	_	
156-23	27720-27722	to	_	
156-24	27723-27726	the	_	
156-25	27727-27735	controls	_	
156-26	27736-27738	in	_	
156-27	27739-27743	four	_	
156-28	27744-27752	clusters	_	
156-29	27753-27759	within	_	
156-30	27760-27763	the	_	
156-31	27764-27772	striatum	_	
156-32	27773-27774	(	_	
156-33	27774-27781	cluster	_	
156-34	27782-27783	1	_	
156-35	27783-27784	:	_	
156-36	27785-27786	t	_	
156-37	27787-27788	=	_	
156-38	27789-27793	4.69	_	
156-39	27793-27794	,	_	
156-40	27795-27796	p	_	
156-41	27797-27798	=	_	
156-42	27799-27804	0.002	_	
156-43	27805-27808	FWE	_	
156-44	27809-27818	corrected	_	
156-45	27818-27819	,	_	
156-46	27820-27824	1141	_	
156-47	27825-27831	voxels	_	
156-48	27831-27832	;	_	
156-49	27833-27840	maximal	_	
156-50	27841-27851	difference	_	
156-51	27852-27854	at	_	
156-52	27855-27856	x	_	
156-53	27857-27858	=	_	
156-54	27859-27861	12	_	
156-55	27861-27862	,	_	
156-56	27863-27864	y	_	
156-57	27865-27866	=	_	
156-58	27867-27869	14	_	
156-59	27869-27870	,	_	
156-60	27871-27872	z	_	
156-61	27873-27874	=	_	
156-62	27875-27877	12	_	
156-63	27877-27878	;	_	
156-64	27879-27886	cluster	_	
156-65	27887-27888	2	_	
156-66	27888-27889	:	_	
156-67	27890-27891	t	_	
156-68	27892-27893	=	_	
156-69	27894-27898	4.11	_	
156-70	27898-27899	,	_	
156-71	27900-27901	p	_	
156-72	27902-27903	=	_	
156-73	27904-27909	0.008	_	
156-74	27910-27913	FWE	_	
156-75	27914-27923	corrected	_	
156-76	27923-27924	,	_	
156-77	27925-27928	320	_	
156-78	27929-27935	voxels	_	
156-79	27935-27936	;	_	
156-80	27937-27944	maximal	_	
156-81	27945-27955	difference	_	
156-82	27956-27958	at	_	
156-83	27959-27960	x	_	
156-84	27961-27962	=	_	
156-85	27963-27964	−	_	
156-86	27964-27965	8	_	
156-87	27965-27966	,	_	
156-88	27967-27968	y	_	
156-89	27969-27970	=	_	
156-90	27971-27972	−	_	
156-91	27972-27973	6	_	
156-92	27973-27974	,	_	
156-93	27975-27976	z	_	
156-94	27977-27978	=	_	
156-95	27979-27980	−	_	
156-96	27980-27982	16	_	
156-97	27982-27983	;	_	
156-98	27984-27991	cluster	_	
156-99	27992-27993	3	_	
156-100	27993-27994	:	_	
156-101	27995-27996	t	_	
156-102	27997-27998	=	_	
156-103	27999-28003	3.53	_	
156-104	28003-28004	,	_	
156-105	28005-28006	p	_	
156-106	28007-28008	=	_	
156-107	28009-28014	0.019	_	
156-108	28015-28018	FWE	_	
156-109	28019-28028	corrected	_	
156-110	28028-28029	,	_	
156-111	28030-28033	309	_	
156-112	28034-28040	voxels	_	
156-113	28040-28041	;	_	
156-114	28042-28049	maximal	_	
156-115	28050-28060	difference	_	
156-116	28061-28063	at	_	
156-117	28064-28065	x	_	
156-118	28066-28067	=	_	
156-119	28068-28069	−	_	
156-120	28069-28071	12	_	
156-121	28071-28072	,	_	
156-122	28073-28074	y	_	
156-123	28075-28076	=	_	
156-124	28077-28078	6	_	
156-125	28078-28079	,	_	
156-126	28080-28081	z	_	
156-127	28082-28083	=	_	
156-128	28084-28085	−	_	
156-129	28085-28087	14	_	
156-130	28087-28088	;	_	
156-131	28089-28096	cluster	_	
156-132	28097-28098	4	_	
156-133	28098-28099	:	_	
156-134	28100-28101	t	_	
156-135	28102-28103	=	_	
156-136	28104-28108	2.58	_	
156-137	28108-28109	,	_	
156-138	28110-28111	p	_	
156-139	28112-28113	=	_	
156-140	28114-28119	0.048	_	
156-141	28120-28123	FWE	_	
156-142	28124-28133	corrected	_	
156-143	28133-28134	,	_	
156-144	28135-28136	5	_	
156-145	28137-28143	voxels	_	
156-146	28143-28144	;	_	
156-147	28145-28152	maximal	_	
156-148	28153-28163	difference	_	
156-149	28164-28166	at	_	
156-150	28167-28168	x	_	
156-151	28169-28170	=	_	
156-152	28171-28172	−	_	
156-153	28172-28174	14	_	
156-154	28174-28175	,	_	
156-155	28176-28177	y	_	
156-156	28178-28179	=	_	
156-157	28180-28182	22	_	
156-158	28182-28183	,	_	
156-159	28184-28185	z	_	
156-160	28186-28187	=	_	
156-161	28188-28189	−	_	
156-162	28189-28190	2	_	
156-163	28190-28191	)	_	
156-164	28191-28192	.	_	

#Text=See Fig. 3a, b.
157-1	28193-28196	See	_	
157-2	28197-28200	Fig	_	
157-3	28200-28201	.	_	
157-4	28202-28204	3a	_	
157-5	28204-28205	,	_	
157-6	28206-28207	b	_	
157-7	28207-28208	.	_	

#Text=On whole brain analysis, psychosis patients showed a significant reduction of activation in the amygdala, parahippocampal gyrus, lingual gyrus, striatum, cerebellum and the anterior cingulate gyrus (Table 3).
158-1	28209-28211	On	_	
158-2	28212-28217	whole	_	
158-3	28218-28223	brain	_	
158-4	28224-28232	analysis	_	
158-5	28232-28233	,	_	
158-6	28234-28243	psychosis	_	
158-7	28244-28252	patients	_	
158-8	28253-28259	showed	_	
158-9	28260-28261	a	_	
158-10	28262-28273	significant	_	
158-11	28274-28283	reduction	_	
158-12	28284-28286	of	_	
158-13	28287-28297	activation	_	
158-14	28298-28300	in	_	
158-15	28301-28304	the	_	
158-16	28305-28313	amygdala	_	
158-17	28313-28314	,	_	
158-18	28315-28330	parahippocampal	_	
158-19	28331-28336	gyrus	_	
158-20	28336-28337	,	_	
158-21	28338-28345	lingual	_	
158-22	28346-28351	gyrus	_	
158-23	28351-28352	,	_	
158-24	28353-28361	striatum	_	
158-25	28361-28362	,	_	
158-26	28363-28373	cerebellum	_	
158-27	28374-28377	and	_	
158-28	28378-28381	the	_	
158-29	28382-28390	anterior	_	
158-30	28391-28400	cingulate	_	
158-31	28401-28406	gyrus	_	
158-32	28407-28408	(	_	
158-33	28408-28413	Table	_	
158-34	28414-28415	3	_	
158-35	28415-28416	)	_	
158-36	28416-28417	.	_	

#Text=Targetness (target–neutral oddballs)
#Text=In our primary ROI, the SN/VTA, psychosis patients showed a marginal reduction of activation compared to the controls (t = 3.84, p = 0.066 FWE corrected, 5 voxels; maximal difference at x = 0, y = −22, z = −8).
159-1	28418-28428	Targetness	_	
159-2	28429-28430	(	_	
159-3	28430-28444	target–neutral	_	
159-4	28445-28453	oddballs	_	
159-5	28453-28454	)	_	
159-6	28455-28457	In	_	
159-7	28458-28461	our	_	
159-8	28462-28469	primary	_	
159-9	28470-28473	ROI	_	
159-10	28473-28474	,	_	
159-11	28475-28478	the	_	
159-12	28479-28481	SN	_	
159-13	28481-28482	/	_	
159-14	28482-28485	VTA	_	
159-15	28485-28486	,	_	
159-16	28487-28496	psychosis	_	
159-17	28497-28505	patients	_	
159-18	28506-28512	showed	_	
159-19	28513-28514	a	_	
159-20	28515-28523	marginal	_	
159-21	28524-28533	reduction	_	
159-22	28534-28536	of	_	
159-23	28537-28547	activation	_	
159-24	28548-28556	compared	_	
159-25	28557-28559	to	_	
159-26	28560-28563	the	_	
159-27	28564-28572	controls	_	
159-28	28573-28574	(	_	
159-29	28574-28575	t	_	
159-30	28576-28577	=	_	
159-31	28578-28582	3.84	_	
159-32	28582-28583	,	_	
159-33	28584-28585	p	_	
159-34	28586-28587	=	_	
159-35	28588-28593	0.066	_	
159-36	28594-28597	FWE	_	
159-37	28598-28607	corrected	_	
159-38	28607-28608	,	_	
159-39	28609-28610	5	_	
159-40	28611-28617	voxels	_	
159-41	28617-28618	;	_	
159-42	28619-28626	maximal	_	
159-43	28627-28637	difference	_	
159-44	28638-28640	at	_	
159-45	28641-28642	x	_	
159-46	28643-28644	=	_	
159-47	28645-28646	0	_	
159-48	28646-28647	,	_	
159-49	28648-28649	y	_	
159-50	28650-28651	=	_	
159-51	28652-28653	−	_	
159-52	28653-28655	22	_	
159-53	28655-28656	,	_	
159-54	28657-28658	z	_	
159-55	28659-28660	=	_	
159-56	28661-28662	−	_	
159-57	28662-28663	8	_	
159-58	28663-28664	)	_	
159-59	28664-28665	.	_	

#Text=On whole brain analysis, there were no significant group differences.
160-1	28666-28668	On	_	
160-2	28669-28674	whole	_	
160-3	28675-28680	brain	_	
160-4	28681-28689	analysis	_	
160-5	28689-28690	,	_	
160-6	28691-28696	there	_	
160-7	28697-28701	were	_	
160-8	28702-28704	no	_	
160-9	28705-28716	significant	_	
160-10	28717-28722	group	_	
160-11	28723-28734	differences	_	
160-12	28734-28735	.	_	

#Text=Rareness/deviance (neutral oddballs-standard trials)
#Text=Our ROI analysis in the SN/VTA was not significant.
161-1	28736-28744	Rareness	_	
161-2	28744-28745	/	_	
161-3	28745-28753	deviance	_	
161-4	28754-28755	(	_	
161-5	28755-28762	neutral	_	
161-6	28763-28780	oddballs-standard	_	
161-7	28781-28787	trials	_	
161-8	28787-28788	)	_	
161-9	28789-28792	Our	_	
161-10	28793-28796	ROI	_	
161-11	28797-28805	analysis	_	
161-12	28806-28808	in	_	
161-13	28809-28812	the	_	
161-14	28813-28815	SN	_	
161-15	28815-28816	/	_	
161-16	28816-28819	VTA	_	
161-17	28820-28823	was	_	
161-18	28824-28827	not	_	
161-19	28828-28839	significant	_	
161-20	28839-28840	.	_	

#Text=Similarly, on the whole brain analysis, there were no group differences that passed our statistical threshold, corrected for multiple comparisons.
162-1	28841-28850	Similarly	_	
162-2	28850-28851	,	_	
162-3	28852-28854	on	_	
162-4	28855-28858	the	_	
162-5	28859-28864	whole	_	
162-6	28865-28870	brain	_	
162-7	28871-28879	analysis	_	
162-8	28879-28880	,	_	
162-9	28881-28886	there	_	
162-10	28887-28891	were	_	
162-11	28892-28894	no	_	
162-12	28895-28900	group	_	
162-13	28901-28912	differences	_	
162-14	28913-28917	that	_	
162-15	28918-28924	passed	_	
162-16	28925-28928	our	_	
162-17	28929-28940	statistical	_	
162-18	28941-28950	threshold	_	
162-19	28950-28951	,	_	
162-20	28952-28961	corrected	_	
162-21	28962-28965	for	_	
162-22	28966-28974	multiple	_	
162-23	28975-28986	comparisons	_	
162-24	28986-28987	.	_	

#Text=Salience responses in controls only
#Text=The results for the same analysis as presented above have been conducted in controls only.
163-1	28988-28996	Salience	_	
163-2	28997-29006	responses	_	
163-3	29007-29009	in	_	
163-4	29010-29018	controls	_	
163-5	29019-29023	only	_	
163-6	29024-29027	The	_	
163-7	29028-29035	results	_	
163-8	29036-29039	for	_	
163-9	29040-29043	the	_	
163-10	29044-29048	same	_	
163-11	29049-29057	analysis	_	
163-12	29058-29060	as	_	
163-13	29061-29070	presented	_	
163-14	29071-29076	above	_	
163-15	29077-29081	have	_	
163-16	29082-29086	been	_	
163-17	29087-29096	conducted	_	
163-18	29097-29099	in	_	
163-19	29100-29108	controls	_	
163-20	29109-29113	only	_	
163-21	29113-29114	.	_	

#Text=Details for the whole brain analysis are presented in Supplementary Table 3, details for the ROI analysis in Supplementary Table 4.
164-1	29115-29122	Details	_	
164-2	29123-29126	for	_	
164-3	29127-29130	the	_	
164-4	29131-29136	whole	_	
164-5	29137-29142	brain	_	
164-6	29143-29151	analysis	_	
164-7	29152-29155	are	_	
164-8	29156-29165	presented	_	
164-9	29166-29168	in	_	
164-10	29169-29182	Supplementary	_	
164-11	29183-29188	Table	_	
164-12	29189-29190	3	_	
164-13	29190-29191	,	_	
164-14	29192-29199	details	_	
164-15	29200-29203	for	_	
164-16	29204-29207	the	_	
164-17	29208-29211	ROI	_	
164-18	29212-29220	analysis	_	
164-19	29221-29223	in	_	
164-20	29224-29237	Supplementary	_	
164-21	29238-29243	Table	_	
164-22	29244-29245	4	_	
164-23	29245-29246	.	_	

#Text=Furthermore, Supplementary Figure 9 shows the activation in the SN/VTA to emotional salience and novelty salience.
165-1	29247-29258	Furthermore	_	
165-2	29258-29259	,	_	
165-3	29260-29273	Supplementary	_	
165-4	29274-29280	Figure	_	
165-5	29281-29282	9	_	
165-6	29283-29288	shows	_	
165-7	29289-29292	the	_	
165-8	29293-29303	activation	_	
165-9	29304-29306	in	_	
165-10	29307-29310	the	_	
165-11	29311-29313	SN	_	
165-12	29313-29314	/	_	
165-13	29314-29317	VTA	_	
165-14	29318-29320	to	_	
165-15	29321-29330	emotional	_	
165-16	29331-29339	salience	_	
165-17	29340-29343	and	_	
165-18	29344-29351	novelty	_	
165-19	29352-29360	salience	_	
165-20	29360-29361	.	_	

#Text=As novelty and negative emotional salience activate different, though adjacent, voxels also in the group comparison, we furthermore show the non-overlapping activation for the group comparison at various levels in the z direction (−6, −8, −10, −12, −14, −16 and −18) in Supplementary Figure 10.
166-1	29362-29364	As	_	
166-2	29365-29372	novelty	_	
166-3	29373-29376	and	_	
166-4	29377-29385	negative	_	
166-5	29386-29395	emotional	_	
166-6	29396-29404	salience	_	
166-7	29405-29413	activate	_	
166-8	29414-29423	different	_	
166-9	29423-29424	,	_	
166-10	29425-29431	though	_	
166-11	29432-29440	adjacent	_	
166-12	29440-29441	,	_	
166-13	29442-29448	voxels	_	
166-14	29449-29453	also	_	
166-15	29454-29456	in	_	
166-16	29457-29460	the	_	
166-17	29461-29466	group	_	
166-18	29467-29477	comparison	_	
166-19	29477-29478	,	_	
166-20	29479-29481	we	_	
166-21	29482-29493	furthermore	_	
166-22	29494-29498	show	_	
166-23	29499-29502	the	_	
166-24	29503-29518	non-overlapping	_	
166-25	29519-29529	activation	_	
166-26	29530-29533	for	_	
166-27	29534-29537	the	_	
166-28	29538-29543	group	_	
166-29	29544-29554	comparison	_	
166-30	29555-29557	at	_	
166-31	29558-29565	various	_	
166-32	29566-29572	levels	_	
166-33	29573-29575	in	_	
166-34	29576-29579	the	_	
166-35	29580-29581	z	_	
166-36	29582-29591	direction	_	
166-37	29592-29593	(	_	
166-38	29593-29594	−	_	
166-39	29594-29595	6	_	
166-40	29595-29596	,	_	
166-41	29597-29598	−	_	
166-42	29598-29599	8	_	
166-43	29599-29600	,	_	
166-44	29601-29602	−	_	
166-45	29602-29604	10	_	
166-46	29604-29605	,	_	
166-47	29606-29607	−	_	
166-48	29607-29609	12	_	
166-49	29609-29610	,	_	
166-50	29611-29612	−	_	
166-51	29612-29614	14	_	
166-52	29614-29615	,	_	
166-53	29616-29617	−	_	
166-54	29617-29619	16	_	
166-55	29620-29623	and	_	
166-56	29624-29625	−	_	
166-57	29625-29627	18	_	
166-58	29627-29628	)	_	
166-59	29629-29631	in	_	
166-60	29632-29645	Supplementary	_	
166-61	29646-29652	Figure	_	
166-62	29653-29655	10	_	
166-63	29655-29656	.	_	

#Text=Correlations of symptom score and brain responses in patients
#Text=Correlation between signal strength and symptom score in patients.
#Text=a, b Significant symptom correlations with activation in the SN/VTA in response to novelty. c Significant correlation between total PANS score and striatal activation in response to negative emotional salience. d, e Significant symptom correlations with activation in the amygdala in response to negative emotional salience.
167-1	29657-29669	Correlations	_	
167-2	29670-29672	of	_	
167-3	29673-29680	symptom	_	
167-4	29681-29686	score	_	
167-5	29687-29690	and	_	
167-6	29691-29696	brain	_	
167-7	29697-29706	responses	_	
167-8	29707-29709	in	_	
167-9	29710-29718	patients	_	
167-10	29719-29730	Correlation	_	
167-11	29731-29738	between	_	
167-12	29739-29745	signal	_	
167-13	29746-29754	strength	_	
167-14	29755-29758	and	_	
167-15	29759-29766	symptom	_	
167-16	29767-29772	score	_	
167-17	29773-29775	in	_	
167-18	29776-29784	patients	_	
167-19	29784-29785	.	_	
167-20	29786-29787	a	_	
167-21	29787-29788	,	_	
167-22	29789-29790	b	_	
167-23	29791-29802	Significant	_	
167-24	29803-29810	symptom	_	
167-25	29811-29823	correlations	_	
167-26	29824-29828	with	_	
167-27	29829-29839	activation	_	
167-28	29840-29842	in	_	
167-29	29843-29846	the	_	
167-30	29847-29849	SN	_	
167-31	29849-29850	/	_	
167-32	29850-29853	VTA	_	
167-33	29854-29856	in	_	
167-34	29857-29865	response	_	
167-35	29866-29868	to	_	
167-36	29869-29876	novelty	_	
167-37	29876-29877	.	_	
167-38	29878-29879	c	_	
167-39	29880-29891	Significant	_	
167-40	29892-29903	correlation	_	
167-41	29904-29911	between	_	
167-42	29912-29917	total	_	
167-43	29918-29922	PANS	_	
167-44	29923-29928	score	_	
167-45	29929-29932	and	_	
167-46	29933-29941	striatal	_	
167-47	29942-29952	activation	_	
167-48	29953-29955	in	_	
167-49	29956-29964	response	_	
167-50	29965-29967	to	_	
167-51	29968-29976	negative	_	
167-52	29977-29986	emotional	_	
167-53	29987-29995	salience	_	
167-54	29995-29996	.	_	
167-55	29997-29998	d	_	
167-56	29998-29999	,	_	
167-57	30000-30001	e	_	
167-58	30002-30013	Significant	_	
167-59	30014-30021	symptom	_	
167-60	30022-30034	correlations	_	
167-61	30035-30039	with	_	
167-62	30040-30050	activation	_	
167-63	30051-30053	in	_	
167-64	30054-30057	the	_	
167-65	30058-30066	amygdala	_	
167-66	30067-30069	in	_	
167-67	30070-30078	response	_	
167-68	30079-30081	to	_	
167-69	30082-30090	negative	_	
167-70	30091-30100	emotional	_	
167-71	30101-30109	salience	_	
167-72	30109-30110	.	_	

#Text=Lines indicate fitted regression lines
#Text=We found positive correlations between SN/VTA signalling and the total score of negative symptoms (SANS; rho = 0.66, p = 0.047; Fig. 4a), and delusions (P1; rho = 0.77, p = 0.002; Fig. 4b) in response to novelty.
168-1	30111-30116	Lines	_	
168-2	30117-30125	indicate	_	
168-3	30126-30132	fitted	_	
168-4	30133-30143	regression	_	
168-5	30144-30149	lines	_	
168-6	30150-30152	We	_	
168-7	30153-30158	found	_	
168-8	30159-30167	positive	_	
168-9	30168-30180	correlations	_	
168-10	30181-30188	between	_	
168-11	30189-30191	SN	_	
168-12	30191-30192	/	_	
168-13	30192-30195	VTA	_	
168-14	30196-30206	signalling	_	
168-15	30207-30210	and	_	
168-16	30211-30214	the	_	
168-17	30215-30220	total	_	
168-18	30221-30226	score	_	
168-19	30227-30229	of	_	
168-20	30230-30238	negative	_	
168-21	30239-30247	symptoms	_	
168-22	30248-30249	(	_	
168-23	30249-30253	SANS	_	
168-24	30253-30254	;	_	
168-25	30255-30258	rho	_	
168-26	30259-30260	=	_	
168-27	30261-30265	0.66	_	
168-28	30265-30266	,	_	
168-29	30267-30268	p	_	
168-30	30269-30270	=	_	
168-31	30271-30276	0.047	_	
168-32	30276-30277	;	_	
168-33	30278-30281	Fig	_	
168-34	30281-30282	.	_	
168-35	30283-30285	4a	_	
168-36	30285-30286	)	_	
168-37	30286-30287	,	_	
168-38	30288-30291	and	_	
168-39	30292-30301	delusions	_	
168-40	30302-30303	(	_	
168-41	30303-30305	P1	_	
168-42	30305-30306	;	_	
168-43	30307-30310	rho	_	
168-44	30311-30312	=	_	
168-45	30313-30317	0.77	_	
168-46	30317-30318	,	_	
168-47	30319-30320	p	_	
168-48	30321-30322	=	_	
168-49	30323-30328	0.002	_	
168-50	30328-30329	;	_	
168-51	30330-30333	Fig	_	
168-52	30333-30334	.	_	
168-53	30335-30337	4b	_	
168-54	30337-30338	)	_	
168-55	30339-30341	in	_	
168-56	30342-30350	response	_	
168-57	30351-30353	to	_	
168-58	30354-30361	novelty	_	
168-59	30361-30362	.	_	

#Text=Furthermore, in response to negative emotional salience, we found a positive correlations between striatal signalling and the total score of positive symptoms (PANS positive; rho = 0.65, p = 0.028; Fig. 4c), a positive correlation between amygdala signalling and the Beck depression inventory (BDI; rho = 0.64, p = 0.048; Fig. 4d), and a positive correlation between amygdala signalling and delusional behaviour (P3; rho = 0.59, p = 0.035; Fig. 4e).
169-1	30363-30374	Furthermore	_	
169-2	30374-30375	,	_	
169-3	30376-30378	in	_	
169-4	30379-30387	response	_	
169-5	30388-30390	to	_	
169-6	30391-30399	negative	_	
169-7	30400-30409	emotional	_	
169-8	30410-30418	salience	_	
169-9	30418-30419	,	_	
169-10	30420-30422	we	_	
169-11	30423-30428	found	_	
169-12	30429-30430	a	_	
169-13	30431-30439	positive	_	
169-14	30440-30452	correlations	_	
169-15	30453-30460	between	_	
169-16	30461-30469	striatal	_	
169-17	30470-30480	signalling	_	
169-18	30481-30484	and	_	
169-19	30485-30488	the	_	
169-20	30489-30494	total	_	
169-21	30495-30500	score	_	
169-22	30501-30503	of	_	
169-23	30504-30512	positive	_	
169-24	30513-30521	symptoms	_	
169-25	30522-30523	(	_	
169-26	30523-30527	PANS	_	
169-27	30528-30536	positive	_	
169-28	30536-30537	;	_	
169-29	30538-30541	rho	_	
169-30	30542-30543	=	_	
169-31	30544-30548	0.65	_	
169-32	30548-30549	,	_	
169-33	30550-30551	p	_	
169-34	30552-30553	=	_	
169-35	30554-30559	0.028	_	
169-36	30559-30560	;	_	
169-37	30561-30564	Fig	_	
169-38	30564-30565	.	_	
169-39	30566-30568	4c	_	
169-40	30568-30569	)	_	
169-41	30569-30570	,	_	
169-42	30571-30572	a	_	
169-43	30573-30581	positive	_	
169-44	30582-30593	correlation	_	
169-45	30594-30601	between	_	
169-46	30602-30610	amygdala	_	
169-47	30611-30621	signalling	_	
169-48	30622-30625	and	_	
169-49	30626-30629	the	_	
169-50	30630-30634	Beck	_	
169-51	30635-30645	depression	_	
169-52	30646-30655	inventory	_	
169-53	30656-30657	(	_	
169-54	30657-30660	BDI	_	
169-55	30660-30661	;	_	
169-56	30662-30665	rho	_	
169-57	30666-30667	=	_	
169-58	30668-30672	0.64	_	
169-59	30672-30673	,	_	
169-60	30674-30675	p	_	
169-61	30676-30677	=	_	
169-62	30678-30683	0.048	_	
169-63	30683-30684	;	_	
169-64	30685-30688	Fig	_	
169-65	30688-30689	.	_	
169-66	30690-30692	4d	_	
169-67	30692-30693	)	_	
169-68	30693-30694	,	_	
169-69	30695-30698	and	_	
169-70	30699-30700	a	_	
169-71	30701-30709	positive	_	
169-72	30710-30721	correlation	_	
169-73	30722-30729	between	_	
169-74	30730-30738	amygdala	_	
169-75	30739-30749	signalling	_	
169-76	30750-30753	and	_	
169-77	30754-30764	delusional	_	
169-78	30765-30774	behaviour	_	
169-79	30775-30776	(	_	
169-80	30776-30778	P3	_	
169-81	30778-30779	;	_	
169-82	30780-30783	rho	_	
169-83	30784-30785	=	_	
169-84	30786-30790	0.59	_	
169-85	30790-30791	,	_	
169-86	30792-30793	p	_	
169-87	30794-30795	=	_	
169-88	30796-30801	0.035	_	
169-89	30801-30802	;	_	
169-90	30803-30806	Fig	_	
169-91	30806-30807	.	_	
169-92	30808-30810	4e	_	
169-93	30810-30811	)	_	
169-94	30811-30812	.	_	

#Text=Correlations were computed using a nonparametric Spearmen’s correlation.
170-1	30813-30825	Correlations	_	
170-2	30826-30830	were	_	
170-3	30831-30839	computed	_	
170-4	30840-30845	using	_	
170-5	30846-30847	a	_	
170-6	30848-30861	nonparametric	_	
170-7	30862-30870	Spearmen	_	
170-8	30870-30871	’	_	
170-9	30871-30872	s	_	
170-10	30873-30884	correlation	_	
170-11	30884-30885	.	_	

#Text=We emphasize that we are presenting exploratory correlation analyses (given the small sample size); when controlling for multiple comparisons (correcting for all symptoms tested on each contrast) using a strict Bonferroni-approach only the correlation between SN/VTA signalling and delusional ideation in response to novelty would be retained as statistically significant.
171-1	30886-30888	We	_	
171-2	30889-30898	emphasize	_	
171-3	30899-30903	that	_	
171-4	30904-30906	we	_	
171-5	30907-30910	are	_	
171-6	30911-30921	presenting	_	
171-7	30922-30933	exploratory	_	
171-8	30934-30945	correlation	_	
171-9	30946-30954	analyses	_	
171-10	30955-30956	(	_	
171-11	30956-30961	given	_	
171-12	30962-30965	the	_	
171-13	30966-30971	small	_	
171-14	30972-30978	sample	_	
171-15	30979-30983	size	_	
171-16	30983-30984	)	_	
171-17	30984-30985	;	_	
171-18	30986-30990	when	_	
171-19	30991-31002	controlling	_	
171-20	31003-31006	for	_	
171-21	31007-31015	multiple	_	
171-22	31016-31027	comparisons	_	
171-23	31028-31029	(	_	
171-24	31029-31039	correcting	_	
171-25	31040-31043	for	_	
171-26	31044-31047	all	_	
171-27	31048-31056	symptoms	_	
171-28	31057-31063	tested	_	
171-29	31064-31066	on	_	
171-30	31067-31071	each	_	
171-31	31072-31080	contrast	_	
171-32	31080-31081	)	_	
171-33	31082-31087	using	_	
171-34	31088-31089	a	_	
171-35	31090-31096	strict	_	
171-36	31097-31116	Bonferroni-approach	_	
171-37	31117-31121	only	_	
171-38	31122-31125	the	_	
171-39	31126-31137	correlation	_	
171-40	31138-31145	between	_	
171-41	31146-31148	SN	_	
171-42	31148-31149	/	_	
171-43	31149-31152	VTA	_	
171-44	31153-31163	signalling	_	
171-45	31164-31167	and	_	
171-46	31168-31178	delusional	_	
171-47	31179-31187	ideation	_	
171-48	31188-31190	in	_	
171-49	31191-31199	response	_	
171-50	31200-31202	to	_	
171-51	31203-31210	novelty	_	
171-52	31211-31216	would	_	
171-53	31217-31219	be	_	
171-54	31220-31228	retained	_	
171-55	31229-31231	as	_	
171-56	31232-31245	statistically	_	
171-57	31246-31257	significant	_	
171-58	31257-31258	.	_	

#Text=Additionally, we did not find any significant correlations between IQ and brain responses in any ROI (all p < 0.05, no correction for multiple comparison applied).
172-1	31259-31271	Additionally	_	
172-2	31271-31272	,	_	
172-3	31273-31275	we	_	
172-4	31276-31279	did	_	
172-5	31280-31283	not	_	
172-6	31284-31288	find	_	
172-7	31289-31292	any	_	
172-8	31293-31304	significant	_	
172-9	31305-31317	correlations	_	
172-10	31318-31325	between	_	
172-11	31326-31328	IQ	_	
172-12	31329-31332	and	_	
172-13	31333-31338	brain	_	
172-14	31339-31348	responses	_	
172-15	31349-31351	in	_	
172-16	31352-31355	any	_	
172-17	31356-31359	ROI	_	
172-18	31360-31361	(	_	
172-19	31361-31364	all	_	
172-20	31365-31366	p	_	
172-21	31367-31368	<	_	
172-22	31369-31373	0.05	_	
172-23	31373-31374	,	_	
172-24	31375-31377	no	_	
172-25	31378-31388	correction	_	
172-26	31389-31392	for	_	
172-27	31393-31401	multiple	_	
172-28	31402-31412	comparison	_	
172-29	31413-31420	applied	_	
172-30	31420-31421	)	_	
172-31	31421-31422	.	_	

#Text=Discussion
#Text=We investigated brain responses to four different types of salience, including novelty, negative emotional salience, targetness and rareness/deviance in healthy volunteers and first episode psychosis patients.
173-1	31423-31433	Discussion	_	
173-2	31434-31436	We	_	
173-3	31437-31449	investigated	_	
173-4	31450-31455	brain	_	
173-5	31456-31465	responses	_	
173-6	31466-31468	to	_	
173-7	31469-31473	four	_	
173-8	31474-31483	different	_	
173-9	31484-31489	types	_	
173-10	31490-31492	of	_	
173-11	31493-31501	salience	_	
173-12	31501-31502	,	_	
173-13	31503-31512	including	_	
173-14	31513-31520	novelty	_	
173-15	31520-31521	,	_	
173-16	31522-31530	negative	_	
173-17	31531-31540	emotional	_	
173-18	31541-31549	salience	_	
173-19	31549-31550	,	_	
173-20	31551-31561	targetness	_	
173-21	31562-31565	and	_	
173-22	31566-31574	rareness	_	
173-23	31574-31575	/	_	
173-24	31575-31583	deviance	_	
173-25	31584-31586	in	_	
173-26	31587-31594	healthy	_	
173-27	31595-31605	volunteers	_	
173-28	31606-31609	and	_	
173-29	31610-31615	first	_	
173-30	31616-31623	episode	_	
173-31	31624-31633	psychosis	_	
173-32	31634-31642	patients	_	
173-33	31642-31643	.	_	

#Text=In psychosis patients, our results show reduced SN/VTA (primary ROI), striatal (secondary ROI) and cingulate (whole brain) signalling to novelty, reduced SN/VTA and amygdala (both primary ROIs), striatal (secondary ROI) and cingulate (whole brain) signalling to negative emotional salience, and reduced SN/VTA (primary ROI) and cingulate (whole brain) signalling to targetness.
174-1	31644-31646	In	_	
174-2	31647-31656	psychosis	_	
174-3	31657-31665	patients	_	
174-4	31665-31666	,	_	
174-5	31667-31670	our	_	
174-6	31671-31678	results	_	
174-7	31679-31683	show	_	
174-8	31684-31691	reduced	_	
174-9	31692-31694	SN	_	
174-10	31694-31695	/	_	
174-11	31695-31698	VTA	_	
174-12	31699-31700	(	_	
174-13	31700-31707	primary	_	
174-14	31708-31711	ROI	_	
174-15	31711-31712	)	_	
174-16	31712-31713	,	_	
174-17	31714-31722	striatal	_	
174-18	31723-31724	(	_	
174-19	31724-31733	secondary	_	
174-20	31734-31737	ROI	_	
174-21	31737-31738	)	_	
174-22	31739-31742	and	_	
174-23	31743-31752	cingulate	_	
174-24	31753-31754	(	_	
174-25	31754-31759	whole	_	
174-26	31760-31765	brain	_	
174-27	31765-31766	)	_	
174-28	31767-31777	signalling	_	
174-29	31778-31780	to	_	
174-30	31781-31788	novelty	_	
174-31	31788-31789	,	_	
174-32	31790-31797	reduced	_	
174-33	31798-31800	SN	_	
174-34	31800-31801	/	_	
174-35	31801-31804	VTA	_	
174-36	31805-31808	and	_	
174-37	31809-31817	amygdala	_	
174-38	31818-31819	(	_	
174-39	31819-31823	both	_	
174-40	31824-31831	primary	_	
174-41	31832-31836	ROIs	_	
174-42	31836-31837	)	_	
174-43	31837-31838	,	_	
174-44	31839-31847	striatal	_	
174-45	31848-31849	(	_	
174-46	31849-31858	secondary	_	
174-47	31859-31862	ROI	_	
174-48	31862-31863	)	_	
174-49	31864-31867	and	_	
174-50	31868-31877	cingulate	_	
174-51	31878-31879	(	_	
174-52	31879-31884	whole	_	
174-53	31885-31890	brain	_	
174-54	31890-31891	)	_	
174-55	31892-31902	signalling	_	
174-56	31903-31905	to	_	
174-57	31906-31914	negative	_	
174-58	31915-31924	emotional	_	
174-59	31925-31933	salience	_	
174-60	31933-31934	,	_	
174-61	31935-31938	and	_	
174-62	31939-31946	reduced	_	
174-63	31947-31949	SN	_	
174-64	31949-31950	/	_	
174-65	31950-31953	VTA	_	
174-66	31954-31955	(	_	
174-67	31955-31962	primary	_	
174-68	31963-31966	ROI	_	
174-69	31966-31967	)	_	
174-70	31968-31971	and	_	
174-71	31972-31981	cingulate	_	
174-72	31982-31983	(	_	
174-73	31983-31988	whole	_	
174-74	31989-31994	brain	_	
174-75	31994-31995	)	_	
174-76	31996-32006	signalling	_	
174-77	32007-32009	to	_	
174-78	32010-32020	targetness	_	
174-79	32020-32021	.	_	

#Text=These results are unconfounded by antipsychotic medication as we tested an antipsychotic naïve patient sample.
175-1	32022-32027	These	_	
175-2	32028-32035	results	_	
175-3	32036-32039	are	_	
175-4	32040-32052	unconfounded	_	
175-5	32053-32055	by	_	
175-6	32056-32069	antipsychotic	_	
175-7	32070-32080	medication	_	
175-8	32081-32083	as	_	
175-9	32084-32086	we	_	
175-10	32087-32093	tested	_	
175-11	32094-32096	an	_	
175-12	32097-32110	antipsychotic	_	
175-13	32111-32116	naïve	_	
175-14	32117-32124	patient	_	
175-15	32125-32131	sample	_	
175-16	32131-32132	.	_	

#Text=This study is first, to our knowledge, to present SN/VTA signalling alterations in psychosis in response to different forms of salience, all in absence of rewarding feedback.
176-1	32133-32137	This	_	
176-2	32138-32143	study	_	
176-3	32144-32146	is	_	
176-4	32147-32152	first	_	
176-5	32152-32153	,	_	
176-6	32154-32156	to	_	
176-7	32157-32160	our	_	
176-8	32161-32170	knowledge	_	
176-9	32170-32171	,	_	
176-10	32172-32174	to	_	
176-11	32175-32182	present	_	
176-12	32183-32185	SN	_	
176-13	32185-32186	/	_	
176-14	32186-32189	VTA	_	
176-15	32190-32200	signalling	_	
176-16	32201-32212	alterations	_	
176-17	32213-32215	in	_	
176-18	32216-32225	psychosis	_	
176-19	32226-32228	in	_	
176-20	32229-32237	response	_	
176-21	32238-32240	to	_	
176-22	32241-32250	different	_	
176-23	32251-32256	forms	_	
176-24	32257-32259	of	_	
176-25	32260-32268	salience	_	
176-26	32268-32269	,	_	
176-27	32270-32273	all	_	
176-28	32274-32276	in	_	
176-29	32277-32284	absence	_	
176-30	32285-32287	of	_	
176-31	32288-32297	rewarding	_	
176-32	32298-32306	feedback	_	
176-33	32306-32307	.	_	

#Text=Our results, therefore, extend findings reporting midbrain and cortical abnormalities in response to reward prediction error signals in medicated and unmedicated psychosis patients at different stages of the disease, fronto-limbic connectivity alterations in response to novelty in acute, unmedicated psychosis patients and striatal abnormalities in response to emotional salience in chronic, medicated and a small sample of unmedicated acute psychosis patients.
177-1	32308-32311	Our	_	
177-2	32312-32319	results	_	
177-3	32319-32320	,	_	
177-4	32321-32330	therefore	_	
177-5	32330-32331	,	_	
177-6	32332-32338	extend	_	
177-7	32339-32347	findings	_	
177-8	32348-32357	reporting	_	
177-9	32358-32366	midbrain	_	
177-10	32367-32370	and	_	
177-11	32371-32379	cortical	_	
177-12	32380-32393	abnormalities	_	
177-13	32394-32396	in	_	
177-14	32397-32405	response	_	
177-15	32406-32408	to	_	
177-16	32409-32415	reward	_	
177-17	32416-32426	prediction	_	
177-18	32427-32432	error	_	
177-19	32433-32440	signals	_	
177-20	32441-32443	in	_	
177-21	32444-32453	medicated	_	
177-22	32454-32457	and	_	
177-23	32458-32469	unmedicated	_	
177-24	32470-32479	psychosis	_	
177-25	32480-32488	patients	_	
177-26	32489-32491	at	_	
177-27	32492-32501	different	_	
177-28	32502-32508	stages	_	
177-29	32509-32511	of	_	
177-30	32512-32515	the	_	
177-31	32516-32523	disease	_	
177-32	32523-32524	,	_	
177-33	32525-32538	fronto-limbic	_	
177-34	32539-32551	connectivity	_	
177-35	32552-32563	alterations	_	
177-36	32564-32566	in	_	
177-37	32567-32575	response	_	
177-38	32576-32578	to	_	
177-39	32579-32586	novelty	_	
177-40	32587-32589	in	_	
177-41	32590-32595	acute	_	
177-42	32595-32596	,	_	
177-43	32597-32608	unmedicated	_	
177-44	32609-32618	psychosis	_	
177-45	32619-32627	patients	_	
177-46	32628-32631	and	_	
177-47	32632-32640	striatal	_	
177-48	32641-32654	abnormalities	_	
177-49	32655-32657	in	_	
177-50	32658-32666	response	_	
177-51	32667-32669	to	_	
177-52	32670-32679	emotional	_	
177-53	32680-32688	salience	_	
177-54	32689-32691	in	_	
177-55	32692-32699	chronic	_	
177-56	32699-32700	,	_	
177-57	32701-32710	medicated	_	
177-58	32711-32714	and	_	
177-59	32715-32716	a	_	
177-60	32717-32722	small	_	
177-61	32723-32729	sample	_	
177-62	32730-32732	of	_	
177-63	32733-32744	unmedicated	_	
177-64	32745-32750	acute	_	
177-65	32751-32760	psychosis	_	
177-66	32761-32769	patients	_	
177-67	32769-32770	.	_	

#Text=Our results suggest that salience processing in the dopaminergic SN/VTA may be generally impaired in patients with psychosis.
178-1	32771-32774	Our	_	
178-2	32775-32782	results	_	
178-3	32783-32790	suggest	_	
178-4	32791-32795	that	_	
178-5	32796-32804	salience	_	
178-6	32805-32815	processing	_	
178-7	32816-32818	in	_	
178-8	32819-32822	the	_	
178-9	32823-32835	dopaminergic	_	
178-10	32836-32838	SN	_	
178-11	32838-32839	/	_	
178-12	32839-32842	VTA	_	
178-13	32843-32846	may	_	
178-14	32847-32849	be	_	
178-15	32850-32859	generally	_	
178-16	32860-32868	impaired	_	
178-17	32869-32871	in	_	
178-18	32872-32880	patients	_	
178-19	32881-32885	with	_	
178-20	32886-32895	psychosis	_	
178-21	32895-32896	.	_	

#Text=The ‘aberrant salience’ hypothesis of psychosis postulates that dysregulated dopaminergic signalling in the mesolimbic system in people with psychosis results in the attribution of salience to irrelevant or non-significant stimuli.
179-1	32897-32900	The	_	
179-2	32901-32902	‘	_	
179-3	32902-32910	aberrant	_	
179-4	32911-32919	salience	_	
179-5	32919-32920	’	_	
179-6	32921-32931	hypothesis	_	
179-7	32932-32934	of	_	
179-8	32935-32944	psychosis	_	
179-9	32945-32955	postulates	_	
179-10	32956-32960	that	_	
179-11	32961-32973	dysregulated	_	
179-12	32974-32986	dopaminergic	_	
179-13	32987-32997	signalling	_	
179-14	32998-33000	in	_	
179-15	33001-33004	the	_	
179-16	33005-33015	mesolimbic	_	
179-17	33016-33022	system	_	
179-18	33023-33025	in	_	
179-19	33026-33032	people	_	
179-20	33033-33037	with	_	
179-21	33038-33047	psychosis	_	
179-22	33048-33055	results	_	
179-23	33056-33058	in	_	
179-24	33059-33062	the	_	
179-25	33063-33074	attribution	_	
179-26	33075-33077	of	_	
179-27	33078-33086	salience	_	
179-28	33087-33089	to	_	
179-29	33090-33100	irrelevant	_	
179-30	33101-33103	or	_	
179-31	33104-33119	non-significant	_	
179-32	33120-33127	stimuli	_	
179-33	33127-33128	.	_	

#Text=These unusually salient representations may lead to the formation of hallucinations or generally altered perceptions.
180-1	33129-33134	These	_	
180-2	33135-33144	unusually	_	
180-3	33145-33152	salient	_	
180-4	33153-33168	representations	_	
180-5	33169-33172	may	_	
180-6	33173-33177	lead	_	
180-7	33178-33180	to	_	
180-8	33181-33184	the	_	
180-9	33185-33194	formation	_	
180-10	33195-33197	of	_	
180-11	33198-33212	hallucinations	_	
180-12	33213-33215	or	_	
180-13	33216-33225	generally	_	
180-14	33226-33233	altered	_	
180-15	33234-33245	perceptions	_	
180-16	33245-33246	.	_	

#Text=As a result, patients may construct delusional explanations in order to explain these altered perceptions.
181-1	33247-33249	As	_	
181-2	33250-33251	a	_	
181-3	33252-33258	result	_	
181-4	33258-33259	,	_	
181-5	33260-33268	patients	_	
181-6	33269-33272	may	_	
181-7	33273-33282	construct	_	
181-8	33283-33293	delusional	_	
181-9	33294-33306	explanations	_	
181-10	33307-33309	in	_	
181-11	33310-33315	order	_	
181-12	33316-33318	to	_	
181-13	33319-33326	explain	_	
181-14	33327-33332	these	_	
181-15	33333-33340	altered	_	
181-16	33341-33352	perceptions	_	
181-17	33352-33353	.	_	

#Text=Abnormal salience attribution is present from early and even prodromal stages of the disease.
182-1	33354-33362	Abnormal	_	
182-2	33363-33371	salience	_	
182-3	33372-33383	attribution	_	
182-4	33384-33386	is	_	
182-5	33387-33394	present	_	
182-6	33395-33399	from	_	
182-7	33400-33405	early	_	
182-8	33406-33409	and	_	
182-9	33410-33414	even	_	
182-10	33415-33424	prodromal	_	
182-11	33425-33431	stages	_	
182-12	33432-33434	of	_	
182-13	33435-33438	the	_	
182-14	33439-33446	disease	_	
182-15	33446-33447	.	_	

#Text=Usually, this theory is investigated in the context of motivational salience using reward prediction paradims.
183-1	33448-33455	Usually	_	
183-2	33455-33456	,	_	
183-3	33457-33461	this	_	
183-4	33462-33468	theory	_	
183-5	33469-33471	is	_	
183-6	33472-33484	investigated	_	
183-7	33485-33487	in	_	
183-8	33488-33491	the	_	
183-9	33492-33499	context	_	
183-10	33500-33502	of	_	
183-11	33503-33515	motivational	_	
183-12	33516-33524	salience	_	
183-13	33525-33530	using	_	
183-14	33531-33537	reward	_	
183-15	33538-33548	prediction	_	
183-16	33549-33557	paradims	_	
183-17	33557-33558	.	_	

#Text=Here, however, salience was investigated in the absence of the reward.
184-1	33559-33563	Here	_	
184-2	33563-33564	,	_	
184-3	33565-33572	however	_	
184-4	33572-33573	,	_	
184-5	33574-33582	salience	_	
184-6	33583-33586	was	_	
184-7	33587-33599	investigated	_	
184-8	33600-33602	in	_	
184-9	33603-33606	the	_	
184-10	33607-33614	absence	_	
184-11	33615-33617	of	_	
184-12	33618-33621	the	_	
184-13	33622-33628	reward	_	
184-14	33628-33629	.	_	

#Text=For various forms of salience, the psychosis patient group showed significantly attenuated SN/VTA activation for the contrasts between salient and non-salient events.
185-1	33630-33633	For	_	
185-2	33634-33641	various	_	
185-3	33642-33647	forms	_	
185-4	33648-33650	of	_	
185-5	33651-33659	salience	_	
185-6	33659-33660	,	_	
185-7	33661-33664	the	_	
185-8	33665-33674	psychosis	_	
185-9	33675-33682	patient	_	
185-10	33683-33688	group	_	
185-11	33689-33695	showed	_	
185-12	33696-33709	significantly	_	
185-13	33710-33720	attenuated	_	
185-14	33721-33723	SN	_	
185-15	33723-33724	/	_	
185-16	33724-33727	VTA	_	
185-17	33728-33738	activation	_	
185-18	33739-33742	for	_	
185-19	33743-33746	the	_	
185-20	33747-33756	contrasts	_	
185-21	33757-33764	between	_	
185-22	33765-33772	salient	_	
185-23	33773-33776	and	_	
185-24	33777-33788	non-salient	_	
185-25	33789-33795	events	_	
185-26	33795-33796	.	_	

#Text=This impaired differentiation between salient and non-salient events could reflect dysregulated dopamine neuron activity, leading to the excessive attribution of salience to normally non-salient stimuli, and reducing salience to normally salient stimuli.
186-1	33797-33801	This	_	
186-2	33802-33810	impaired	_	
186-3	33811-33826	differentiation	_	
186-4	33827-33834	between	_	
186-5	33835-33842	salient	_	
186-6	33843-33846	and	_	
186-7	33847-33858	non-salient	_	
186-8	33859-33865	events	_	
186-9	33866-33871	could	_	
186-10	33872-33879	reflect	_	
186-11	33880-33892	dysregulated	_	
186-12	33893-33901	dopamine	_	
186-13	33902-33908	neuron	_	
186-14	33909-33917	activity	_	
186-15	33917-33918	,	_	
186-16	33919-33926	leading	_	
186-17	33927-33929	to	_	
186-18	33930-33933	the	_	
186-19	33934-33943	excessive	_	
186-20	33944-33955	attribution	_	
186-21	33956-33958	of	_	
186-22	33959-33967	salience	_	
186-23	33968-33970	to	_	
186-24	33971-33979	normally	_	
186-25	33980-33991	non-salient	_	
186-26	33992-33999	stimuli	_	
186-27	33999-34000	,	_	
186-28	34001-34004	and	_	
186-29	34005-34013	reducing	_	
186-30	34014-34022	salience	_	
186-31	34023-34025	to	_	
186-32	34026-34034	normally	_	
186-33	34035-34042	salient	_	
186-34	34043-34050	stimuli	_	
186-35	34050-34051	.	_	

#Text=In healthy subjects, novelty identification is processed by a number of brain regions, including SN/VTA, striatum, parietal, and prefrontal cortices.
187-1	34052-34054	In	_	
187-2	34055-34062	healthy	_	
187-3	34063-34071	subjects	_	
187-4	34071-34072	,	_	
187-5	34073-34080	novelty	_	
187-6	34081-34095	identification	_	
187-7	34096-34098	is	_	
187-8	34099-34108	processed	_	
187-9	34109-34111	by	_	
187-10	34112-34113	a	_	
187-11	34114-34120	number	_	
187-12	34121-34123	of	_	
187-13	34124-34129	brain	_	
187-14	34130-34137	regions	_	
187-15	34137-34138	,	_	
187-16	34139-34148	including	_	
187-17	34149-34151	SN	_	
187-18	34151-34152	/	_	
187-19	34152-34155	VTA	_	
187-20	34155-34156	,	_	
187-21	34157-34165	striatum	_	
187-22	34165-34166	,	_	
187-23	34167-34175	parietal	_	
187-24	34175-34176	,	_	
187-25	34177-34180	and	_	
187-26	34181-34191	prefrontal	_	
187-27	34192-34200	cortices	_	
187-28	34200-34201	.	_	

#Text=Consistent with this, we observed group differences in the SN/VTA and the striatum in response to novelty.
188-1	34202-34212	Consistent	_	
188-2	34213-34217	with	_	
188-3	34218-34222	this	_	
188-4	34222-34223	,	_	
188-5	34224-34226	we	_	
188-6	34227-34235	observed	_	
188-7	34236-34241	group	_	
188-8	34242-34253	differences	_	
188-9	34254-34256	in	_	
188-10	34257-34260	the	_	
188-11	34261-34263	SN	_	
188-12	34263-34264	/	_	
188-13	34264-34267	VTA	_	
188-14	34268-34271	and	_	
188-15	34272-34275	the	_	
188-16	34276-34284	striatum	_	
188-17	34285-34287	in	_	
188-18	34288-34296	response	_	
188-19	34297-34299	to	_	
188-20	34300-34307	novelty	_	
188-21	34307-34308	.	_	

#Text=Our findings extend results of a study by Schott and colleagues; although, this study did not detect clear differences in the midbrain or striatum in psychosis, they found an increase in functional connectivity of the hippocampus and the orbitofrontal cortex with the rostral anterior cingulate gyrus and the ventral striatum.
189-1	34309-34312	Our	_	
189-2	34313-34321	findings	_	
189-3	34322-34328	extend	_	
189-4	34329-34336	results	_	
189-5	34337-34339	of	_	
189-6	34340-34341	a	_	
189-7	34342-34347	study	_	
189-8	34348-34350	by	_	
189-9	34351-34357	Schott	_	
189-10	34358-34361	and	_	
189-11	34362-34372	colleagues	_	
189-12	34372-34373	;	_	
189-13	34374-34382	although	_	
189-14	34382-34383	,	_	
189-15	34384-34388	this	_	
189-16	34389-34394	study	_	
189-17	34395-34398	did	_	
189-18	34399-34402	not	_	
189-19	34403-34409	detect	_	
189-20	34410-34415	clear	_	
189-21	34416-34427	differences	_	
189-22	34428-34430	in	_	
189-23	34431-34434	the	_	
189-24	34435-34443	midbrain	_	
189-25	34444-34446	or	_	
189-26	34447-34455	striatum	_	
189-27	34456-34458	in	_	
189-28	34459-34468	psychosis	_	
189-29	34468-34469	,	_	
189-30	34470-34474	they	_	
189-31	34475-34480	found	_	
189-32	34481-34483	an	_	
189-33	34484-34492	increase	_	
189-34	34493-34495	in	_	
189-35	34496-34506	functional	_	
189-36	34507-34519	connectivity	_	
189-37	34520-34522	of	_	
189-38	34523-34526	the	_	
189-39	34527-34538	hippocampus	_	
189-40	34539-34542	and	_	
189-41	34543-34546	the	_	
189-42	34547-34560	orbitofrontal	_	
189-43	34561-34567	cortex	_	
189-44	34568-34572	with	_	
189-45	34573-34576	the	_	
189-46	34577-34584	rostral	_	
189-47	34585-34593	anterior	_	
189-48	34594-34603	cingulate	_	
189-49	34604-34609	gyrus	_	
189-50	34610-34613	and	_	
189-51	34614-34617	the	_	
189-52	34618-34625	ventral	_	
189-53	34626-34634	striatum	_	
189-54	34634-34635	.	_	

#Text=Our study also demonstrates significantly reduced activation in response to negative emotional salience compared to controls in right amygdala, the SN/VTA and the striatum in psychosis patients compared to controls.
190-1	34636-34639	Our	_	
190-2	34640-34645	study	_	
190-3	34646-34650	also	_	
190-4	34651-34663	demonstrates	_	
190-5	34664-34677	significantly	_	
190-6	34678-34685	reduced	_	
190-7	34686-34696	activation	_	
190-8	34697-34699	in	_	
190-9	34700-34708	response	_	
190-10	34709-34711	to	_	
190-11	34712-34720	negative	_	
190-12	34721-34730	emotional	_	
190-13	34731-34739	salience	_	
190-14	34740-34748	compared	_	
190-15	34749-34751	to	_	
190-16	34752-34760	controls	_	
190-17	34761-34763	in	_	
190-18	34764-34769	right	_	
190-19	34770-34778	amygdala	_	
190-20	34778-34779	,	_	
190-21	34780-34783	the	_	
190-22	34784-34786	SN	_	
190-23	34786-34787	/	_	
190-24	34787-34790	VTA	_	
190-25	34791-34794	and	_	
190-26	34795-34798	the	_	
190-27	34799-34807	striatum	_	
190-28	34808-34810	in	_	
190-29	34811-34820	psychosis	_	
190-30	34821-34829	patients	_	
190-31	34830-34838	compared	_	
190-32	34839-34841	to	_	
190-33	34842-34850	controls	_	
190-34	34850-34851	.	_	

#Text=This result is consistent with the literature indicating reduced arousal to emotional stimuli.
191-1	34852-34856	This	_	
191-2	34857-34863	result	_	
191-3	34864-34866	is	_	
191-4	34867-34877	consistent	_	
191-5	34878-34882	with	_	
191-6	34883-34886	the	_	
191-7	34887-34897	literature	_	
191-8	34898-34908	indicating	_	
191-9	34909-34916	reduced	_	
191-10	34917-34924	arousal	_	
191-11	34925-34927	to	_	
191-12	34928-34937	emotional	_	
191-13	34938-34945	stimuli	_	
191-14	34945-34946	.	_	

#Text=Our study also supports findings of a PET study indicating tonic over-activation of the amygdala and impaired striatal signalling during emotional salience processing.
192-1	34947-34950	Our	_	
192-2	34951-34956	study	_	
192-3	34957-34961	also	_	
192-4	34962-34970	supports	_	
192-5	34971-34979	findings	_	
192-6	34980-34982	of	_	
192-7	34983-34984	a	_	
192-8	34985-34988	PET	_	
192-9	34989-34994	study	_	
192-10	34995-35005	indicating	_	
192-11	35006-35011	tonic	_	
192-12	35012-35027	over-activation	_	
192-13	35028-35030	of	_	
192-14	35031-35034	the	_	
192-15	35035-35043	amygdala	_	
192-16	35044-35047	and	_	
192-17	35048-35056	impaired	_	
192-18	35057-35065	striatal	_	
192-19	35066-35076	signalling	_	
192-20	35077-35083	during	_	
192-21	35084-35093	emotional	_	
192-22	35094-35102	salience	_	
192-23	35103-35113	processing	_	
192-24	35113-35114	.	_	

#Text=Jabbi and colleagues reported increased dopaminergic releases in the amygdala and midbrain in response to emotional salience, which might be altered in psychosis.
193-1	35115-35120	Jabbi	_	
193-2	35121-35124	and	_	
193-3	35125-35135	colleagues	_	
193-4	35136-35144	reported	_	
193-5	35145-35154	increased	_	
193-6	35155-35167	dopaminergic	_	
193-7	35168-35176	releases	_	
193-8	35177-35179	in	_	
193-9	35180-35183	the	_	
193-10	35184-35192	amygdala	_	
193-11	35193-35196	and	_	
193-12	35197-35205	midbrain	_	
193-13	35206-35208	in	_	
193-14	35209-35217	response	_	
193-15	35218-35220	to	_	
193-16	35221-35230	emotional	_	
193-17	35231-35239	salience	_	
193-18	35239-35240	,	_	
193-19	35241-35246	which	_	
193-20	35247-35252	might	_	
193-21	35253-35255	be	_	
193-22	35256-35263	altered	_	
193-23	35264-35266	in	_	
193-24	35267-35276	psychosis	_	
193-25	35276-35277	.	_	

#Text=Our results, furthermore, reveal reduced activation in the thalamus of psychosis patients compared to healthy controls for negative emotional salience.
194-1	35278-35281	Our	_	
194-2	35282-35289	results	_	
194-3	35289-35290	,	_	
194-4	35291-35302	furthermore	_	
194-5	35302-35303	,	_	
194-6	35304-35310	reveal	_	
194-7	35311-35318	reduced	_	
194-8	35319-35329	activation	_	
194-9	35330-35332	in	_	
194-10	35333-35336	the	_	
194-11	35337-35345	thalamus	_	
194-12	35346-35348	of	_	
194-13	35349-35358	psychosis	_	
194-14	35359-35367	patients	_	
194-15	35368-35376	compared	_	
194-16	35377-35379	to	_	
194-17	35380-35387	healthy	_	
194-18	35388-35396	controls	_	
194-19	35397-35400	for	_	
194-20	35401-35409	negative	_	
194-21	35410-35419	emotional	_	
194-22	35420-35428	salience	_	
194-23	35428-35429	.	_	

#Text=The thalamus is a relay station of multiple neural connections and has dopaminergic synapses.
195-1	35430-35433	The	_	
195-2	35434-35442	thalamus	_	
195-3	35443-35445	is	_	
195-4	35446-35447	a	_	
195-5	35448-35453	relay	_	
195-6	35454-35461	station	_	
195-7	35462-35464	of	_	
195-8	35465-35473	multiple	_	
195-9	35474-35480	neural	_	
195-10	35481-35492	connections	_	
195-11	35493-35496	and	_	
195-12	35497-35500	has	_	
195-13	35501-35513	dopaminergic	_	
195-14	35514-35522	synapses	_	
195-15	35522-35523	.	_	

#Text=Consistent with this and our findings, a study by Hadley and colleagues reported reduced connectivity between the VTA/midbrain and the thalamus in schizophrenia patients.
196-1	35524-35534	Consistent	_	
196-2	35535-35539	with	_	
196-3	35540-35544	this	_	
196-4	35545-35548	and	_	
196-5	35549-35552	our	_	
196-6	35553-35561	findings	_	
196-7	35561-35562	,	_	
196-8	35563-35564	a	_	
196-9	35565-35570	study	_	
196-10	35571-35573	by	_	
196-11	35574-35580	Hadley	_	
196-12	35581-35584	and	_	
196-13	35585-35595	colleagues	_	
196-14	35596-35604	reported	_	
196-15	35605-35612	reduced	_	
196-16	35613-35625	connectivity	_	
196-17	35626-35633	between	_	
196-18	35634-35637	the	_	
196-19	35638-35641	VTA	_	
196-20	35641-35642	/	_	
196-21	35642-35650	midbrain	_	
196-22	35651-35654	and	_	
196-23	35655-35658	the	_	
196-24	35659-35667	thalamus	_	
196-25	35668-35670	in	_	
196-26	35671-35684	schizophrenia	_	
196-27	35685-35693	patients	_	
196-28	35693-35694	.	_	

#Text=In addition to reduced SN/VTA processing in response to novelty and negative emotional salience, we also found reduced signalling in response to targetness in patients.
197-1	35695-35697	In	_	
197-2	35698-35706	addition	_	
197-3	35707-35709	to	_	
197-4	35710-35717	reduced	_	
197-5	35718-35720	SN	_	
197-6	35720-35721	/	_	
197-7	35721-35724	VTA	_	
197-8	35725-35735	processing	_	
197-9	35736-35738	in	_	
197-10	35739-35747	response	_	
197-11	35748-35750	to	_	
197-12	35751-35758	novelty	_	
197-13	35759-35762	and	_	
197-14	35763-35771	negative	_	
197-15	35772-35781	emotional	_	
197-16	35782-35790	salience	_	
197-17	35790-35791	,	_	
197-18	35792-35794	we	_	
197-19	35795-35799	also	_	
197-20	35800-35805	found	_	
197-21	35806-35813	reduced	_	
197-22	35814-35824	signalling	_	
197-23	35825-35827	in	_	
197-24	35828-35836	response	_	
197-25	35837-35839	to	_	
197-26	35840-35850	targetness	_	
197-27	35851-35853	in	_	
197-28	35854-35862	patients	_	
197-29	35862-35863	.	_	

#Text=Therefore, our study is first to provide clear evidence for reduced SN/VTA processing in response to these different forms of non-motivational salience in psychosis.
198-1	35864-35873	Therefore	_	
198-2	35873-35874	,	_	
198-3	35875-35878	our	_	
198-4	35879-35884	study	_	
198-5	35885-35887	is	_	
198-6	35888-35893	first	_	
198-7	35894-35896	to	_	
198-8	35897-35904	provide	_	
198-9	35905-35910	clear	_	
198-10	35911-35919	evidence	_	
198-11	35920-35923	for	_	
198-12	35924-35931	reduced	_	
198-13	35932-35934	SN	_	
198-14	35934-35935	/	_	
198-15	35935-35938	VTA	_	
198-16	35939-35949	processing	_	
198-17	35950-35952	in	_	
198-18	35953-35961	response	_	
198-19	35962-35964	to	_	
198-20	35965-35970	these	_	
198-21	35971-35980	different	_	
198-22	35981-35986	forms	_	
198-23	35987-35989	of	_	
198-24	35990-36006	non-motivational	_	
198-25	36007-36015	salience	_	
198-26	36016-36018	in	_	
198-27	36019-36028	psychosis	_	
198-28	36028-36029	.	_	

#Text=Together with the striatal findings of altered novelty and emotional salience signalling, the findings in the patients support the aberrant salience hypothesis for general (not just reward-related) salience dysfunction.
199-1	36030-36038	Together	_	
199-2	36039-36043	with	_	
199-3	36044-36047	the	_	
199-4	36048-36056	striatal	_	
199-5	36057-36065	findings	_	
199-6	36066-36068	of	_	
199-7	36069-36076	altered	_	
199-8	36077-36084	novelty	_	
199-9	36085-36088	and	_	
199-10	36089-36098	emotional	_	
199-11	36099-36107	salience	_	
199-12	36108-36118	signalling	_	
199-13	36118-36119	,	_	
199-14	36120-36123	the	_	
199-15	36124-36132	findings	_	
199-16	36133-36135	in	_	
199-17	36136-36139	the	_	
199-18	36140-36148	patients	_	
199-19	36149-36156	support	_	
199-20	36157-36160	the	_	
199-21	36161-36169	aberrant	_	
199-22	36170-36178	salience	_	
199-23	36179-36189	hypothesis	_	
199-24	36190-36193	for	_	
199-25	36194-36201	general	_	
199-26	36202-36203	(	_	
199-27	36203-36206	not	_	
199-28	36207-36211	just	_	
199-29	36212-36226	reward-related	_	
199-30	36226-36227	)	_	
199-31	36228-36236	salience	_	
199-32	36237-36248	dysfunction	_	
199-33	36248-36249	.	_	

#Text=As both the midbrain and the striatum are dopaminergic key regions, it also provides supporting (though not definitive) evidence for a dysregulated dopaminergic system during salience processing in psychosis.
200-1	36250-36252	As	_	
200-2	36253-36257	both	_	
200-3	36258-36261	the	_	
200-4	36262-36270	midbrain	_	
200-5	36271-36274	and	_	
200-6	36275-36278	the	_	
200-7	36279-36287	striatum	_	
200-8	36288-36291	are	_	
200-9	36292-36304	dopaminergic	_	
200-10	36305-36308	key	_	
200-11	36309-36316	regions	_	
200-12	36316-36317	,	_	
200-13	36318-36320	it	_	
200-14	36321-36325	also	_	
200-15	36326-36334	provides	_	
200-16	36335-36345	supporting	_	
200-17	36346-36347	(	_	
200-18	36347-36353	though	_	
200-19	36354-36357	not	_	
200-20	36358-36368	definitive	_	
200-21	36368-36369	)	_	
200-22	36370-36378	evidence	_	
200-23	36379-36382	for	_	
200-24	36383-36384	a	_	
200-25	36385-36397	dysregulated	_	
200-26	36398-36410	dopaminergic	_	
200-27	36411-36417	system	_	
200-28	36418-36424	during	_	
200-29	36425-36433	salience	_	
200-30	36434-36444	processing	_	
200-31	36445-36447	in	_	
200-32	36448-36457	psychosis	_	
200-33	36457-36458	.	_	

#Text=In healthy controls, Bunzeck and Düzel reported significantly enhanced SN/VTA activation in response to novelty, and also positive, but not statistically significant, activation in response to negative emotional salience, providing supportive evidence for a differential activation of the SN/VTA in response to novelty.
201-1	36459-36461	In	_	
201-2	36462-36469	healthy	_	
201-3	36470-36478	controls	_	
201-4	36478-36479	,	_	
201-5	36480-36487	Bunzeck	_	
201-6	36488-36491	and	_	
201-7	36492-36497	Düzel	_	
201-8	36498-36506	reported	_	
201-9	36507-36520	significantly	_	
201-10	36521-36529	enhanced	_	
201-11	36530-36532	SN	_	
201-12	36532-36533	/	_	
201-13	36533-36536	VTA	_	
201-14	36537-36547	activation	_	
201-15	36548-36550	in	_	
201-16	36551-36559	response	_	
201-17	36560-36562	to	_	
201-18	36563-36570	novelty	_	
201-19	36570-36571	,	_	
201-20	36572-36575	and	_	
201-21	36576-36580	also	_	
201-22	36581-36589	positive	_	
201-23	36589-36590	,	_	
201-24	36591-36594	but	_	
201-25	36595-36598	not	_	
201-26	36599-36612	statistically	_	
201-27	36613-36624	significant	_	
201-28	36624-36625	,	_	
201-29	36626-36636	activation	_	
201-30	36637-36639	in	_	
201-31	36640-36648	response	_	
201-32	36649-36651	to	_	
201-33	36652-36660	negative	_	
201-34	36661-36670	emotional	_	
201-35	36671-36679	salience	_	
201-36	36679-36680	,	_	
201-37	36681-36690	providing	_	
201-38	36691-36701	supportive	_	
201-39	36702-36710	evidence	_	
201-40	36711-36714	for	_	
201-41	36715-36716	a	_	
201-42	36717-36729	differential	_	
201-43	36730-36740	activation	_	
201-44	36741-36743	of	_	
201-45	36744-36747	the	_	
201-46	36748-36750	SN	_	
201-47	36750-36751	/	_	
201-48	36751-36754	VTA	_	
201-49	36755-36757	in	_	
201-50	36758-36766	response	_	
201-51	36767-36769	to	_	
201-52	36770-36777	novelty	_	
201-53	36777-36778	.	_	

#Text=Using a larger sample size than previous studies and a slightly different regional specification used for the SN/VTA, we, however, find significant SN/VTA activation to novelty and negative emotional salience in controls.
202-1	36779-36784	Using	_	
202-2	36785-36786	a	_	
202-3	36787-36793	larger	_	
202-4	36794-36800	sample	_	
202-5	36801-36805	size	_	
202-6	36806-36810	than	_	
202-7	36811-36819	previous	_	
202-8	36820-36827	studies	_	
202-9	36828-36831	and	_	
202-10	36832-36833	a	_	
202-11	36834-36842	slightly	_	
202-12	36843-36852	different	_	
202-13	36853-36861	regional	_	
202-14	36862-36875	specification	_	
202-15	36876-36880	used	_	
202-16	36881-36884	for	_	
202-17	36885-36888	the	_	
202-18	36889-36891	SN	_	
202-19	36891-36892	/	_	
202-20	36892-36895	VTA	_	
202-21	36895-36896	,	_	
202-22	36897-36899	we	_	
202-23	36899-36900	,	_	
202-24	36901-36908	however	_	
202-25	36908-36909	,	_	
202-26	36910-36914	find	_	
202-27	36915-36926	significant	_	
202-28	36927-36929	SN	_	
202-29	36929-36930	/	_	
202-30	36930-36933	VTA	_	
202-31	36934-36944	activation	_	
202-32	36945-36947	to	_	
202-33	36948-36955	novelty	_	
202-34	36956-36959	and	_	
202-35	36960-36968	negative	_	
202-36	36969-36978	emotional	_	
202-37	36979-36987	salience	_	
202-38	36988-36990	in	_	
202-39	36991-36999	controls	_	
202-40	36999-37000	.	_	

#Text=Our results, therefore, support the view of general processing of salience in the SN/VTA, including novelty, negative emotional salience and targetness.
203-1	37001-37004	Our	_	
203-2	37005-37012	results	_	
203-3	37012-37013	,	_	
203-4	37014-37023	therefore	_	
203-5	37023-37024	,	_	
203-6	37025-37032	support	_	
203-7	37033-37036	the	_	
203-8	37037-37041	view	_	
203-9	37042-37044	of	_	
203-10	37045-37052	general	_	
203-11	37053-37063	processing	_	
203-12	37064-37066	of	_	
203-13	37067-37075	salience	_	
203-14	37076-37078	in	_	
203-15	37079-37082	the	_	
203-16	37083-37085	SN	_	
203-17	37085-37086	/	_	
203-18	37086-37089	VTA	_	
203-19	37089-37090	,	_	
203-20	37091-37100	including	_	
203-21	37101-37108	novelty	_	
203-22	37108-37109	,	_	
203-23	37110-37118	negative	_	
203-24	37119-37128	emotional	_	
203-25	37129-37137	salience	_	
203-26	37138-37141	and	_	
203-27	37142-37152	targetness	_	
203-28	37152-37153	.	_	

#Text=An account reconciling these results with those of Bunzeck and Düzel, may be that SN/VTA is highly sensitive to novelty, but is also sensitive to (at least some) other forms of salience.
204-1	37154-37156	An	_	
204-2	37157-37164	account	_	
204-3	37165-37176	reconciling	_	
204-4	37177-37182	these	_	
204-5	37183-37190	results	_	
204-6	37191-37195	with	_	
204-7	37196-37201	those	_	
204-8	37202-37204	of	_	
204-9	37205-37212	Bunzeck	_	
204-10	37213-37216	and	_	
204-11	37217-37222	Düzel	_	
204-12	37222-37223	,	_	
204-13	37224-37227	may	_	
204-14	37228-37230	be	_	
204-15	37231-37235	that	_	
204-16	37236-37238	SN	_	
204-17	37238-37239	/	_	
204-18	37239-37242	VTA	_	
204-19	37243-37245	is	_	
204-20	37246-37252	highly	_	
204-21	37253-37262	sensitive	_	
204-22	37263-37265	to	_	
204-23	37266-37273	novelty	_	
204-24	37273-37274	,	_	
204-25	37275-37278	but	_	
204-26	37279-37281	is	_	
204-27	37282-37286	also	_	
204-28	37287-37296	sensitive	_	
204-29	37297-37299	to	_	
204-30	37300-37301	(	_	
204-31	37301-37303	at	_	
204-32	37304-37309	least	_	
204-33	37310-37314	some	_	
204-34	37314-37315	)	_	
204-35	37316-37321	other	_	
204-36	37322-37327	forms	_	
204-37	37328-37330	of	_	
204-38	37331-37339	salience	_	
204-39	37339-37340	.	_	

#Text=On the other hand, we do note that the precise voxels within the SN/VTA that activate and/or show significant group differences to the different salient conditions do not overlap, though they are sometimes adjacent (see Supplementary Figure 9 and 10 for example).
205-1	37341-37343	On	_	
205-2	37344-37347	the	_	
205-3	37348-37353	other	_	
205-4	37354-37358	hand	_	
205-5	37358-37359	,	_	
205-6	37360-37362	we	_	
205-7	37363-37365	do	_	
205-8	37366-37370	note	_	
205-9	37371-37375	that	_	
205-10	37376-37379	the	_	
205-11	37380-37387	precise	_	
205-12	37388-37394	voxels	_	
205-13	37395-37401	within	_	
205-14	37402-37405	the	_	
205-15	37406-37408	SN	_	
205-16	37408-37409	/	_	
205-17	37409-37412	VTA	_	
205-18	37413-37417	that	_	
205-19	37418-37426	activate	_	
205-20	37427-37430	and	_	
205-21	37430-37431	/	_	
205-22	37431-37433	or	_	
205-23	37434-37438	show	_	
205-24	37439-37450	significant	_	
205-25	37451-37456	group	_	
205-26	37457-37468	differences	_	
205-27	37469-37471	to	_	
205-28	37472-37475	the	_	
205-29	37476-37485	different	_	
205-30	37486-37493	salient	_	
205-31	37494-37504	conditions	_	
205-32	37505-37507	do	_	
205-33	37508-37511	not	_	
205-34	37512-37519	overlap	_	
205-35	37519-37520	,	_	
205-36	37521-37527	though	_	
205-37	37528-37532	they	_	
205-38	37533-37536	are	_	
205-39	37537-37546	sometimes	_	
205-40	37547-37555	adjacent	_	
205-41	37556-37557	(	_	
205-42	37557-37560	see	_	
205-43	37561-37574	Supplementary	_	
205-44	37575-37581	Figure	_	
205-45	37582-37583	9	_	
205-46	37584-37587	and	_	
205-47	37588-37590	10	_	
205-48	37591-37594	for	_	
205-49	37595-37602	example	_	
205-50	37602-37603	)	_	
205-51	37603-37604	.	_	

#Text=Furthermore, our focus of maximal group difference in novelty activation is slightly more rostral as compared to Bunzeck and Düzel’s findings of novelty associated activity in controls but still lies within the SN/VTA ROI as defined by Murty et al.
206-1	37605-37616	Furthermore	_	
206-2	37616-37617	,	_	
206-3	37618-37621	our	_	
206-4	37622-37627	focus	_	
206-5	37628-37630	of	_	
206-6	37631-37638	maximal	_	
206-7	37639-37644	group	_	
206-8	37645-37655	difference	_	
206-9	37656-37658	in	_	
206-10	37659-37666	novelty	_	
206-11	37667-37677	activation	_	
206-12	37678-37680	is	_	
206-13	37681-37689	slightly	_	
206-14	37690-37694	more	_	
206-15	37695-37702	rostral	_	
206-16	37703-37705	as	_	
206-17	37706-37714	compared	_	
206-18	37715-37717	to	_	
206-19	37718-37725	Bunzeck	_	
206-20	37726-37729	and	_	
206-21	37730-37735	Düzel	_	
206-22	37735-37736	’	_	
206-23	37736-37737	s	_	
206-24	37738-37746	findings	_	
206-25	37747-37749	of	_	
206-26	37750-37757	novelty	_	
206-27	37758-37768	associated	_	
206-28	37769-37777	activity	_	
206-29	37778-37780	in	_	
206-30	37781-37789	controls	_	
206-31	37790-37793	but	_	
206-32	37794-37799	still	_	
206-33	37800-37804	lies	_	
206-34	37805-37811	within	_	
206-35	37812-37815	the	_	
206-36	37816-37818	SN	_	
206-37	37818-37819	/	_	
206-38	37819-37822	VTA	_	
206-39	37823-37826	ROI	_	
206-40	37827-37829	as	_	
206-41	37830-37837	defined	_	
206-42	37838-37840	by	_	
206-43	37841-37846	Murty	_	
206-44	37847-37849	et	_	
206-45	37850-37852	al	_	
206-46	37852-37853	.	_	

#Text=Given this variation in precise location of voxel clusters within the SN/VTA ROI, combined with the spatial resolution of the current study, we cannot definitively determine within this region whether the exact same neurons activate to diverse or specific stimuli.
207-1	37854-37859	Given	_	
207-2	37860-37864	this	_	
207-3	37865-37874	variation	_	
207-4	37875-37877	in	_	
207-5	37878-37885	precise	_	
207-6	37886-37894	location	_	
207-7	37895-37897	of	_	
207-8	37898-37903	voxel	_	
207-9	37904-37912	clusters	_	
207-10	37913-37919	within	_	
207-11	37920-37923	the	_	
207-12	37924-37926	SN	_	
207-13	37926-37927	/	_	
207-14	37927-37930	VTA	_	
207-15	37931-37934	ROI	_	
207-16	37934-37935	,	_	
207-17	37936-37944	combined	_	
207-18	37945-37949	with	_	
207-19	37950-37953	the	_	
207-20	37954-37961	spatial	_	
207-21	37962-37972	resolution	_	
207-22	37973-37975	of	_	
207-23	37976-37979	the	_	
207-24	37980-37987	current	_	
207-25	37988-37993	study	_	
207-26	37993-37994	,	_	
207-27	37995-37997	we	_	
207-28	37998-38004	cannot	_	
207-29	38005-38017	definitively	_	
207-30	38018-38027	determine	_	
207-31	38028-38034	within	_	
207-32	38035-38039	this	_	
207-33	38040-38046	region	_	
207-34	38047-38054	whether	_	
207-35	38055-38058	the	_	
207-36	38059-38064	exact	_	
207-37	38065-38069	same	_	
207-38	38070-38077	neurons	_	
207-39	38078-38086	activate	_	
207-40	38087-38089	to	_	
207-41	38090-38097	diverse	_	
207-42	38098-38100	or	_	
207-43	38101-38109	specific	_	
207-44	38110-38117	stimuli	_	
207-45	38117-38118	.	_	

#Text=However, future studies could employ higher resolution at higher field strengths, to address these questions.
208-1	38119-38126	However	_	
208-2	38126-38127	,	_	
208-3	38128-38134	future	_	
208-4	38135-38142	studies	_	
208-5	38143-38148	could	_	
208-6	38149-38155	employ	_	
208-7	38156-38162	higher	_	
208-8	38163-38173	resolution	_	
208-9	38174-38176	at	_	
208-10	38177-38183	higher	_	
208-11	38184-38189	field	_	
208-12	38190-38199	strengths	_	
208-13	38199-38200	,	_	
208-14	38201-38203	to	_	
208-15	38204-38211	address	_	
208-16	38212-38217	these	_	
208-17	38218-38227	questions	_	
208-18	38227-38228	.	_	

#Text=Experiments using observational fMRI alone cannot prove that the abnormal SN/VTA patterns of various forms of salience signalling in psychosis have the same precise underlying pathophysiology, but future work combining the same or related fMRI paradigms with an intervention (pharmacological or brain stimulation) could further elucidate pathophysiological causal mechanisms.
209-1	38229-38240	Experiments	_	
209-2	38241-38246	using	_	
209-3	38247-38260	observational	_	
209-4	38261-38265	fMRI	_	
209-5	38266-38271	alone	_	
209-6	38272-38278	cannot	_	
209-7	38279-38284	prove	_	
209-8	38285-38289	that	_	
209-9	38290-38293	the	_	
209-10	38294-38302	abnormal	_	
209-11	38303-38305	SN	_	
209-12	38305-38306	/	_	
209-13	38306-38309	VTA	_	
209-14	38310-38318	patterns	_	
209-15	38319-38321	of	_	
209-16	38322-38329	various	_	
209-17	38330-38335	forms	_	
209-18	38336-38338	of	_	
209-19	38339-38347	salience	_	
209-20	38348-38358	signalling	_	
209-21	38359-38361	in	_	
209-22	38362-38371	psychosis	_	
209-23	38372-38376	have	_	
209-24	38377-38380	the	_	
209-25	38381-38385	same	_	
209-26	38386-38393	precise	_	
209-27	38394-38404	underlying	_	
209-28	38405-38420	pathophysiology	_	
209-29	38420-38421	,	_	
209-30	38422-38425	but	_	
209-31	38426-38432	future	_	
209-32	38433-38437	work	_	
209-33	38438-38447	combining	_	
209-34	38448-38451	the	_	
209-35	38452-38456	same	_	
209-36	38457-38459	or	_	
209-37	38460-38467	related	_	
209-38	38468-38472	fMRI	_	
209-39	38473-38482	paradigms	_	
209-40	38483-38487	with	_	
209-41	38488-38490	an	_	
209-42	38491-38503	intervention	_	
209-43	38504-38505	(	_	
209-44	38505-38520	pharmacological	_	
209-45	38521-38523	or	_	
209-46	38524-38529	brain	_	
209-47	38530-38541	stimulation	_	
209-48	38541-38542	)	_	
209-49	38543-38548	could	_	
209-50	38549-38556	further	_	
209-51	38557-38566	elucidate	_	
209-52	38567-38585	pathophysiological	_	
209-53	38586-38592	causal	_	
209-54	38593-38603	mechanisms	_	
209-55	38603-38604	.	_	

#Text=Moreover, the whole brain analysis revealed reductions in anterior cingulate gyrus activity in psychosis patients compared to healthy controls in response to negative emotional salience.
210-1	38605-38613	Moreover	_	
210-2	38613-38614	,	_	
210-3	38615-38618	the	_	
210-4	38619-38624	whole	_	
210-5	38625-38630	brain	_	
210-6	38631-38639	analysis	_	
210-7	38640-38648	revealed	_	
210-8	38649-38659	reductions	_	
210-9	38660-38662	in	_	
210-10	38663-38671	anterior	_	
210-11	38672-38681	cingulate	_	
210-12	38682-38687	gyrus	_	
210-13	38688-38696	activity	_	
210-14	38697-38699	in	_	
210-15	38700-38709	psychosis	_	
210-16	38710-38718	patients	_	
210-17	38719-38727	compared	_	
210-18	38728-38730	to	_	
210-19	38731-38738	healthy	_	
210-20	38739-38747	controls	_	
210-21	38748-38750	in	_	
210-22	38751-38759	response	_	
210-23	38760-38762	to	_	
210-24	38763-38771	negative	_	
210-25	38772-38781	emotional	_	
210-26	38782-38790	salience	_	
210-27	38790-38791	.	_	

#Text=The cingulate cortex, as part of the salience network, has been found to show aberrant connectivity and structure in psychosis.
211-1	38792-38795	The	_	
211-2	38796-38805	cingulate	_	
211-3	38806-38812	cortex	_	
211-4	38812-38813	,	_	
211-5	38814-38816	as	_	
211-6	38817-38821	part	_	
211-7	38822-38824	of	_	
211-8	38825-38828	the	_	
211-9	38829-38837	salience	_	
211-10	38838-38845	network	_	
211-11	38845-38846	,	_	
211-12	38847-38850	has	_	
211-13	38851-38855	been	_	
211-14	38856-38861	found	_	
211-15	38862-38864	to	_	
211-16	38865-38869	show	_	
211-17	38870-38878	aberrant	_	
211-18	38879-38891	connectivity	_	
211-19	38892-38895	and	_	
211-20	38896-38905	structure	_	
211-21	38906-38908	in	_	
211-22	38909-38918	psychosis	_	
211-23	38918-38919	.	_	

#Text=We previously showed that the severity of psychotic symptoms in healthy volunteers induced by methamphetamine, significantly correlated with the degree of drug induced disruption of the incentive value signal disruption in the posterior cingulate cortex, suggesting a dopamine-mediated mechanism in this region.
212-1	38920-38922	We	_	
212-2	38923-38933	previously	_	
212-3	38934-38940	showed	_	
212-4	38941-38945	that	_	
212-5	38946-38949	the	_	
212-6	38950-38958	severity	_	
212-7	38959-38961	of	_	
212-8	38962-38971	psychotic	_	
212-9	38972-38980	symptoms	_	
212-10	38981-38983	in	_	
212-11	38984-38991	healthy	_	
212-12	38992-39002	volunteers	_	
212-13	39003-39010	induced	_	
212-14	39011-39013	by	_	
212-15	39014-39029	methamphetamine	_	
212-16	39029-39030	,	_	
212-17	39031-39044	significantly	_	
212-18	39045-39055	correlated	_	
212-19	39056-39060	with	_	
212-20	39061-39064	the	_	
212-21	39065-39071	degree	_	
212-22	39072-39074	of	_	
212-23	39075-39079	drug	_	
212-24	39080-39087	induced	_	
212-25	39088-39098	disruption	_	
212-26	39099-39101	of	_	
212-27	39102-39105	the	_	
212-28	39106-39115	incentive	_	
212-29	39116-39121	value	_	
212-30	39122-39128	signal	_	
212-31	39129-39139	disruption	_	
212-32	39140-39142	in	_	
212-33	39143-39146	the	_	
212-34	39147-39156	posterior	_	
212-35	39157-39166	cingulate	_	
212-36	39167-39173	cortex	_	
212-37	39173-39174	,	_	
212-38	39175-39185	suggesting	_	
212-39	39186-39187	a	_	
212-40	39188-39205	dopamine-mediated	_	
212-41	39206-39215	mechanism	_	
212-42	39216-39218	in	_	
212-43	39219-39223	this	_	
212-44	39224-39230	region	_	
212-45	39230-39231	.	_	

#Text=A study by Gradin and colleagues reported dysfunctional connectivity between the salience network and the midbrain during a reward learning task leading to abnormal reward processing in schizophrenia patients.
213-1	39232-39233	A	_	
213-2	39234-39239	study	_	
213-3	39240-39242	by	_	
213-4	39243-39249	Gradin	_	
213-5	39250-39253	and	_	
213-6	39254-39264	colleagues	_	
213-7	39265-39273	reported	_	
213-8	39274-39287	dysfunctional	_	
213-9	39288-39300	connectivity	_	
213-10	39301-39308	between	_	
213-11	39309-39312	the	_	
213-12	39313-39321	salience	_	
213-13	39322-39329	network	_	
213-14	39330-39333	and	_	
213-15	39334-39337	the	_	
213-16	39338-39346	midbrain	_	
213-17	39347-39353	during	_	
213-18	39354-39355	a	_	
213-19	39356-39362	reward	_	
213-20	39363-39371	learning	_	
213-21	39372-39376	task	_	
213-22	39377-39384	leading	_	
213-23	39385-39387	to	_	
213-24	39388-39396	abnormal	_	
213-25	39397-39403	reward	_	
213-26	39404-39414	processing	_	
213-27	39415-39417	in	_	
213-28	39418-39431	schizophrenia	_	
213-29	39432-39440	patients	_	
213-30	39440-39441	.	_	

#Text=Furthermore, structural alterations have consistently been documented in patients with psychosis.
214-1	39442-39453	Furthermore	_	
214-2	39453-39454	,	_	
214-3	39455-39465	structural	_	
214-4	39466-39477	alterations	_	
214-5	39478-39482	have	_	
214-6	39483-39495	consistently	_	
214-7	39496-39500	been	_	
214-8	39501-39511	documented	_	
214-9	39512-39514	in	_	
214-10	39515-39523	patients	_	
214-11	39524-39528	with	_	
214-12	39529-39538	psychosis	_	
214-13	39538-39539	.	_	

#Text=Therefore, our results may provide an indication that possible dysfunctional interactions between the salience network and the SN/VTA may also lead to aberrant processing of different types of salience.
215-1	39540-39549	Therefore	_	
215-2	39549-39550	,	_	
215-3	39551-39554	our	_	
215-4	39555-39562	results	_	
215-5	39563-39566	may	_	
215-6	39567-39574	provide	_	
215-7	39575-39577	an	_	
215-8	39578-39588	indication	_	
215-9	39589-39593	that	_	
215-10	39594-39602	possible	_	
215-11	39603-39616	dysfunctional	_	
215-12	39617-39629	interactions	_	
215-13	39630-39637	between	_	
215-14	39638-39641	the	_	
215-15	39642-39650	salience	_	
215-16	39651-39658	network	_	
215-17	39659-39662	and	_	
215-18	39663-39666	the	_	
215-19	39667-39669	SN	_	
215-20	39669-39670	/	_	
215-21	39670-39673	VTA	_	
215-22	39674-39677	may	_	
215-23	39678-39682	also	_	
215-24	39683-39687	lead	_	
215-25	39688-39690	to	_	
215-26	39691-39699	aberrant	_	
215-27	39700-39710	processing	_	
215-28	39711-39713	of	_	
215-29	39714-39723	different	_	
215-30	39724-39729	types	_	
215-31	39730-39732	of	_	
215-32	39733-39741	salience	_	
215-33	39741-39742	.	_	

#Text=We expected to see increased activity in the visual cortices due to the use of a visual oddball paradigm across all stimuli.
216-1	39743-39745	We	_	
216-2	39746-39754	expected	_	
216-3	39755-39757	to	_	
216-4	39758-39761	see	_	
216-5	39762-39771	increased	_	
216-6	39772-39780	activity	_	
216-7	39781-39783	in	_	
216-8	39784-39787	the	_	
216-9	39788-39794	visual	_	
216-10	39795-39803	cortices	_	
216-11	39804-39807	due	_	
216-12	39808-39810	to	_	
216-13	39811-39814	the	_	
216-14	39815-39818	use	_	
216-15	39819-39821	of	_	
216-16	39822-39823	a	_	
216-17	39824-39830	visual	_	
216-18	39831-39838	oddball	_	
216-19	39839-39847	paradigm	_	
216-20	39848-39854	across	_	
216-21	39855-39858	all	_	
216-22	39859-39866	stimuli	_	
216-23	39866-39867	.	_	

#Text=Here, we observed group differences in response to novelty and negative emotional salience, potentially in line with impaired visual perceptions often reported in schizophrenia (see review in Ref. ).
217-1	39868-39872	Here	_	
217-2	39872-39873	,	_	
217-3	39874-39876	we	_	
217-4	39877-39885	observed	_	
217-5	39886-39891	group	_	
217-6	39892-39903	differences	_	
217-7	39904-39906	in	_	
217-8	39907-39915	response	_	
217-9	39916-39918	to	_	
217-10	39919-39926	novelty	_	
217-11	39927-39930	and	_	
217-12	39931-39939	negative	_	
217-13	39940-39949	emotional	_	
217-14	39950-39958	salience	_	
217-15	39958-39959	,	_	
217-16	39960-39971	potentially	_	
217-17	39972-39974	in	_	
217-18	39975-39979	line	_	
217-19	39980-39984	with	_	
217-20	39985-39993	impaired	_	
217-21	39994-40000	visual	_	
217-22	40001-40012	perceptions	_	
217-23	40013-40018	often	_	
217-24	40019-40027	reported	_	
217-25	40028-40030	in	_	
217-26	40031-40044	schizophrenia	_	
217-27	40045-40046	(	_	
217-28	40046-40049	see	_	
217-29	40050-40056	review	_	
217-30	40057-40059	in	_	
217-31	40060-40063	Ref	_	
217-32	40063-40064	.	_	
217-33	40065-40066	)	_	
217-34	40066-40067	.	_	

#Text=In contrast with the previous literature, which reported hippocampal activity in response to salience, we did not find any activity in the hippocampus, neither in a group difference nor in a healthy volunteers separately.
218-1	40068-40070	In	_	
218-2	40071-40079	contrast	_	
218-3	40080-40084	with	_	
218-4	40085-40088	the	_	
218-5	40089-40097	previous	_	
218-6	40098-40108	literature	_	
218-7	40108-40109	,	_	
218-8	40110-40115	which	_	
218-9	40116-40124	reported	_	
218-10	40125-40136	hippocampal	_	
218-11	40137-40145	activity	_	
218-12	40146-40148	in	_	
218-13	40149-40157	response	_	
218-14	40158-40160	to	_	
218-15	40161-40169	salience	_	
218-16	40169-40170	,	_	
218-17	40171-40173	we	_	
218-18	40174-40177	did	_	
218-19	40178-40181	not	_	
218-20	40182-40186	find	_	
218-21	40187-40190	any	_	
218-22	40191-40199	activity	_	
218-23	40200-40202	in	_	
218-24	40203-40206	the	_	
218-25	40207-40218	hippocampus	_	
218-26	40218-40219	,	_	
218-27	40220-40227	neither	_	
218-28	40228-40230	in	_	
218-29	40231-40232	a	_	
218-30	40233-40238	group	_	
218-31	40239-40249	difference	_	
218-32	40250-40253	nor	_	
218-33	40254-40256	in	_	
218-34	40257-40258	a	_	
218-35	40259-40266	healthy	_	
218-36	40267-40277	volunteers	_	
218-37	40278-40288	separately	_	
218-38	40288-40289	.	_	

#Text=It is possible that signal in this region may not have been reliably captured during fMRI scanning.
219-1	40290-40292	It	_	
219-2	40293-40295	is	_	
219-3	40296-40304	possible	_	
219-4	40305-40309	that	_	
219-5	40310-40316	signal	_	
219-6	40317-40319	in	_	
219-7	40320-40324	this	_	
219-8	40325-40331	region	_	
219-9	40332-40335	may	_	
219-10	40336-40339	not	_	
219-11	40340-40344	have	_	
219-12	40345-40349	been	_	
219-13	40350-40358	reliably	_	
219-14	40359-40367	captured	_	
219-15	40368-40374	during	_	
219-16	40375-40379	fMRI	_	
219-17	40380-40388	scanning	_	
219-18	40388-40389	.	_	

#Text=In an exploratory analysis, we found positive correlations between SN/VTA activity to novelty and symptom scores for delusion and negative symptoms, between amygdala signalling to negative emotional salience and the Beck depression inventory and delusions, and between striatal signalling and total score for positive symptoms.
220-1	40390-40392	In	_	
220-2	40393-40395	an	_	
220-3	40396-40407	exploratory	_	
220-4	40408-40416	analysis	_	
220-5	40416-40417	,	_	
220-6	40418-40420	we	_	
220-7	40421-40426	found	_	
220-8	40427-40435	positive	_	
220-9	40436-40448	correlations	_	
220-10	40449-40456	between	_	
220-11	40457-40459	SN	_	
220-12	40459-40460	/	_	
220-13	40460-40463	VTA	_	
220-14	40464-40472	activity	_	
220-15	40473-40475	to	_	
220-16	40476-40483	novelty	_	
220-17	40484-40487	and	_	
220-18	40488-40495	symptom	_	
220-19	40496-40502	scores	_	
220-20	40503-40506	for	_	
220-21	40507-40515	delusion	_	
220-22	40516-40519	and	_	
220-23	40520-40528	negative	_	
220-24	40529-40537	symptoms	_	
220-25	40537-40538	,	_	
220-26	40539-40546	between	_	
220-27	40547-40555	amygdala	_	
220-28	40556-40566	signalling	_	
220-29	40567-40569	to	_	
220-30	40570-40578	negative	_	
220-31	40579-40588	emotional	_	
220-32	40589-40597	salience	_	
220-33	40598-40601	and	_	
220-34	40602-40605	the	_	
220-35	40606-40610	Beck	_	
220-36	40611-40621	depression	_	
220-37	40622-40631	inventory	_	
220-38	40632-40635	and	_	
220-39	40636-40645	delusions	_	
220-40	40645-40646	,	_	
220-41	40647-40650	and	_	
220-42	40651-40658	between	_	
220-43	40659-40667	striatal	_	
220-44	40668-40678	signalling	_	
220-45	40679-40682	and	_	
220-46	40683-40688	total	_	
220-47	40689-40694	score	_	
220-48	40695-40698	for	_	
220-49	40699-40707	positive	_	
220-50	40708-40716	symptoms	_	
220-51	40716-40717	.	_	

#Text=However, when controlling for multiple comparisons, only the correlation between SN/VTA activation to novelty and delusions remains significant.
221-1	40718-40725	However	_	
221-2	40725-40726	,	_	
221-3	40727-40731	when	_	
221-4	40732-40743	controlling	_	
221-5	40744-40747	for	_	
221-6	40748-40756	multiple	_	
221-7	40757-40768	comparisons	_	
221-8	40768-40769	,	_	
221-9	40770-40774	only	_	
221-10	40775-40778	the	_	
221-11	40779-40790	correlation	_	
221-12	40791-40798	between	_	
221-13	40799-40801	SN	_	
221-14	40801-40802	/	_	
221-15	40802-40805	VTA	_	
221-16	40806-40816	activation	_	
221-17	40817-40819	to	_	
221-18	40820-40827	novelty	_	
221-19	40828-40831	and	_	
221-20	40832-40841	delusions	_	
221-21	40842-40849	remains	_	
221-22	40850-40861	significant	_	
221-23	40861-40862	.	_	

#Text=Here, we would have rather predicted a negative correlation showing a decrease of SN/VTA activation with increased symptom scores, especially given the group difference that showed lower activation in the patient group as a whole.
222-1	40863-40867	Here	_	
222-2	40867-40868	,	_	
222-3	40869-40871	we	_	
222-4	40872-40877	would	_	
222-5	40878-40882	have	_	
222-6	40883-40889	rather	_	
222-7	40890-40899	predicted	_	
222-8	40900-40901	a	_	
222-9	40902-40910	negative	_	
222-10	40911-40922	correlation	_	
222-11	40923-40930	showing	_	
222-12	40931-40932	a	_	
222-13	40933-40941	decrease	_	
222-14	40942-40944	of	_	
222-15	40945-40947	SN	_	
222-16	40947-40948	/	_	
222-17	40948-40951	VTA	_	
222-18	40952-40962	activation	_	
222-19	40963-40967	with	_	
222-20	40968-40977	increased	_	
222-21	40978-40985	symptom	_	
222-22	40986-40992	scores	_	
222-23	40992-40993	,	_	
222-24	40994-41004	especially	_	
222-25	41005-41010	given	_	
222-26	41011-41014	the	_	
222-27	41015-41020	group	_	
222-28	41021-41031	difference	_	
222-29	41032-41036	that	_	
222-30	41037-41043	showed	_	
222-31	41044-41049	lower	_	
222-32	41050-41060	activation	_	
222-33	41061-41063	in	_	
222-34	41064-41067	the	_	
222-35	41068-41075	patient	_	
222-36	41076-41081	group	_	
222-37	41082-41084	as	_	
222-38	41085-41086	a	_	
222-39	41087-41092	whole	_	
222-40	41092-41093	.	_	

#Text=It is thought-provoking that in this small study, several forms of salience showed reduced activation across regions in the average patient, but greater activation associated with greater symptoms.
223-1	41094-41096	It	_	
223-2	41097-41099	is	_	
223-3	41100-41117	thought-provoking	_	
223-4	41118-41122	that	_	
223-5	41123-41125	in	_	
223-6	41126-41130	this	_	
223-7	41131-41136	small	_	
223-8	41137-41142	study	_	
223-9	41142-41143	,	_	
223-10	41144-41151	several	_	
223-11	41152-41157	forms	_	
223-12	41158-41160	of	_	
223-13	41161-41169	salience	_	
223-14	41170-41176	showed	_	
223-15	41177-41184	reduced	_	
223-16	41185-41195	activation	_	
223-17	41196-41202	across	_	
223-18	41203-41210	regions	_	
223-19	41211-41213	in	_	
223-20	41214-41217	the	_	
223-21	41218-41225	average	_	
223-22	41226-41233	patient	_	
223-23	41233-41234	,	_	
223-24	41235-41238	but	_	
223-25	41239-41246	greater	_	
223-26	41247-41257	activation	_	
223-27	41258-41268	associated	_	
223-28	41269-41273	with	_	
223-29	41274-41281	greater	_	
223-30	41282-41290	symptoms	_	
223-31	41290-41291	.	_	

#Text=One speculation is that reduced activation (between group results) could reflect a trait abnormality, and superimposed on this are state dysfunctions closely linked to symptom expression.
224-1	41292-41295	One	_	
224-2	41296-41307	speculation	_	
224-3	41308-41310	is	_	
224-4	41311-41315	that	_	
224-5	41316-41323	reduced	_	
224-6	41324-41334	activation	_	
224-7	41335-41336	(	_	
224-8	41336-41343	between	_	
224-9	41344-41349	group	_	
224-10	41350-41357	results	_	
224-11	41357-41358	)	_	
224-12	41359-41364	could	_	
224-13	41365-41372	reflect	_	
224-14	41373-41374	a	_	
224-15	41375-41380	trait	_	
224-16	41381-41392	abnormality	_	
224-17	41392-41393	,	_	
224-18	41394-41397	and	_	
224-19	41398-41410	superimposed	_	
224-20	41411-41413	on	_	
224-21	41414-41418	this	_	
224-22	41419-41422	are	_	
224-23	41423-41428	state	_	
224-24	41429-41441	dysfunctions	_	
224-25	41442-41449	closely	_	
224-26	41450-41456	linked	_	
224-27	41457-41459	to	_	
224-28	41460-41467	symptom	_	
224-29	41468-41478	expression	_	
224-30	41478-41479	.	_	

#Text=However, symptom correlations with functional imaging have often yielded inconsistent results in schizophrenia research.
225-1	41480-41487	However	_	
225-2	41487-41488	,	_	
225-3	41489-41496	symptom	_	
225-4	41497-41509	correlations	_	
225-5	41510-41514	with	_	
225-6	41515-41525	functional	_	
225-7	41526-41533	imaging	_	
225-8	41534-41538	have	_	
225-9	41539-41544	often	_	
225-10	41545-41552	yielded	_	
225-11	41553-41565	inconsistent	_	
225-12	41566-41573	results	_	
225-13	41574-41576	in	_	
225-14	41577-41590	schizophrenia	_	
225-15	41591-41599	research	_	
225-16	41599-41600	.	_	

#Text=One of the most important difficulties to reliably detect symptom correlations is gathering a large enough sample, and our small sample size of 14 patients is a clear limitation to assess symptom correlations.
226-1	41601-41604	One	_	
226-2	41605-41607	of	_	
226-3	41608-41611	the	_	
226-4	41612-41616	most	_	
226-5	41617-41626	important	_	
226-6	41627-41639	difficulties	_	
226-7	41640-41642	to	_	
226-8	41643-41651	reliably	_	
226-9	41652-41658	detect	_	
226-10	41659-41666	symptom	_	
226-11	41667-41679	correlations	_	
226-12	41680-41682	is	_	
226-13	41683-41692	gathering	_	
226-14	41693-41694	a	_	
226-15	41695-41700	large	_	
226-16	41701-41707	enough	_	
226-17	41708-41714	sample	_	
226-18	41714-41715	,	_	
226-19	41716-41719	and	_	
226-20	41720-41723	our	_	
226-21	41724-41729	small	_	
226-22	41730-41736	sample	_	
226-23	41737-41741	size	_	
226-24	41742-41744	of	_	
226-25	41745-41747	14	_	
226-26	41748-41756	patients	_	
226-27	41757-41759	is	_	
226-28	41760-41761	a	_	
226-29	41762-41767	clear	_	
226-30	41768-41778	limitation	_	
226-31	41779-41781	to	_	
226-32	41782-41788	assess	_	
226-33	41789-41796	symptom	_	
226-34	41797-41809	correlations	_	
226-35	41809-41810	.	_	

#Text=However, we report it to generate future hypotheses and to be available for future meta-analysis.
227-1	41811-41818	However	_	
227-2	41818-41819	,	_	
227-3	41820-41822	we	_	
227-4	41823-41829	report	_	
227-5	41830-41832	it	_	
227-6	41833-41835	to	_	
227-7	41836-41844	generate	_	
227-8	41845-41851	future	_	
227-9	41852-41862	hypotheses	_	
227-10	41863-41866	and	_	
227-11	41867-41869	to	_	
227-12	41870-41872	be	_	
227-13	41873-41882	available	_	
227-14	41883-41886	for	_	
227-15	41887-41893	future	_	
227-16	41894-41907	meta-analysis	_	
227-17	41907-41908	.	_	

#Text=In conclusion, this study provides concise evidence for aberrant SN/VTA, striatal and cingulate signalling during non-motivational salience processing in a sample of antipsychotic naïve early psychosis patients.
228-1	41909-41911	In	_	
228-2	41912-41922	conclusion	_	
228-3	41922-41923	,	_	
228-4	41924-41928	this	_	
228-5	41929-41934	study	_	
228-6	41935-41943	provides	_	
228-7	41944-41951	concise	_	
228-8	41952-41960	evidence	_	
228-9	41961-41964	for	_	
228-10	41965-41973	aberrant	_	
228-11	41974-41976	SN	_	
228-12	41976-41977	/	_	
228-13	41977-41980	VTA	_	
228-14	41980-41981	,	_	
228-15	41982-41990	striatal	_	
228-16	41991-41994	and	_	
228-17	41995-42004	cingulate	_	
228-18	42005-42015	signalling	_	
228-19	42016-42022	during	_	
228-20	42023-42039	non-motivational	_	
228-21	42040-42048	salience	_	
228-22	42049-42059	processing	_	
228-23	42060-42062	in	_	
228-24	42063-42064	a	_	
228-25	42065-42071	sample	_	
228-26	42072-42074	of	_	
228-27	42075-42088	antipsychotic	_	
228-28	42089-42094	naïve	_	
228-29	42095-42100	early	_	
228-30	42101-42110	psychosis	_	
228-31	42111-42119	patients	_	
228-32	42119-42120	.	_	

#Text=The results extend previous research by giving supportive evidence for the aberrant salience hypothesis of psychosis involving motivational and non-motivational forms of salience and the involvement of dopaminergic dysregulation in the development of psychotic disorder.
229-1	42121-42124	The	_	
229-2	42125-42132	results	_	
229-3	42133-42139	extend	_	
229-4	42140-42148	previous	_	
229-5	42149-42157	research	_	
229-6	42158-42160	by	_	
229-7	42161-42167	giving	_	
229-8	42168-42178	supportive	_	
229-9	42179-42187	evidence	_	
229-10	42188-42191	for	_	
229-11	42192-42195	the	_	
229-12	42196-42204	aberrant	_	
229-13	42205-42213	salience	_	
229-14	42214-42224	hypothesis	_	
229-15	42225-42227	of	_	
229-16	42228-42237	psychosis	_	
229-17	42238-42247	involving	_	
229-18	42248-42260	motivational	_	
229-19	42261-42264	and	_	
229-20	42265-42281	non-motivational	_	
229-21	42282-42287	forms	_	
229-22	42288-42290	of	_	
229-23	42291-42299	salience	_	
229-24	42300-42303	and	_	
229-25	42304-42307	the	_	
229-26	42308-42319	involvement	_	
229-27	42320-42322	of	_	
229-28	42323-42335	dopaminergic	_	
229-29	42336-42349	dysregulation	_	
229-30	42350-42352	in	_	
229-31	42353-42356	the	_	
229-32	42357-42368	development	_	
229-33	42369-42371	of	_	
229-34	42372-42381	psychotic	_	
229-35	42382-42390	disorder	_	
229-36	42390-42391	.	_	

#Text=Electronic supplementary material
#Text=joint first author with equal: Franziska Knolle and Anna O Ermakova.
230-1	42392-42402	Electronic	_	
230-2	42403-42416	supplementary	_	
230-3	42417-42425	material	_	
230-4	42426-42431	joint	_	
230-5	42432-42437	first	_	
230-6	42438-42444	author	_	
230-7	42445-42449	with	_	
230-8	42450-42455	equal	_	
230-9	42455-42456	:	_	
230-10	42457-42466	Franziska	_	
230-11	42467-42473	Knolle	_	
230-12	42474-42477	and	_	
230-13	42478-42482	Anna	_	
230-14	42483-42484	O	_	
230-15	42485-42493	Ermakova	_	
230-16	42493-42494	.	_	

#Text=Publisher's note: Springer Nature remains neutral with regard to jurisdictional claims in published maps and institutional affiliations.
231-1	42495-42506	Publisher's	_	
231-2	42507-42511	note	_	
231-3	42511-42512	:	_	
231-4	42513-42521	Springer	_	
231-5	42522-42528	Nature	_	
231-6	42529-42536	remains	_	
231-7	42537-42544	neutral	_	
231-8	42545-42549	with	_	
231-9	42550-42556	regard	_	
231-10	42557-42559	to	_	
231-11	42560-42574	jurisdictional	_	
231-12	42575-42581	claims	_	
231-13	42582-42584	in	_	
231-14	42585-42594	published	_	
231-15	42595-42599	maps	_	
231-16	42600-42603	and	_	
231-17	42604-42617	institutional	_	
231-18	42618-42630	affiliations	_	
231-19	42630-42631	.	_	

#Text=Electronic supplementary material
#Text=Supplementary Information accompanies this paper at (10.1038/s41398-018-0250-3).
232-1	42632-42642	Electronic	_	
232-2	42643-42656	supplementary	_	
232-3	42657-42665	material	_	
232-4	42666-42679	Supplementary	_	
232-5	42680-42691	Information	_	
232-6	42692-42703	accompanies	_	
232-7	42704-42708	this	_	
232-8	42709-42714	paper	_	
232-9	42715-42717	at	_	
232-10	42718-42719	(	_	
232-11	42719-42726	10.1038	_	
232-12	42726-42727	/	_	
232-13	42727-42733	s41398	_	
232-14	42733-42734	-	_	
232-15	42734-42737	018	_	
232-16	42737-42738	-	_	
232-17	42738-42742	0250	_	
232-18	42742-42743	-	_	
232-19	42743-42744	3	_	
232-20	42744-42745	)	_	
232-21	42745-42746	.	_	

#Text=Competing interests
#Text=P.C.F. has consulted for GlaxoSmithKline and Lundbeck and received compensation.
233-1	42747-42756	Competing	_	
233-2	42757-42766	interests	_	
233-3	42767-42772	P.C.F	_	
233-4	42772-42773	.	_	
233-5	42774-42777	has	_	
233-6	42778-42787	consulted	_	
233-7	42788-42791	for	_	
233-8	42792-42807	GlaxoSmithKline	_	
233-9	42808-42811	and	_	
233-10	42812-42820	Lundbeck	_	
233-11	42821-42824	and	_	
233-12	42825-42833	received	_	
233-13	42834-42846	compensation	_	
233-14	42846-42847	.	_	

#Text=The remaining authors declare no competing interests.
234-1	42848-42851	The	_	
234-2	42852-42861	remaining	_	
234-3	42862-42869	authors	_	
234-4	42870-42877	declare	_	
234-5	42878-42880	no	_	
234-6	42881-42890	competing	_	
234-7	42891-42900	interests	_	
234-8	42900-42901	.	_	

#Text=References
#Text=Dopaminergic basis of salience dysregulation in psychosis
#Text=Predictive reward signal of dopamine neurons
#Text=Dopamine reward prediction-error signalling: a two-component response
#Text=Dopamine-dependent prediction errors underpin reward-seeking behaviour in humans
#Text=Mesolimbocortical and nigrostriatal dopamine responses to salient non-reward events
#Text=Contextual interaction between novelty and reward processing within the mesolimbic system
#Text=Dopamine: the salient issue
#Text=Dopamine in motivational control: rewarding, aversive, and alerting
#Text=Dopamine and the aberrant salience hypothesis of schizophrenia
#Text=Psychosis as a state of aberrant salience: a framework linking biology, phenomenology, and pharmacology in schizophrenia
#Text=Are persistent delusions in schizophrenia associated with aberrant salience?
235-1	42902-42912	References	_	
235-2	42913-42925	Dopaminergic	_	
235-3	42926-42931	basis	_	
235-4	42932-42934	of	_	
235-5	42935-42943	salience	_	
235-6	42944-42957	dysregulation	_	
235-7	42958-42960	in	_	
235-8	42961-42970	psychosis	_	
235-9	42971-42981	Predictive	_	
235-10	42982-42988	reward	_	
235-11	42989-42995	signal	_	
235-12	42996-42998	of	_	
235-13	42999-43007	dopamine	_	
235-14	43008-43015	neurons	_	
235-15	43016-43024	Dopamine	_	
235-16	43025-43031	reward	_	
235-17	43032-43048	prediction-error	_	
235-18	43049-43059	signalling	_	
235-19	43059-43060	:	_	
235-20	43061-43062	a	_	
235-21	43063-43076	two-component	_	
235-22	43077-43085	response	_	
235-23	43086-43104	Dopamine-dependent	_	
235-24	43105-43115	prediction	_	
235-25	43116-43122	errors	_	
235-26	43123-43131	underpin	_	
235-27	43132-43146	reward-seeking	_	
235-28	43147-43156	behaviour	_	
235-29	43157-43159	in	_	
235-30	43160-43166	humans	_	
235-31	43167-43184	Mesolimbocortical	_	
235-32	43185-43188	and	_	
235-33	43189-43202	nigrostriatal	_	
235-34	43203-43211	dopamine	_	
235-35	43212-43221	responses	_	
235-36	43222-43224	to	_	
235-37	43225-43232	salient	_	
235-38	43233-43243	non-reward	_	
235-39	43244-43250	events	_	
235-40	43251-43261	Contextual	_	
235-41	43262-43273	interaction	_	
235-42	43274-43281	between	_	
235-43	43282-43289	novelty	_	
235-44	43290-43293	and	_	
235-45	43294-43300	reward	_	
235-46	43301-43311	processing	_	
235-47	43312-43318	within	_	
235-48	43319-43322	the	_	
235-49	43323-43333	mesolimbic	_	
235-50	43334-43340	system	_	
235-51	43341-43349	Dopamine	_	
235-52	43349-43350	:	_	
235-53	43351-43354	the	_	
235-54	43355-43362	salient	_	
235-55	43363-43368	issue	_	
235-56	43369-43377	Dopamine	_	
235-57	43378-43380	in	_	
235-58	43381-43393	motivational	_	
235-59	43394-43401	control	_	
235-60	43401-43402	:	_	
235-61	43403-43412	rewarding	_	
235-62	43412-43413	,	_	
235-63	43414-43422	aversive	_	
235-64	43422-43423	,	_	
235-65	43424-43427	and	_	
235-66	43428-43436	alerting	_	
235-67	43437-43445	Dopamine	_	
235-68	43446-43449	and	_	
235-69	43450-43453	the	_	
235-70	43454-43462	aberrant	_	
235-71	43463-43471	salience	_	
235-72	43472-43482	hypothesis	_	
235-73	43483-43485	of	_	
235-74	43486-43499	schizophrenia	_	
235-75	43500-43509	Psychosis	_	
235-76	43510-43512	as	_	
235-77	43513-43514	a	_	
235-78	43515-43520	state	_	
235-79	43521-43523	of	_	
235-80	43524-43532	aberrant	_	
235-81	43533-43541	salience	_	
235-82	43541-43542	:	_	
235-83	43543-43544	a	_	
235-84	43545-43554	framework	_	
235-85	43555-43562	linking	_	
235-86	43563-43570	biology	_	
235-87	43570-43571	,	_	
235-88	43572-43585	phenomenology	_	
235-89	43585-43586	,	_	
235-90	43587-43590	and	_	
235-91	43591-43603	pharmacology	_	
235-92	43604-43606	in	_	
235-93	43607-43620	schizophrenia	_	
235-94	43621-43624	Are	_	
235-95	43625-43635	persistent	_	
235-96	43636-43645	delusions	_	
235-97	43646-43648	in	_	
235-98	43649-43662	schizophrenia	_	
235-99	43663-43673	associated	_	
235-100	43674-43678	with	_	
235-101	43679-43687	aberrant	_	
235-102	43688-43696	salience	_	
235-103	43696-43697	?	_	

#Text=Toward a neurobiology of delusions
#Text=The neural underpinnings of associative learning in health and psychosis: how can performance be preserved when brain responses are abnormal?
236-1	43698-43704	Toward	_	
236-2	43705-43706	a	_	
236-3	43707-43719	neurobiology	_	
236-4	43720-43722	of	_	
236-5	43723-43732	delusions	_	
236-6	43733-43736	The	_	
236-7	43737-43743	neural	_	
236-8	43744-43757	underpinnings	_	
236-9	43758-43760	of	_	
236-10	43761-43772	associative	_	
236-11	43773-43781	learning	_	
236-12	43782-43784	in	_	
236-13	43785-43791	health	_	
236-14	43792-43795	and	_	
236-15	43796-43805	psychosis	_	
236-16	43805-43806	:	_	
236-17	43807-43810	how	_	
236-18	43811-43814	can	_	
236-19	43815-43826	performance	_	
236-20	43827-43829	be	_	
236-21	43830-43839	preserved	_	
236-22	43840-43844	when	_	
236-23	43845-43850	brain	_	
236-24	43851-43860	responses	_	
236-25	43861-43864	are	_	
236-26	43865-43873	abnormal	_	
236-27	43873-43874	?	_	

#Text=Aberrant hippocampal activity underlies the dopamine dysregulation in an animal model of Schizophrenia
#Text=Mechanisms underlying psychosis and antipsychotic treatment response in Schizophrenia: insights from PET and SPECT imaging
#Text=Elevated striatal dopamine function linked to prodromal signs of schizophrenia
#Text=Expected value and prediction error abnormalities in depression and schizophrenia
#Text=Disambiguating ventral striatum fMRI-related BOLD signal during reward prediction in schizophrenia
#Text=Substantia nigra / ventral tegmental reward prediction error disruption in psychosis
#Text=Striatal dysfunction during reversal learning in unmedicated schizophrenia patients
#Text=Disrupted prediction-error signal in psychosis: evidence for an associative account of delusions
#Text=Abnormal reward prediction-error signalling in antipsychotic naive individuals with first-episode psychosis or clinical risk for psychosis
#Text=Neural and behavioral correlates of aberrant salience in individuals at risk for psychosis
#Text=Anticipation of novelty recruits reward system and hippocampus while promoting recollection
#Text=Absolute coding of stimulus novelty in the human substantia nigra/VTA
#Text=Dopamine: generalization and bonuses
#Text=Schott B.
237-1	43875-43883	Aberrant	_	
237-2	43884-43895	hippocampal	_	
237-3	43896-43904	activity	_	
237-4	43905-43914	underlies	_	
237-5	43915-43918	the	_	
237-6	43919-43927	dopamine	_	
237-7	43928-43941	dysregulation	_	
237-8	43942-43944	in	_	
237-9	43945-43947	an	_	
237-10	43948-43954	animal	_	
237-11	43955-43960	model	_	
237-12	43961-43963	of	_	
237-13	43964-43977	Schizophrenia	_	
237-14	43978-43988	Mechanisms	_	
237-15	43989-43999	underlying	_	
237-16	44000-44009	psychosis	_	
237-17	44010-44013	and	_	
237-18	44014-44027	antipsychotic	_	
237-19	44028-44037	treatment	_	
237-20	44038-44046	response	_	
237-21	44047-44049	in	_	
237-22	44050-44063	Schizophrenia	_	
237-23	44063-44064	:	_	
237-24	44065-44073	insights	_	
237-25	44074-44078	from	_	
237-26	44079-44082	PET	_	
237-27	44083-44086	and	_	
237-28	44087-44092	SPECT	_	
237-29	44093-44100	imaging	_	
237-30	44101-44109	Elevated	_	
237-31	44110-44118	striatal	_	
237-32	44119-44127	dopamine	_	
237-33	44128-44136	function	_	
237-34	44137-44143	linked	_	
237-35	44144-44146	to	_	
237-36	44147-44156	prodromal	_	
237-37	44157-44162	signs	_	
237-38	44163-44165	of	_	
237-39	44166-44179	schizophrenia	_	
237-40	44180-44188	Expected	_	
237-41	44189-44194	value	_	
237-42	44195-44198	and	_	
237-43	44199-44209	prediction	_	
237-44	44210-44215	error	_	
237-45	44216-44229	abnormalities	_	
237-46	44230-44232	in	_	
237-47	44233-44243	depression	_	
237-48	44244-44247	and	_	
237-49	44248-44261	schizophrenia	_	
237-50	44262-44276	Disambiguating	_	
237-51	44277-44284	ventral	_	
237-52	44285-44293	striatum	_	
237-53	44294-44306	fMRI-related	_	
237-54	44307-44311	BOLD	_	
237-55	44312-44318	signal	_	
237-56	44319-44325	during	_	
237-57	44326-44332	reward	_	
237-58	44333-44343	prediction	_	
237-59	44344-44346	in	_	
237-60	44347-44360	schizophrenia	_	
237-61	44361-44371	Substantia	_	
237-62	44372-44377	nigra	_	
237-63	44378-44379	/	_	
237-64	44380-44387	ventral	_	
237-65	44388-44397	tegmental	_	
237-66	44398-44404	reward	_	
237-67	44405-44415	prediction	_	
237-68	44416-44421	error	_	
237-69	44422-44432	disruption	_	
237-70	44433-44435	in	_	
237-71	44436-44445	psychosis	_	
237-72	44446-44454	Striatal	_	
237-73	44455-44466	dysfunction	_	
237-74	44467-44473	during	_	
237-75	44474-44482	reversal	_	
237-76	44483-44491	learning	_	
237-77	44492-44494	in	_	
237-78	44495-44506	unmedicated	_	
237-79	44507-44520	schizophrenia	_	
237-80	44521-44529	patients	_	
237-81	44530-44539	Disrupted	_	
237-82	44540-44556	prediction-error	_	
237-83	44557-44563	signal	_	
237-84	44564-44566	in	_	
237-85	44567-44576	psychosis	_	
237-86	44576-44577	:	_	
237-87	44578-44586	evidence	_	
237-88	44587-44590	for	_	
237-89	44591-44593	an	_	
237-90	44594-44605	associative	_	
237-91	44606-44613	account	_	
237-92	44614-44616	of	_	
237-93	44617-44626	delusions	_	
237-94	44627-44635	Abnormal	_	
237-95	44636-44642	reward	_	
237-96	44643-44659	prediction-error	_	
237-97	44660-44670	signalling	_	
237-98	44671-44673	in	_	
237-99	44674-44687	antipsychotic	_	
237-100	44688-44693	naive	_	
237-101	44694-44705	individuals	_	
237-102	44706-44710	with	_	
237-103	44711-44724	first-episode	_	
237-104	44725-44734	psychosis	_	
237-105	44735-44737	or	_	
237-106	44738-44746	clinical	_	
237-107	44747-44751	risk	_	
237-108	44752-44755	for	_	
237-109	44756-44765	psychosis	_	
237-110	44766-44772	Neural	_	
237-111	44773-44776	and	_	
237-112	44777-44787	behavioral	_	
237-113	44788-44798	correlates	_	
237-114	44799-44801	of	_	
237-115	44802-44810	aberrant	_	
237-116	44811-44819	salience	_	
237-117	44820-44822	in	_	
237-118	44823-44834	individuals	_	
237-119	44835-44837	at	_	
237-120	44838-44842	risk	_	
237-121	44843-44846	for	_	
237-122	44847-44856	psychosis	_	
237-123	44857-44869	Anticipation	_	
237-124	44870-44872	of	_	
237-125	44873-44880	novelty	_	
237-126	44881-44889	recruits	_	
237-127	44890-44896	reward	_	
237-128	44897-44903	system	_	
237-129	44904-44907	and	_	
237-130	44908-44919	hippocampus	_	
237-131	44920-44925	while	_	
237-132	44926-44935	promoting	_	
237-133	44936-44948	recollection	_	
237-134	44949-44957	Absolute	_	
237-135	44958-44964	coding	_	
237-136	44965-44967	of	_	
237-137	44968-44976	stimulus	_	
237-138	44977-44984	novelty	_	
237-139	44985-44987	in	_	
237-140	44988-44991	the	_	
237-141	44992-44997	human	_	
237-142	44998-45008	substantia	_	
237-143	45009-45014	nigra	_	
237-144	45014-45015	/	_	
237-145	45015-45018	VTA	_	
237-146	45019-45027	Dopamine	_	
237-147	45027-45028	:	_	
237-148	45029-45043	generalization	_	
237-149	45044-45047	and	_	
237-150	45048-45055	bonuses	_	
237-151	45056-45062	Schott	_	
237-152	45063-45064	B	_	
237-153	45064-45065	.	_	

#Text=H. et al.
238-1	45066-45067	H	_	
238-2	45067-45068	.	_	
238-3	45069-45071	et	_	
238-4	45072-45074	al	_	
238-5	45074-45075	.	_	

#Text=Fronto-limbic novelty processing in acute psychosis: disrupted relationship with memory performance and potential implications for delusions.
239-1	45076-45089	Fronto-limbic	_	
239-2	45090-45097	novelty	_	
239-3	45098-45108	processing	_	
239-4	45109-45111	in	_	
239-5	45112-45117	acute	_	
239-6	45118-45127	psychosis	_	
239-7	45127-45128	:	_	
239-8	45129-45138	disrupted	_	
239-9	45139-45151	relationship	_	
239-10	45152-45156	with	_	
239-11	45157-45163	memory	_	
239-12	45164-45175	performance	_	
239-13	45176-45179	and	_	
239-14	45180-45189	potential	_	
239-15	45190-45202	implications	_	
239-16	45203-45206	for	_	
239-17	45207-45216	delusions	_	
239-18	45216-45217	.	_	

#Text=Front.
240-1	45218-45223	Front	_	
240-2	45223-45224	.	_	

#Text=Behav.
241-1	45225-45230	Behav	_	
241-2	45230-45231	.	_	

#Text=Neurosci.9 (2015). 10.3389/fnbeh.2015.00144.
242-1	45232-45240	Neurosci	_	
242-2	45240-45242	.9	_	
242-3	45243-45244	(	_	
242-4	45244-45248	2015	_	
242-5	45248-45249	)	_	
242-6	45249-45250	.	_	
242-7	45251-45258	10.3389	_	
242-8	45258-45259	/	_	
242-9	45259-45264	fnbeh	_	
242-10	45264-45275	.2015.00144	_	
242-11	45275-45276	.	_	

#Text=Midbrain presynaptic dopamine tone predicts sustained and transient neural response to emotional salience in humans: fMRI, MEG and FDOPA PET
#Text=Deficits in domains of social cognition in schizophrenia: a meta-analysis of the empirical evidence
#Text=Neural response to emotional salience in schizophrenia
#Text=The hippocampal-VTA loop: controlling the entry of information into long-term memory
#Text=The positive and negative syndrome scale (PANSS) for schizophrenia
#Text=Scale for the assessment of negative symptoms (SANS)
#Text=Global assessment of functioning: a modified scale
#Text=Beck, Aaron T., Robert A.
243-1	45277-45285	Midbrain	_	
243-2	45286-45297	presynaptic	_	
243-3	45298-45306	dopamine	_	
243-4	45307-45311	tone	_	
243-5	45312-45320	predicts	_	
243-6	45321-45330	sustained	_	
243-7	45331-45334	and	_	
243-8	45335-45344	transient	_	
243-9	45345-45351	neural	_	
243-10	45352-45360	response	_	
243-11	45361-45363	to	_	
243-12	45364-45373	emotional	_	
243-13	45374-45382	salience	_	
243-14	45383-45385	in	_	
243-15	45386-45392	humans	_	
243-16	45392-45393	:	_	
243-17	45394-45398	fMRI	_	
243-18	45398-45399	,	_	
243-19	45400-45403	MEG	_	
243-20	45404-45407	and	_	
243-21	45408-45413	FDOPA	_	
243-22	45414-45417	PET	_	
243-23	45418-45426	Deficits	_	
243-24	45427-45429	in	_	
243-25	45430-45437	domains	_	
243-26	45438-45440	of	_	
243-27	45441-45447	social	_	
243-28	45448-45457	cognition	_	
243-29	45458-45460	in	_	
243-30	45461-45474	schizophrenia	_	
243-31	45474-45475	:	_	
243-32	45476-45477	a	_	
243-33	45478-45491	meta-analysis	_	
243-34	45492-45494	of	_	
243-35	45495-45498	the	_	
243-36	45499-45508	empirical	_	
243-37	45509-45517	evidence	_	
243-38	45518-45524	Neural	_	
243-39	45525-45533	response	_	
243-40	45534-45536	to	_	
243-41	45537-45546	emotional	_	
243-42	45547-45555	salience	_	
243-43	45556-45558	in	_	
243-44	45559-45572	schizophrenia	_	
243-45	45573-45576	The	_	
243-46	45577-45592	hippocampal-VTA	_	
243-47	45593-45597	loop	_	
243-48	45597-45598	:	_	
243-49	45599-45610	controlling	_	
243-50	45611-45614	the	_	
243-51	45615-45620	entry	_	
243-52	45621-45623	of	_	
243-53	45624-45635	information	_	
243-54	45636-45640	into	_	
243-55	45641-45650	long-term	_	
243-56	45651-45657	memory	_	
243-57	45658-45661	The	_	
243-58	45662-45670	positive	_	
243-59	45671-45674	and	_	
243-60	45675-45683	negative	_	
243-61	45684-45692	syndrome	_	
243-62	45693-45698	scale	_	
243-63	45699-45700	(	_	
243-64	45700-45705	PANSS	_	
243-65	45705-45706	)	_	
243-66	45707-45710	for	_	
243-67	45711-45724	schizophrenia	_	
243-68	45725-45730	Scale	_	
243-69	45731-45734	for	_	
243-70	45735-45738	the	_	
243-71	45739-45749	assessment	_	
243-72	45750-45752	of	_	
243-73	45753-45761	negative	_	
243-74	45762-45770	symptoms	_	
243-75	45771-45772	(	_	
243-76	45772-45776	SANS	_	
243-77	45776-45777	)	_	
243-78	45778-45784	Global	_	
243-79	45785-45795	assessment	_	
243-80	45796-45798	of	_	
243-81	45799-45810	functioning	_	
243-82	45810-45811	:	_	
243-83	45812-45813	a	_	
243-84	45814-45822	modified	_	
243-85	45823-45828	scale	_	
243-86	45829-45833	Beck	_	
243-87	45833-45834	,	_	
243-88	45835-45840	Aaron	_	
243-89	45841-45842	T	_	
243-90	45842-45843	.	_	
243-91	45843-45844	,	_	
243-92	45845-45851	Robert	_	
243-93	45852-45853	A	_	
243-94	45853-45854	.	_	

#Text=Steer, and Gregory K.
244-1	45855-45860	Steer	_	
244-2	45860-45861	,	_	
244-3	45862-45865	and	_	
244-4	45866-45873	Gregory	_	
244-5	45874-45875	K	_	
244-6	45875-45876	.	_	

#Text=Brown.
245-1	45877-45882	Brown	_	
245-2	45882-45883	.	_	

#Text="Beck depression inventory-II."
246-1	45884-45885	"	_	
246-2	45885-45889	Beck	_	
246-3	45890-45900	depression	_	
246-4	45901-45913	inventory-II	_	
246-5	45913-45914	.	_	
246-6	45914-45915	"	_	

#Text=San Antonio 78, 490–498 (1996).
247-1	45916-45919	San	_	
247-2	45920-45927	Antonio	_	
247-3	45928-45930	78	_	
247-4	45930-45931	,	_	
247-5	45932-45935	490	_	
247-6	45935-45936	–	_	
247-7	45936-45939	498	_	
247-8	45940-45941	(	_	
247-9	45941-45945	1996	_	
247-10	45945-45946	)	_	
247-11	45946-45947	.	_	

#Text=Cattell R.
248-1	45948-45955	Cattell	_	
248-2	45956-45957	R	_	
248-3	45957-45958	.	_	

#Text=B. & Cattell A.
249-1	45959-45960	B	_	
249-2	45960-45961	.	_	
249-3	45962-45963	&	_	
249-4	45964-45971	Cattell	_	
249-5	45972-45973	A	_	
249-6	45973-45974	.	_	

#Text=K.
250-1	45975-45976	K	_	
250-2	45976-45977	.	_	

#Text=S.
251-1	45978-45979	S	_	
251-2	45979-45980	.	_	

#Text=Measuring Intelligence with the Culture Fair Tests.
252-1	45981-45990	Measuring	_	
252-2	45991-46003	Intelligence	_	
252-3	46004-46008	with	_	
252-4	46009-46012	the	_	
252-5	46013-46020	Culture	_	
252-6	46021-46025	Fair	_	
252-7	46026-46031	Tests	_	
252-8	46031-46032	.	_	

#Text=Champaign, IL: IPAT. (1977).
253-1	46033-46042	Champaign	_	
253-2	46042-46043	,	_	
253-3	46044-46046	IL	_	
253-4	46046-46047	:	_	
253-5	46048-46052	IPAT	_	
253-6	46052-46053	.	_	
253-7	46054-46055	(	_	
253-8	46055-46059	1977	_	
253-9	46059-46060	)	_	
253-10	46060-46061	.	_	

#Text=Mesolimbic novelty processing in older adults
#Text=Improved optimization for the robust and accurate linear registration and motion correction of brain images
#Text=Permutation inference for the general linear model
#Text=Nonparametric permutation tests for functional neuroimaging: a primer with examples
#Text=Resting state networks distinguish human ventral tegmental area from substantia nigra
#Text=Fronto-limbic novelty processing in acute psychosis: inefficient hippocampal encoding and potential implications for delusions
#Text=Salience and psychosis: moving from theory to practise
#Text=Neural mechanisms for detecting and remembering novel events
#Text=Subjective emotional over-arousal to neutral social scenes in paranoid schizophrenia
#Text=Ventral tegmental area/midbrain functional connectivity and response to antipsychotic medication in schizophrenia
#Text=Diversity and homogeneity in responses of midbrain dopamine neurons
#Text=Aberrant salience network (bilateral insula and anterior cingulate cortex) connectivity during information processing in schizophrenia
#Text=Does the salience network play a cardinal role in psychosis?
254-1	46062-46072	Mesolimbic	_	
254-2	46073-46080	novelty	_	
254-3	46081-46091	processing	_	
254-4	46092-46094	in	_	
254-5	46095-46100	older	_	
254-6	46101-46107	adults	_	
254-7	46108-46116	Improved	_	
254-8	46117-46129	optimization	_	
254-9	46130-46133	for	_	
254-10	46134-46137	the	_	
254-11	46138-46144	robust	_	
254-12	46145-46148	and	_	
254-13	46149-46157	accurate	_	
254-14	46158-46164	linear	_	
254-15	46165-46177	registration	_	
254-16	46178-46181	and	_	
254-17	46182-46188	motion	_	
254-18	46189-46199	correction	_	
254-19	46200-46202	of	_	
254-20	46203-46208	brain	_	
254-21	46209-46215	images	_	
254-22	46216-46227	Permutation	_	
254-23	46228-46237	inference	_	
254-24	46238-46241	for	_	
254-25	46242-46245	the	_	
254-26	46246-46253	general	_	
254-27	46254-46260	linear	_	
254-28	46261-46266	model	_	
254-29	46267-46280	Nonparametric	_	
254-30	46281-46292	permutation	_	
254-31	46293-46298	tests	_	
254-32	46299-46302	for	_	
254-33	46303-46313	functional	_	
254-34	46314-46326	neuroimaging	_	
254-35	46326-46327	:	_	
254-36	46328-46329	a	_	
254-37	46330-46336	primer	_	
254-38	46337-46341	with	_	
254-39	46342-46350	examples	_	
254-40	46351-46358	Resting	_	
254-41	46359-46364	state	_	
254-42	46365-46373	networks	_	
254-43	46374-46385	distinguish	_	
254-44	46386-46391	human	_	
254-45	46392-46399	ventral	_	
254-46	46400-46409	tegmental	_	
254-47	46410-46414	area	_	
254-48	46415-46419	from	_	
254-49	46420-46430	substantia	_	
254-50	46431-46436	nigra	_	
254-51	46437-46450	Fronto-limbic	_	
254-52	46451-46458	novelty	_	
254-53	46459-46469	processing	_	
254-54	46470-46472	in	_	
254-55	46473-46478	acute	_	
254-56	46479-46488	psychosis	_	
254-57	46488-46489	:	_	
254-58	46490-46501	inefficient	_	
254-59	46502-46513	hippocampal	_	
254-60	46514-46522	encoding	_	
254-61	46523-46526	and	_	
254-62	46527-46536	potential	_	
254-63	46537-46549	implications	_	
254-64	46550-46553	for	_	
254-65	46554-46563	delusions	_	
254-66	46564-46572	Salience	_	
254-67	46573-46576	and	_	
254-68	46577-46586	psychosis	_	
254-69	46586-46587	:	_	
254-70	46588-46594	moving	_	
254-71	46595-46599	from	_	
254-72	46600-46606	theory	_	
254-73	46607-46609	to	_	
254-74	46610-46618	practise	_	
254-75	46619-46625	Neural	_	
254-76	46626-46636	mechanisms	_	
254-77	46637-46640	for	_	
254-78	46641-46650	detecting	_	
254-79	46651-46654	and	_	
254-80	46655-46666	remembering	_	
254-81	46667-46672	novel	_	
254-82	46673-46679	events	_	
254-83	46680-46690	Subjective	_	
254-84	46691-46700	emotional	_	
254-85	46701-46713	over-arousal	_	
254-86	46714-46716	to	_	
254-87	46717-46724	neutral	_	
254-88	46725-46731	social	_	
254-89	46732-46738	scenes	_	
254-90	46739-46741	in	_	
254-91	46742-46750	paranoid	_	
254-92	46751-46764	schizophrenia	_	
254-93	46765-46772	Ventral	_	
254-94	46773-46782	tegmental	_	
254-95	46783-46787	area	_	
254-96	46787-46788	/	_	
254-97	46788-46796	midbrain	_	
254-98	46797-46807	functional	_	
254-99	46808-46820	connectivity	_	
254-100	46821-46824	and	_	
254-101	46825-46833	response	_	
254-102	46834-46836	to	_	
254-103	46837-46850	antipsychotic	_	
254-104	46851-46861	medication	_	
254-105	46862-46864	in	_	
254-106	46865-46878	schizophrenia	_	
254-107	46879-46888	Diversity	_	
254-108	46889-46892	and	_	
254-109	46893-46904	homogeneity	_	
254-110	46905-46907	in	_	
254-111	46908-46917	responses	_	
254-112	46918-46920	of	_	
254-113	46921-46929	midbrain	_	
254-114	46930-46938	dopamine	_	
254-115	46939-46946	neurons	_	
254-116	46947-46955	Aberrant	_	
254-117	46956-46964	salience	_	
254-118	46965-46972	network	_	
254-119	46973-46974	(	_	
254-120	46974-46983	bilateral	_	
254-121	46984-46990	insula	_	
254-122	46991-46994	and	_	
254-123	46995-47003	anterior	_	
254-124	47004-47013	cingulate	_	
254-125	47014-47020	cortex	_	
254-126	47020-47021	)	_	
254-127	47022-47034	connectivity	_	
254-128	47035-47041	during	_	
254-129	47042-47053	information	_	
254-130	47054-47064	processing	_	
254-131	47065-47067	in	_	
254-132	47068-47081	schizophrenia	_	
254-133	47082-47086	Does	_	
254-134	47087-47090	the	_	
254-135	47091-47099	salience	_	
254-136	47100-47107	network	_	
254-137	47108-47112	play	_	
254-138	47113-47114	a	_	
254-139	47115-47123	cardinal	_	
254-140	47124-47128	role	_	
254-141	47129-47131	in	_	
254-142	47132-47141	psychosis	_	
254-143	47141-47142	?	_	

#Text=An emerging hypothesis of insular dysfunction
#Text=Methamphetamine-induced disruption of Frontostriatal reward learning signals: relation to psychotic symptoms
#Text=Salience network-midbrain dysconnectivity and blunted reward signals in schizophrenia
#Text=A cross-sectional and longitudinal magnetic resonance imaging study of cingulate gyrus gray matter volume abnormalities in first-episode schizophrenia and first-episode affective psychosis
#Text=Multimodal meta-analysis of structural and functional brain changes in first episode psychosis and the effects of antipsychotic medication
#Text=Borgwardt S.
255-1	47143-47145	An	_	
255-2	47146-47154	emerging	_	
255-3	47155-47165	hypothesis	_	
255-4	47166-47168	of	_	
255-5	47169-47176	insular	_	
255-6	47177-47188	dysfunction	_	
255-7	47189-47212	Methamphetamine-induced	_	
255-8	47213-47223	disruption	_	
255-9	47224-47226	of	_	
255-10	47227-47241	Frontostriatal	_	
255-11	47242-47248	reward	_	
255-12	47249-47257	learning	_	
255-13	47258-47265	signals	_	
255-14	47265-47266	:	_	
255-15	47267-47275	relation	_	
255-16	47276-47278	to	_	
255-17	47279-47288	psychotic	_	
255-18	47289-47297	symptoms	_	
255-19	47298-47306	Salience	_	
255-20	47307-47323	network-midbrain	_	
255-21	47324-47339	dysconnectivity	_	
255-22	47340-47343	and	_	
255-23	47344-47351	blunted	_	
255-24	47352-47358	reward	_	
255-25	47359-47366	signals	_	
255-26	47367-47369	in	_	
255-27	47370-47383	schizophrenia	_	
255-28	47384-47385	A	_	
255-29	47386-47401	cross-sectional	_	
255-30	47402-47405	and	_	
255-31	47406-47418	longitudinal	_	
255-32	47419-47427	magnetic	_	
255-33	47428-47437	resonance	_	
255-34	47438-47445	imaging	_	
255-35	47446-47451	study	_	
255-36	47452-47454	of	_	
255-37	47455-47464	cingulate	_	
255-38	47465-47470	gyrus	_	
255-39	47471-47475	gray	_	
255-40	47476-47482	matter	_	
255-41	47483-47489	volume	_	
255-42	47490-47503	abnormalities	_	
255-43	47504-47506	in	_	
255-44	47507-47520	first-episode	_	
255-45	47521-47534	schizophrenia	_	
255-46	47535-47538	and	_	
255-47	47539-47552	first-episode	_	
255-48	47553-47562	affective	_	
255-49	47563-47572	psychosis	_	
255-50	47573-47583	Multimodal	_	
255-51	47584-47597	meta-analysis	_	
255-52	47598-47600	of	_	
255-53	47601-47611	structural	_	
255-54	47612-47615	and	_	
255-55	47616-47626	functional	_	
255-56	47627-47632	brain	_	
255-57	47633-47640	changes	_	
255-58	47641-47643	in	_	
255-59	47644-47649	first	_	
255-60	47650-47657	episode	_	
255-61	47658-47667	psychosis	_	
255-62	47668-47671	and	_	
255-63	47672-47675	the	_	
255-64	47676-47683	effects	_	
255-65	47684-47686	of	_	
255-66	47687-47700	antipsychotic	_	
255-67	47701-47711	medication	_	
255-68	47712-47721	Borgwardt	_	
255-69	47722-47723	S	_	
255-70	47723-47724	.	_	

#Text=J. et al.
256-1	47725-47726	J	_	
256-2	47726-47727	.	_	
256-3	47728-47730	et	_	
256-4	47731-47733	al	_	
256-5	47733-47734	.	_	

#Text=Structural brain abnormalities in individuals with an at-risk mental state who later develop psychosis.
257-1	47735-47745	Structural	_	
257-2	47746-47751	brain	_	
257-3	47752-47765	abnormalities	_	
257-4	47766-47768	in	_	
257-5	47769-47780	individuals	_	
257-6	47781-47785	with	_	
257-7	47786-47788	an	_	
257-8	47789-47796	at-risk	_	
257-9	47797-47803	mental	_	
257-10	47804-47809	state	_	
257-11	47810-47813	who	_	
257-12	47814-47819	later	_	
257-13	47820-47827	develop	_	
257-14	47828-47837	psychosis	_	
257-15	47837-47838	.	_	

#Text=Br.
258-1	47839-47841	Br	_	
258-2	47841-47842	.	_	

#Text=J.
259-1	47843-47844	J	_	
259-2	47844-47845	.	_	

#Text=Psychiatry19110.1192/bjp.191.51.s69 (2007).
260-1	47846-47866	Psychiatry19110.1192	_	
260-2	47866-47867	/	_	
260-3	47867-47870	bjp	_	
260-4	47870-47877	.191.51	_	
260-5	47877-47878	.	_	
260-6	47878-47881	s69	_	
260-7	47882-47883	(	_	
260-8	47883-47887	2007	_	
260-9	47887-47888	)	_	
260-10	47888-47889	.	_	

#Text=The functional connectivity between amygdala and extrastriate visual cortex activity during emotional picture processing depends on stimulus novelty
#Text=Visual perception and its impairment in schizophrenia
#Text=Pharmacological dissociation of novelty responses in the human brain
#Text=Mathalon, D.
261-1	47890-47893	The	_	
261-2	47894-47904	functional	_	
261-3	47905-47917	connectivity	_	
261-4	47918-47925	between	_	
261-5	47926-47934	amygdala	_	
261-6	47935-47938	and	_	
261-7	47939-47951	extrastriate	_	
261-8	47952-47958	visual	_	
261-9	47959-47965	cortex	_	
261-10	47966-47974	activity	_	
261-11	47975-47981	during	_	
261-12	47982-47991	emotional	_	
261-13	47992-47999	picture	_	
261-14	48000-48010	processing	_	
261-15	48011-48018	depends	_	
261-16	48019-48021	on	_	
261-17	48022-48030	stimulus	_	
261-18	48031-48038	novelty	_	
261-19	48039-48045	Visual	_	
261-20	48046-48056	perception	_	
261-21	48057-48060	and	_	
261-22	48061-48064	its	_	
261-23	48065-48075	impairment	_	
261-24	48076-48078	in	_	
261-25	48079-48092	schizophrenia	_	
261-26	48093-48108	Pharmacological	_	
261-27	48109-48121	dissociation	_	
261-28	48122-48124	of	_	
261-29	48125-48132	novelty	_	
261-30	48133-48142	responses	_	
261-31	48143-48145	in	_	
261-32	48146-48149	the	_	
261-33	48150-48155	human	_	
261-34	48156-48161	brain	_	
261-35	48162-48170	Mathalon	_	
261-36	48170-48171	,	_	
261-37	48172-48173	D	_	
261-38	48173-48174	.	_	

#Text=H. & Ford, J.
262-1	48175-48176	H	_	
262-2	48176-48177	.	_	
262-3	48178-48179	&	_	
262-4	48180-48184	Ford	_	
262-5	48184-48185	,	_	
262-6	48186-48187	J	_	
262-7	48187-48188	.	_	

#Text=M.
263-1	48189-48190	M	_	
263-2	48190-48191	.	_	

#Text=Neurobiology of Schizophrenia: search for the elusive correlation with symptoms.
264-1	48192-48204	Neurobiology	_	
264-2	48205-48207	of	_	
264-3	48208-48221	Schizophrenia	_	
264-4	48221-48222	:	_	
264-5	48223-48229	search	_	
264-6	48230-48233	for	_	
264-7	48234-48237	the	_	
264-8	48238-48245	elusive	_	
264-9	48246-48257	correlation	_	
264-10	48258-48262	with	_	
264-11	48263-48271	symptoms	_	
264-12	48271-48272	.	_	

#Text=Front.
265-1	48273-48278	Front	_	
265-2	48278-48279	.	_	

#Text=Hum.
266-1	48280-48283	Hum	_	
266-2	48283-48284	.	_	

#Text=Neurosci.610.3389/fnhum.2012.00136 (2012).
267-1	48285-48293	Neurosci	_	
267-2	48293-48302	.610.3389	_	
267-3	48302-48303	/	_	
267-4	48303-48308	fnhum	_	
267-5	48308-48319	.2012.00136	_	
267-6	48320-48321	(	_	
267-7	48321-48325	2012	_	
267-8	48325-48326	)	_	
267-9	48326-48327	.	_	
